[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f6KzBPYQw2MU4CDIqjsJ10VELkTO_l3D_C130QVIwiz8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":86,"rows":93},"Beth Israel Deaconess Medical Center",[4],555,false,109,21,12862833,40,348,[14,17,20,23,26,28,31,33],{"name":15,"count":16},"Breast Cancer",23,{"name":18,"count":19},"Obesity",17,{"name":21,"count":22},"Schizophrenia",12,{"name":24,"count":25},"Healthy",9,{"name":27,"count":25},"Prostate Cancer",{"name":29,"count":30},"Renal Cell Carcinoma",8,{"name":32,"count":30},"Ovarian Cancer",{"name":34,"count":30},"Septic Shock",[36,41,46,51,56,61,66,71,76,81],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT03637543","Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer","2023-09-30","Nivolumab",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT00799110","Vaccination of Patients With Ovarian Cancer With Dendritic Cell\u002FTumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod","2024-12","GM-CSF",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT05283980","Pectoral Nerve Blocks (PECs) for Cardiovascular Implantable Electronic Device Placement","2025-03","0.25% Bupivacaine",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT03344965","Olaparib In Metastatic Breast Cancer","2025-07-30","Olaparib",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT06948409","NMBA Reversal and Postoperative Urinary Retention","2025-08-31","Choice of reversal agent",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT05683964","Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression","2025-09-18","Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT03377543","Sleep and Inflammatory Resolution Pathway","2025-12-30","Aspirin",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT06597396","Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition\u002FLong COVID","2026-03-27","Abrocitinib",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT03679650","Dendritic Cell\u002FAML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients","2026-03-31","DC\u002FAML fusion cells",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT07224620","Fentanyl Versus Hydromorphone in Patients on Mechanical Ventilation","2026-05","fentanyl",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,136,163,185,213,240,267,293,321,339,362,408,447,505,544,577,611,637,667,692,710,736,754,772,798,816,841,864,891,909,937,965,988,1006,1026,1084,1106,1138,1162,1193,1218,1281,1335,1374,1411,1437,1455,1480,1498,1527,1545,1573,1598,1616,1641,1666,1690,1715,1744,1762,1786,1812,1830,1854,1880,1904,1922,1948,1972,2000,2018,2047,2065,2083,2101,2126,2150,2176,2201,2226,2248,2266,2291,2316,2342,2368,2422,2466,2505,2547,2577,2614,2646,2680,2715,2747,2782,2816,2838,2871,2893,2933,2963,2996,3031,3063,3097,3120,3143,3166,3190,3208,3233,3258,3282,3300,3321,3344,3362,3384,3402,3425,3443,3461,3487,3505,3523,3547,3570,3592,3617,3635,3653,3678,3703,3728,3751,3776,3802,3820,3838,3862,3880,3905,3923,3948,3966,3984,4002,4020,4038,4056,4074,4092,4110,4136,4154,4178,4204,4228,4251,4273,4291,4315,4333,4351,4369,4394,4412,4430,4452,4473,4495,4517,4535,4558,4582,4607,4630,4653,4676,4698,4716,4745,4763,4784,4802,4827,4845,4894,4930,4956,4988,5025,5051,5077,5110,5132,5167,5196,5223,5241,5264,5289,5307,5325,5347,5371,5397,5415,5438,5456,5474,5496,5519,5537,5559,5583,5607,5631,5655,5679,5702,5724,5747,5774,5797,5815,5839,5857,5881,5907,5925,5949],{"intervention":95,"totalTrials":96,"cells":97},"liraglutide",2,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":134},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[],{"trials":106,"activeCount":100},[],{"trials":108,"activeCount":133,"soonestReadout":114},[109,119],{"nctId":110,"briefTitle":111,"status":112,"phases":113,"primaryCompletion":114,"completion":114,"start":115,"enrollment":116,"conditions":117,"interventions":118},"NCT02944500","Saxenda: Underlying Mechanisms and Clinical Outcomes","ACTIVE_NOT_RECRUITING",[91],"2027-06","2016-11",28,[18],[95],{"nctId":120,"briefTitle":121,"status":122,"phases":123,"primaryCompletion":124,"completion":124,"start":125,"enrollment":116,"conditions":126,"interventions":131},"NCT01562678","Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI","COMPLETED",[91],"2014-05","2012-03",[127,128,129,130],"Diabetes","Effects of Liraglutide Administration on Brain Activity","Weight Loss","Hunger",[132],"Liraglutide",1,{"trials":135,"activeCount":100},[],{"intervention":137,"totalTrials":133,"cells":138},"Infliximab",{"EARLY_PHASE1":139,"PHASE1":141,"PHASE2":143,"PHASE3":145,"PHASE4":147,"NA":161},{"trials":140,"activeCount":100},[],{"trials":142,"activeCount":100},[],{"trials":144,"activeCount":100},[],{"trials":146,"activeCount":100},[],{"trials":148,"activeCount":133,"soonestReadout":153},[149],{"nctId":150,"briefTitle":151,"status":112,"phases":152,"primaryCompletion":153,"completion":153,"start":154,"enrollment":155,"conditions":156,"interventions":160},"NCT04835506","Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial",[91],"2026-09","2021-11-01",124,[157,158,159],"Crohn Disease","Ulcerative Colitis","Inflammatory Bowel Diseases",[137],{"trials":162,"activeCount":100},[],{"intervention":164,"totalTrials":133,"cells":165},"Lorcaserin HCl",{"EARLY_PHASE1":166,"PHASE1":168,"PHASE2":170,"PHASE3":172,"PHASE4":174,"NA":183},{"trials":167,"activeCount":100},[],{"trials":169,"activeCount":100},[],{"trials":171,"activeCount":100},[],{"trials":173,"activeCount":100},[],{"trials":175,"activeCount":133,"soonestReadout":114},[176],{"nctId":177,"briefTitle":178,"status":112,"phases":179,"primaryCompletion":114,"completion":114,"start":180,"enrollment":11,"conditions":181,"interventions":182},"NCT02400359","Lorcaserin in Obesity: Identification of CNS Targets Using fMRI",[91],"2014-10",[18,129],[164],{"trials":184,"activeCount":100},[],{"intervention":186,"totalTrials":133,"cells":187},"Nitrous oxide",{"EARLY_PHASE1":188,"PHASE1":190,"PHASE2":192,"PHASE3":194,"PHASE4":196,"NA":211},{"trials":189,"activeCount":100},[],{"trials":191,"activeCount":100},[],{"trials":193,"activeCount":100},[],{"trials":195,"activeCount":100},[],{"trials":197,"activeCount":133,"soonestReadout":203},[198],{"nctId":199,"briefTitle":200,"status":201,"phases":202,"primaryCompletion":203,"completion":203,"start":204,"enrollment":205,"conditions":206,"interventions":210},"NCT05895383","Self-Adjusted Nitrous Oxide: A Feasibility Study in the Setting of Vasectomy","RECRUITING",[91],"2027-01-30","2023-05-24",35,[207,208,209],"Procedural Pain","Pain Catastrophizing","Procedural Anxiety",[186],{"trials":212,"activeCount":100},[],{"intervention":214,"totalTrials":133,"cells":215},"Cabotegravir Injection [Apretude]",{"EARLY_PHASE1":216,"PHASE1":218,"PHASE2":220,"PHASE3":222,"PHASE4":224,"NA":238},{"trials":217,"activeCount":100},[],{"trials":219,"activeCount":100},[],{"trials":221,"activeCount":100},[],{"trials":223,"activeCount":100},[],{"trials":225,"activeCount":133,"soonestReadout":230},[226],{"nctId":227,"briefTitle":228,"status":112,"phases":229,"primaryCompletion":230,"completion":231,"start":232,"enrollment":233,"conditions":234,"interventions":237},"NCT05986084","Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana",[91],"2027-08-31","2027-11-30","2023-11-30",500,[235,236],"Pre-Exposure Prophylaxis (PrEP)","Breast Feeding",[214],{"trials":239,"activeCount":100},[],{"intervention":50,"totalTrials":133,"cells":241},{"EARLY_PHASE1":242,"PHASE1":244,"PHASE2":246,"PHASE3":248,"PHASE4":263,"NA":265},{"trials":243,"activeCount":100},[],{"trials":245,"activeCount":100},[],{"trials":247,"activeCount":100},[],{"trials":249,"activeCount":133,"soonestReadout":49},[250],{"nctId":47,"briefTitle":48,"status":112,"phases":251,"primaryCompletion":49,"completion":49,"start":252,"enrollment":253,"conditions":254,"interventions":262},[89,90],"2022-11-17",62,[255,256,257,258,259,260,261],"Pain, Postoperative","Pain, Acute","Pain, Chest","Pain","Satisfaction, Patient","Opioid Use, Unspecified","Opioids; Harmful Use",[50],{"trials":264,"activeCount":100},[],{"trials":266,"activeCount":100},[],{"intervention":268,"totalTrials":133,"cells":269},"Statins",{"EARLY_PHASE1":270,"PHASE1":272,"PHASE2":274,"PHASE3":276,"PHASE4":289,"NA":291},{"trials":271,"activeCount":100},[],{"trials":273,"activeCount":100},[],{"trials":275,"activeCount":100},[],{"trials":277,"activeCount":133,"soonestReadout":282},[278],{"nctId":279,"briefTitle":280,"status":201,"phases":281,"primaryCompletion":282,"completion":283,"start":284,"enrollment":285,"conditions":286,"interventions":288},"NCT03936361","Statins In Intracerbral Hemorrhage",[90],"2028-12-31","2029-12","2020-06-10",1456,[287],"Intracerebral Hemorrhage",[268],{"trials":290,"activeCount":100},[],{"trials":292,"activeCount":100},[],{"intervention":294,"totalTrials":133,"cells":295},"Sleep Hygiene, Brain Game, and IV Acetaminophen Intervention",{"EARLY_PHASE1":296,"PHASE1":298,"PHASE2":300,"PHASE3":302,"PHASE4":317,"NA":319},{"trials":297,"activeCount":100},[],{"trials":299,"activeCount":100},[],{"trials":301,"activeCount":100},[],{"trials":303,"activeCount":133,"soonestReadout":308},[304],{"nctId":305,"briefTitle":306,"status":201,"phases":307,"primaryCompletion":308,"completion":309,"start":310,"enrollment":311,"conditions":312,"interventions":315},"NCT06721819","The SCOPE Trial: Sleep, Cognition, and Pain Bundle vs. ERAS-cardiac for Postoperative Delirium",[90],"2029-06-30","2030-03-31","2025-06-06",406,[313,314],"Delirium, Postoperative","Delirium in Old Age",[294,316],"Control",{"trials":318,"activeCount":100},[],{"trials":320,"activeCount":100},[],{"intervention":316,"totalTrials":133,"cells":322},{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":327,"PHASE3":329,"PHASE4":335,"NA":337},{"trials":324,"activeCount":100},[],{"trials":326,"activeCount":100},[],{"trials":328,"activeCount":100},[],{"trials":330,"activeCount":133,"soonestReadout":308},[331],{"nctId":305,"briefTitle":306,"status":201,"phases":332,"primaryCompletion":308,"completion":309,"start":310,"enrollment":311,"conditions":333,"interventions":334},[90],[313,314],[294,316],{"trials":336,"activeCount":100},[],{"trials":338,"activeCount":100},[],{"intervention":340,"totalTrials":133,"cells":341},"Tiagabine",{"EARLY_PHASE1":342,"PHASE1":344,"PHASE2":346,"PHASE3":348,"PHASE4":358,"NA":360},{"trials":343,"activeCount":100},[],{"trials":345,"activeCount":100},[],{"trials":347,"activeCount":100},[],{"trials":349,"activeCount":133,"soonestReadout":153},[350],{"nctId":351,"briefTitle":352,"status":112,"phases":353,"primaryCompletion":153,"completion":153,"start":354,"enrollment":355,"conditions":356,"interventions":357},"NCT00179465","Treating Schizophrenia by Correcting Abnormal Brain Development",[90],"2003-11",36,[21],[340],{"trials":359,"activeCount":100},[],{"trials":361,"activeCount":100},[],{"intervention":363,"totalTrials":96,"cells":364},"Finasteride",{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":369,"PHASE3":384,"PHASE4":386,"NA":388},{"trials":366,"activeCount":100},[],{"trials":368,"activeCount":100},[],{"trials":370,"activeCount":133,"soonestReadout":375},[371],{"nctId":372,"briefTitle":373,"status":201,"phases":374,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":379,"interventions":382},"NCT06944145","New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia",[89],"2029-06-01","2030-08-31","2025-12-03",242,[380,381],"BPH (Benign Prostatic Hyperplasia)","Lower Urinary Track Symptoms",[383,363],"raloxifene",{"trials":385,"activeCount":100},[],{"trials":387,"activeCount":100},[],{"trials":389,"activeCount":133,"soonestReadout":394},[390],{"nctId":391,"briefTitle":392,"status":201,"phases":393,"primaryCompletion":394,"completion":395,"start":396,"enrollment":397,"conditions":398,"interventions":407},"NCT04288427","5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy",[92],"2026-06-30","2026-11-30","2020-09-25",120,[399,400,401,402,403,404,405,406],"Benign Prostatic Hyperplasia","Prostate Hyperplasia","Prostate Disease","Prostate Hypertrophy","Prostate Pain","Lower Urinary Tract Symptoms","Urinary Obstruction","Urinary Tract Disease",[363],{"intervention":85,"totalTrials":96,"cells":409},{"EARLY_PHASE1":410,"PHASE1":412,"PHASE2":414,"PHASE3":427,"PHASE4":429,"NA":445},{"trials":411,"activeCount":100},[],{"trials":413,"activeCount":100},[],{"trials":415,"activeCount":133,"soonestReadout":84},[416],{"nctId":82,"briefTitle":83,"status":112,"phases":417,"primaryCompletion":84,"completion":418,"start":419,"enrollment":420,"conditions":421,"interventions":425},[89],"2026-06","2025-11-03",300,[422,423,424],"Mechanical Ventilation","Sedation and Analgesia","Critical Care, Intensive Care",[85,426],"Hydromorphone",{"trials":428,"activeCount":100},[],{"trials":430,"activeCount":100},[431],{"nctId":432,"briefTitle":433,"status":434,"phases":435,"primaryCompletion":436,"completion":436,"start":437,"enrollment":100,"conditions":438,"interventions":440},"NCT03613792","Remifentanil Plus Ketamine for Dynamic Flexible Bronchoscopy","WITHDRAWN",[91],"2023-12","2023-09",[439],"Bronchoscopy",[441,442,443,444],"Remifentanil","Fentanyl","Midazolam","Ketamine",{"trials":446,"activeCount":100},[],{"intervention":448,"totalTrials":449,"cells":450},"Cisplatin",3,{"EARLY_PHASE1":451,"PHASE1":453,"PHASE2":455,"PHASE3":499,"PHASE4":501,"NA":503},{"trials":452,"activeCount":100},[],{"trials":454,"activeCount":100},[],{"trials":456,"activeCount":133,"soonestReadout":474},[457,470,487],{"nctId":458,"briefTitle":459,"status":434,"phases":460,"primaryCompletion":461,"completion":461,"start":461,"enrollment":100,"conditions":462,"interventions":463},"NCT00006123","Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer",[88,89],"2000-07",[15],[464,465,466,467,468,469],"trastuzumab","carboplatin","carmustine","cisplatin","cyclophosphamide","thiotepa",{"nctId":471,"briefTitle":472,"status":201,"phases":473,"primaryCompletion":474,"completion":475,"start":476,"enrollment":477,"conditions":478,"interventions":484},"NCT05655949","Y-90 With Durvalumab\u002FGem\u002FCis in Intrahepatic Cholangio",[89],"2026-12-01","2027-12-01","2024-02-13",30,[479,480,481,482,483],"Bile Duct Cancer","Cholangiocarcinoma","Cholangiocarcinoma Non-resectable","Cholangiocarcinoma Metastatic","Metastatic Intrahepatic Cholangiocarcinoma",[485,448,486],"Gemcitabine","Durvalumab",{"nctId":488,"briefTitle":489,"status":122,"phases":490,"primaryCompletion":491,"completion":492,"start":493,"enrollment":494,"conditions":495,"interventions":496},"NCT01670500","Cisplatin vs. Doxorubicin\u002FCyclophosphamide in BrCa",[89],"2019-05","2025-02-02","2012-10",118,[15],[448,497,498],"Cyclophosphamide","Doxorubicin",{"trials":500,"activeCount":100},[],{"trials":502,"activeCount":100},[],{"trials":504,"activeCount":100},[],{"intervention":506,"totalTrials":96,"cells":507},"Hydrocortisone",{"EARLY_PHASE1":508,"PHASE1":510,"PHASE2":512,"PHASE3":538,"PHASE4":540,"NA":542},{"trials":509,"activeCount":100},[],{"trials":511,"activeCount":100},[],{"trials":513,"activeCount":133,"soonestReadout":518},[514,527],{"nctId":515,"briefTitle":516,"status":201,"phases":517,"primaryCompletion":518,"completion":519,"start":520,"enrollment":521,"conditions":522,"interventions":526},"NCT05160506","Corticosteroids to Treat Pancreatitis",[89],"2027-01","2027-04","2022-03-06",86,[523,524,525,506],"Pancreatitis","Pancreatitis, Acute","Corticosteroid",[506],{"nctId":528,"briefTitle":529,"status":122,"phases":530,"primaryCompletion":531,"completion":531,"start":532,"enrollment":533,"conditions":534,"interventions":536},"NCT00676585","Corticosteroid Therapy in Refractory Shock Following Cardiac Arrest",[88,89],"2014-04","2007-10",50,[535],"Cardiac Arrest",[537,506],"Normal Saline",{"trials":539,"activeCount":100},[],{"trials":541,"activeCount":100},[],{"trials":543,"activeCount":100},[],{"intervention":40,"totalTrials":96,"cells":545},{"EARLY_PHASE1":546,"PHASE1":548,"PHASE2":550,"PHASE3":571,"PHASE4":573,"NA":575},{"trials":547,"activeCount":100},[],{"trials":549,"activeCount":100},[],{"trials":551,"activeCount":133,"soonestReadout":39},[552,564],{"nctId":553,"briefTitle":554,"status":555,"phases":556,"primaryCompletion":557,"completion":557,"start":558,"enrollment":559,"conditions":560,"interventions":562},"NCT03782064","Dendritic Cell (DC)\u002FMyeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma","TERMINATED",[89],"2021-01-31","2019-02-22",5,[561],"Multiple Myeloma",[40,563],"DC\u002Fmyeloma fusions\u002FGM-CSF",{"nctId":37,"briefTitle":38,"status":112,"phases":565,"primaryCompletion":39,"completion":566,"start":567,"enrollment":568,"conditions":569,"interventions":570},[89],"2026-12-31","2018-10-18",29,[27],[40],{"trials":572,"activeCount":100},[],{"trials":574,"activeCount":100},[],{"trials":576,"activeCount":100},[],{"intervention":45,"totalTrials":96,"cells":578},{"EARLY_PHASE1":579,"PHASE1":581,"PHASE2":594,"PHASE3":605,"PHASE4":607,"NA":609},{"trials":580,"activeCount":100},[],{"trials":582,"activeCount":100},[583],{"nctId":584,"briefTitle":585,"status":122,"phases":586,"primaryCompletion":587,"completion":588,"start":589,"enrollment":25,"conditions":590,"interventions":592},"NCT00631072","In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer",[88],"2014-08","2015-04","2008-02",[591],"Malignant Melanoma",[593,45],"INKT",{"trials":595,"activeCount":133,"soonestReadout":44},[596],{"nctId":42,"briefTitle":43,"status":112,"phases":597,"primaryCompletion":44,"completion":44,"start":598,"enrollment":16,"conditions":599,"interventions":602},[89],"2008-08",[32,600,601],"Primary Peritoneal Cancer","Fallopian Tube Cancer",[45,603,604],"Dendritic Cell\u002FTumor Fusion Vaccine","imiquimod",{"trials":606,"activeCount":100},[],{"trials":608,"activeCount":100},[],{"trials":610,"activeCount":100},[],{"intervention":603,"totalTrials":96,"cells":612},{"EARLY_PHASE1":613,"PHASE1":615,"PHASE2":617,"PHASE3":631,"PHASE4":633,"NA":635},{"trials":614,"activeCount":100},[],{"trials":616,"activeCount":100},[],{"trials":618,"activeCount":133,"soonestReadout":44},[619,623],{"nctId":42,"briefTitle":43,"status":112,"phases":620,"primaryCompletion":44,"completion":44,"start":598,"enrollment":16,"conditions":621,"interventions":622},[89],[32,600,601],[45,603,604],{"nctId":624,"briefTitle":625,"status":555,"phases":626,"primaryCompletion":180,"completion":180,"start":627,"enrollment":30,"conditions":628,"interventions":629},"NCT00622401","Vaccination of Patients With Breast Cancer With Dendritic Cell\u002FTumor Fusions and IL-12",[88,89],"2009-12",[15],[603,630,630],"Interleukin-12",{"trials":632,"activeCount":100},[],{"trials":634,"activeCount":100},[],{"trials":636,"activeCount":100},[],{"intervention":55,"totalTrials":133,"cells":638},{"EARLY_PHASE1":639,"PHASE1":641,"PHASE2":643,"PHASE3":661,"PHASE4":663,"NA":665},{"trials":640,"activeCount":100},[],{"trials":642,"activeCount":100},[],{"trials":644,"activeCount":133,"soonestReadout":54},[645],{"nctId":52,"briefTitle":53,"status":112,"phases":646,"primaryCompletion":54,"completion":394,"start":647,"enrollment":648,"conditions":649,"interventions":660},[89],"2018-04-01",114,[650,651,652,653,654,655,656,657,658,659],"Metastatic Breast Cancer","Invasive Breast Cancer","Somatic Mutation Breast Cancer (BRCA1)","Somatic Mutation Breast Cancer (BRCA2)","CHEK2 Gene Mutation","ATM Gene Mutation","PALB2 Gene Mutation","RAD51 Gene Mutation","BRIP1 Gene Mutation","NBN Gene Mutation",[55],{"trials":662,"activeCount":100},[],{"trials":664,"activeCount":100},[],{"trials":666,"activeCount":100},[],{"intervention":668,"totalTrials":133,"cells":669},"topical vaginal application lidocaine gel",{"EARLY_PHASE1":670,"PHASE1":672,"PHASE2":674,"PHASE3":686,"PHASE4":688,"NA":690},{"trials":671,"activeCount":100},[],{"trials":673,"activeCount":100},[],{"trials":675,"activeCount":133,"soonestReadout":114},[676],{"nctId":677,"briefTitle":678,"status":679,"phases":680,"primaryCompletion":114,"completion":114,"start":681,"enrollment":682,"conditions":683,"interventions":685},"NCT07268118","Pain Control for Cervical Ripening Balloon","NOT_YET_RECRUITING",[89],"2026-04",110,[684],"Labor Induction",[668],{"trials":687,"activeCount":100},[],{"trials":689,"activeCount":100},[],{"trials":691,"activeCount":100},[],{"intervention":426,"totalTrials":133,"cells":693},{"EARLY_PHASE1":694,"PHASE1":696,"PHASE2":698,"PHASE3":704,"PHASE4":706,"NA":708},{"trials":695,"activeCount":100},[],{"trials":697,"activeCount":100},[],{"trials":699,"activeCount":133,"soonestReadout":84},[700],{"nctId":82,"briefTitle":83,"status":112,"phases":701,"primaryCompletion":84,"completion":418,"start":419,"enrollment":420,"conditions":702,"interventions":703},[89],[422,423,424],[85,426],{"trials":705,"activeCount":100},[],{"trials":707,"activeCount":100},[],{"trials":709,"activeCount":100},[],{"intervention":711,"totalTrials":133,"cells":712},"Normal Saline 10 mL",{"EARLY_PHASE1":713,"PHASE1":715,"PHASE2":717,"PHASE3":730,"PHASE4":732,"NA":734},{"trials":714,"activeCount":100},[],{"trials":716,"activeCount":100},[],{"trials":718,"activeCount":133,"soonestReadout":723},[719],{"nctId":720,"briefTitle":721,"status":201,"phases":722,"primaryCompletion":723,"completion":724,"start":725,"enrollment":726,"conditions":727,"interventions":729},"NCT07404982","Reversal of Spinal Anesthesia Residual Motor Block Via Intrathecal Catheter",[89],"2026-12","2027-12","2026-03-19",20,[728],"Joint Replacement Surgery",[711],{"trials":731,"activeCount":100},[],{"trials":733,"activeCount":100},[],{"trials":735,"activeCount":100},[],{"intervention":485,"totalTrials":133,"cells":737},{"EARLY_PHASE1":738,"PHASE1":740,"PHASE2":742,"PHASE3":748,"PHASE4":750,"NA":752},{"trials":739,"activeCount":100},[],{"trials":741,"activeCount":100},[],{"trials":743,"activeCount":133,"soonestReadout":474},[744],{"nctId":471,"briefTitle":472,"status":201,"phases":745,"primaryCompletion":474,"completion":475,"start":476,"enrollment":477,"conditions":746,"interventions":747},[89],[479,480,481,482,483],[485,448,486],{"trials":749,"activeCount":100},[],{"trials":751,"activeCount":100},[],{"trials":753,"activeCount":100},[],{"intervention":486,"totalTrials":133,"cells":755},{"EARLY_PHASE1":756,"PHASE1":758,"PHASE2":760,"PHASE3":766,"PHASE4":768,"NA":770},{"trials":757,"activeCount":100},[],{"trials":759,"activeCount":100},[],{"trials":761,"activeCount":133,"soonestReadout":474},[762],{"nctId":471,"briefTitle":472,"status":201,"phases":763,"primaryCompletion":474,"completion":475,"start":476,"enrollment":477,"conditions":764,"interventions":765},[89],[479,480,481,482,483],[485,448,486],{"trials":767,"activeCount":100},[],{"trials":769,"activeCount":100},[],{"trials":771,"activeCount":100},[],{"intervention":773,"totalTrials":133,"cells":774},"DC\u002FAML Fusion Vaccine",{"EARLY_PHASE1":775,"PHASE1":777,"PHASE2":779,"PHASE3":792,"PHASE4":794,"NA":796},{"trials":776,"activeCount":100},[],{"trials":778,"activeCount":100},[],{"trials":780,"activeCount":133,"soonestReadout":785},[781],{"nctId":782,"briefTitle":783,"status":112,"phases":784,"primaryCompletion":785,"completion":786,"start":787,"enrollment":788,"conditions":789,"interventions":791},"NCT03059485","DC\u002FAML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission",[89],"2026-09-04","2026-12-04","2017-06-01",82,[790],"Acute Myelogenous Leukemia",[773],{"trials":793,"activeCount":100},[],{"trials":795,"activeCount":100},[],{"trials":797,"activeCount":100},[],{"intervention":604,"totalTrials":133,"cells":799},{"EARLY_PHASE1":800,"PHASE1":802,"PHASE2":804,"PHASE3":810,"PHASE4":812,"NA":814},{"trials":801,"activeCount":100},[],{"trials":803,"activeCount":100},[],{"trials":805,"activeCount":133,"soonestReadout":44},[806],{"nctId":42,"briefTitle":43,"status":112,"phases":807,"primaryCompletion":44,"completion":44,"start":598,"enrollment":16,"conditions":808,"interventions":809},[89],[32,600,601],[45,603,604],{"trials":811,"activeCount":100},[],{"trials":813,"activeCount":100},[],{"trials":815,"activeCount":100},[],{"intervention":817,"totalTrials":133,"cells":818},"Roflumilast 0.3% topical foam",{"EARLY_PHASE1":819,"PHASE1":821,"PHASE2":823,"PHASE3":835,"PHASE4":837,"NA":839},{"trials":820,"activeCount":100},[],{"trials":822,"activeCount":100},[],{"trials":824,"activeCount":133,"soonestReadout":829},[825],{"nctId":826,"briefTitle":827,"status":201,"phases":828,"primaryCompletion":829,"completion":830,"start":831,"enrollment":726,"conditions":832,"interventions":834},"NCT07263230","The Safety and Efficacy of Roflumilast Foam in HS",[89],"2028-03","2028-12","2026-04-01",[833],"Hidradenitis Suppurativa (HS)",[817],{"trials":836,"activeCount":100},[],{"trials":838,"activeCount":100},[],{"trials":840,"activeCount":100},[],{"intervention":75,"totalTrials":133,"cells":842},{"EARLY_PHASE1":843,"PHASE1":845,"PHASE2":847,"PHASE3":858,"PHASE4":860,"NA":862},{"trials":844,"activeCount":100},[],{"trials":846,"activeCount":100},[],{"trials":848,"activeCount":133,"soonestReadout":74},[849],{"nctId":72,"briefTitle":73,"status":112,"phases":850,"primaryCompletion":74,"completion":851,"start":852,"enrollment":853,"conditions":854,"interventions":857},[89],"2026-09-30","2024-12-27",46,[855,856],"Post-COVID Condition","Fatigue Symptom",[75],{"trials":859,"activeCount":100},[],{"trials":861,"activeCount":100},[],{"trials":863,"activeCount":100},[],{"intervention":865,"totalTrials":133,"cells":866},"Fresh Frozen Plasma",{"EARLY_PHASE1":867,"PHASE1":869,"PHASE2":871,"PHASE3":885,"PHASE4":887,"NA":889},{"trials":868,"activeCount":100},[],{"trials":870,"activeCount":100},[],{"trials":872,"activeCount":133,"soonestReadout":877},[873],{"nctId":874,"briefTitle":875,"status":679,"phases":876,"primaryCompletion":877,"completion":878,"start":879,"enrollment":880,"conditions":881,"interventions":883},"NCT07160426","Study of Protection And Repair of Endothelial-glycocalyx in Sepsis (SPARES)",[89],"2028-06-01","2028-12-01","2026-07-01",45,[882],"Sepsis",[865,884],"MVI and lactated ringers",{"trials":886,"activeCount":100},[],{"trials":888,"activeCount":100},[],{"trials":890,"activeCount":100},[],{"intervention":884,"totalTrials":133,"cells":892},{"EARLY_PHASE1":893,"PHASE1":895,"PHASE2":897,"PHASE3":903,"PHASE4":905,"NA":907},{"trials":894,"activeCount":100},[],{"trials":896,"activeCount":100},[],{"trials":898,"activeCount":133,"soonestReadout":877},[899],{"nctId":874,"briefTitle":875,"status":679,"phases":900,"primaryCompletion":877,"completion":878,"start":879,"enrollment":880,"conditions":901,"interventions":902},[89],[882],[865,884],{"trials":904,"activeCount":100},[],{"trials":906,"activeCount":100},[],{"trials":908,"activeCount":100},[],{"intervention":910,"totalTrials":133,"cells":911},"Pleural Saline Irrigation",{"EARLY_PHASE1":912,"PHASE1":914,"PHASE2":916,"PHASE3":931,"PHASE4":933,"NA":935},{"trials":913,"activeCount":100},[],{"trials":915,"activeCount":100},[],{"trials":917,"activeCount":133,"soonestReadout":922},[918],{"nctId":919,"briefTitle":920,"status":201,"phases":921,"primaryCompletion":922,"completion":923,"start":924,"enrollment":925,"conditions":926,"interventions":930},"NCT06713382","Evaluating the Efficacy and Safety of Saline Irrigation as an Add-On Therapy for Retained Pleural Infections [LYTICS +]",[89],"2026-11-20","2026-12-20","2025-04-10",96,[927,928,929],"Pleural Effusion Associated With Pulmonary Infection","Pleural Effusion Disorder","Pleural Effusions",[910],{"trials":932,"activeCount":100},[],{"trials":934,"activeCount":100},[],{"trials":936,"activeCount":100},[],{"intervention":938,"totalTrials":133,"cells":939},"Epcoritamab",{"EARLY_PHASE1":940,"PHASE1":942,"PHASE2":944,"PHASE3":959,"PHASE4":961,"NA":963},{"trials":941,"activeCount":100},[],{"trials":943,"activeCount":100},[],{"trials":945,"activeCount":133,"soonestReadout":950},[946],{"nctId":947,"briefTitle":948,"status":201,"phases":949,"primaryCompletion":950,"completion":951,"start":952,"enrollment":205,"conditions":953,"interventions":958},"NCT06510361","Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy",[89],"2026-05-01","2028-05-01","2024-11-20",[954,955,956,957],"Lymphoma","Follicular Lymphoma","Lymphoma,Non-Hodgkin","Lymphoma, Non-Hodgkin's, Adult",[938],{"trials":960,"activeCount":100},[],{"trials":962,"activeCount":100},[],{"trials":964,"activeCount":100},[],{"intervention":966,"totalTrials":133,"cells":967},"Fulvestrant",{"EARLY_PHASE1":968,"PHASE1":970,"PHASE2":972,"PHASE3":982,"PHASE4":984,"NA":986},{"trials":969,"activeCount":100},[],{"trials":971,"activeCount":100},[],{"trials":973,"activeCount":133,"soonestReadout":978},[974],{"nctId":975,"briefTitle":976,"status":112,"phases":977,"primaryCompletion":978,"completion":978,"start":979,"enrollment":11,"conditions":980,"interventions":981},"NCT00585507","Efficacy and Safety of 500mg of Fulvestrant",[89],"2027-03-15","2004-04",[15],[966],{"trials":983,"activeCount":100},[],{"trials":985,"activeCount":100},[],{"trials":987,"activeCount":100},[],{"intervention":383,"totalTrials":133,"cells":989},{"EARLY_PHASE1":990,"PHASE1":992,"PHASE2":994,"PHASE3":1000,"PHASE4":1002,"NA":1004},{"trials":991,"activeCount":100},[],{"trials":993,"activeCount":100},[],{"trials":995,"activeCount":133,"soonestReadout":375},[996],{"nctId":372,"briefTitle":373,"status":201,"phases":997,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":998,"interventions":999},[89],[380,381],[383,363],{"trials":1001,"activeCount":100},[],{"trials":1003,"activeCount":100},[],{"trials":1005,"activeCount":100},[],{"intervention":80,"totalTrials":133,"cells":1007},{"EARLY_PHASE1":1008,"PHASE1":1010,"PHASE2":1018,"PHASE3":1020,"PHASE4":1022,"NA":1024},{"trials":1009,"activeCount":100},[],{"trials":1011,"activeCount":133,"soonestReadout":79},[1012],{"nctId":77,"briefTitle":78,"status":112,"phases":1013,"primaryCompletion":79,"completion":1014,"start":1015,"enrollment":116,"conditions":1016,"interventions":1017},[88],"2026-08-31","2018-10-11",[790],[80],{"trials":1019,"activeCount":100},[],{"trials":1021,"activeCount":100},[],{"trials":1023,"activeCount":100},[],{"trials":1025,"activeCount":100},[],{"intervention":70,"totalTrials":1027,"cells":1028},4,{"EARLY_PHASE1":1029,"PHASE1":1062,"PHASE2":1064,"PHASE3":1078,"PHASE4":1080,"NA":1082},{"trials":1030,"activeCount":133,"soonestReadout":69},[1031,1043,1053],{"nctId":1032,"briefTitle":1033,"status":122,"phases":1034,"primaryCompletion":1035,"completion":1036,"start":1037,"enrollment":1038,"conditions":1039,"interventions":1041},"NCT04822363","The Accuracy Of A Novel Platelet Activity Assay In Humans On Antiplatelet Agents: Pharmacodynamics And Comparison With Light Transmission Aggregometry",[87],"2025-05-09","2025-06-30","2021-08-20",112,[1040,24],"Platelet Activation Testing Before\u002FAfter Anti-platelet Therapy",[70,1042],"Clopidogrel",{"nctId":67,"briefTitle":68,"status":112,"phases":1044,"primaryCompletion":69,"completion":69,"start":1045,"enrollment":1046,"conditions":1047,"interventions":1052},[87],"2018-06-06",66,[1048,1049,1050,1051],"Inflammatory Response","Inflammation","Sleep","Sleep Restriction",[70],{"nctId":1054,"briefTitle":1055,"status":122,"phases":1056,"primaryCompletion":1057,"completion":1058,"start":180,"enrollment":30,"conditions":1059,"interventions":1061},"NCT02268565","Preventing the Inflammatory Response to Experimentally-induced Insomnia Symptoms",[87],"2016-10","2016-12",[1060],"Insomnia",[70],{"trials":1063,"activeCount":100},[],{"trials":1065,"activeCount":100},[1066],{"nctId":1067,"briefTitle":1068,"status":122,"phases":1069,"primaryCompletion":1070,"completion":1070,"start":1071,"enrollment":1072,"conditions":1073,"interventions":1076},"NCT01976806","The Effects of DHA on Periodontitis",[89],"2011-09","2009-06",55,[1074,1075,1049],"Periodontitis","Gingivitis",[70,1077],"Docosahexaenoic acid",{"trials":1079,"activeCount":100},[],{"trials":1081,"activeCount":100},[],{"trials":1083,"activeCount":100},[],{"intervention":65,"totalTrials":133,"cells":1085},{"EARLY_PHASE1":1086,"PHASE1":1096,"PHASE2":1098,"PHASE3":1100,"PHASE4":1102,"NA":1104},{"trials":1087,"activeCount":133,"soonestReadout":64},[1088],{"nctId":62,"briefTitle":63,"status":112,"phases":1089,"primaryCompletion":64,"completion":1090,"start":1091,"enrollment":25,"conditions":1092,"interventions":1095},[87],"2026-09-01","2023-01-19",[1093,27,1094],"Prostate Adenocarcinoma","Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)",[65],{"trials":1097,"activeCount":100},[],{"trials":1099,"activeCount":100},[],{"trials":1101,"activeCount":100},[],{"trials":1103,"activeCount":100},[],{"trials":1105,"activeCount":100},[],{"intervention":60,"totalTrials":133,"cells":1107},{"EARLY_PHASE1":1108,"PHASE1":1110,"PHASE2":1112,"PHASE3":1114,"PHASE4":1116,"NA":1118},{"trials":1109,"activeCount":100},[],{"trials":1111,"activeCount":100},[],{"trials":1113,"activeCount":100},[],{"trials":1115,"activeCount":100},[],{"trials":1117,"activeCount":100},[],{"trials":1119,"activeCount":133,"soonestReadout":59},[1120],{"nctId":57,"briefTitle":58,"status":112,"phases":1121,"primaryCompletion":59,"completion":1122,"start":1123,"enrollment":1124,"conditions":1125,"interventions":1137},[],"2026-06-01","2025-06-08",70000,[1126,1127,1128,1129,1130,1131,1132,1133,1134,1135,1136],"Neuromuscular Blocking Agents","Urinary Retention After Procedure","Urinary Retention Postoperative","Neuromuscular Blockade Reversal Agent","Neuromuscular Blockade","Costs","Atropine","Sugammadex","Glycopyrrolate","Neostigmine","Anesthesia",[60],{"intervention":1139,"totalTrials":133,"cells":1140},"Lecanemab",{"EARLY_PHASE1":1141,"PHASE1":1143,"PHASE2":1145,"PHASE3":1147,"PHASE4":1149,"NA":1151},{"trials":1142,"activeCount":100},[],{"trials":1144,"activeCount":100},[],{"trials":1146,"activeCount":100},[],{"trials":1148,"activeCount":100},[],{"trials":1150,"activeCount":100},[],{"trials":1152,"activeCount":133,"soonestReadout":1157},[1153],{"nctId":1154,"briefTitle":1155,"status":201,"phases":1156,"primaryCompletion":1157,"completion":1157,"start":1158,"enrollment":233,"conditions":1159,"interventions":1161},"NCT05925621","Cognitive Neurology Unit Clinical Registry",[],"2028-06","2023-07-16",[1160],"Alzheimer Disease",[1139],{"intervention":1163,"totalTrials":133,"cells":1164},"Anti-Parkinson medication",{"EARLY_PHASE1":1165,"PHASE1":1167,"PHASE2":1169,"PHASE3":1171,"PHASE4":1173,"NA":1175},{"trials":1166,"activeCount":100},[],{"trials":1168,"activeCount":100},[],{"trials":1170,"activeCount":100},[],{"trials":1172,"activeCount":100},[],{"trials":1174,"activeCount":100},[],{"trials":1176,"activeCount":133,"soonestReadout":1181},[1177],{"nctId":1178,"briefTitle":1179,"status":201,"phases":1180,"primaryCompletion":1181,"completion":1181,"start":1182,"enrollment":397,"conditions":1183,"interventions":1192},"NCT02994719","Gait Analysis in Neurological Disease",[],"2026-06-20","2016-03-01",[1184,1185,1186,1187,1188,1189,1190,1191],"Parkinson's Disease","Parkinsonian Disorders","Atypical Parkinson Disease","Progressive Supranuclear Palsy","Multiple System Atrophy","Corticobasal Degeneration","Gait, Frontal","Huntington Disease",[1163],{"intervention":1194,"totalTrials":133,"cells":1195},"Blood sample for DNA analysis",{"EARLY_PHASE1":1196,"PHASE1":1198,"PHASE2":1200,"PHASE3":1202,"PHASE4":1204,"NA":1206},{"trials":1197,"activeCount":100},[],{"trials":1199,"activeCount":100},[],{"trials":1201,"activeCount":100},[],{"trials":1203,"activeCount":100},[],{"trials":1205,"activeCount":100},[],{"trials":1207,"activeCount":133,"soonestReadout":1212},[1208],{"nctId":1209,"briefTitle":1210,"status":201,"phases":1211,"primaryCompletion":1212,"completion":1212,"start":1213,"enrollment":11,"conditions":1214,"interventions":1217},"NCT04352244","The Physiology of Human Brown Adipose Tissue",[],"2027-06-30","2020-03-05",[1215,1216,18],"Adipose Tissue, Brown","Adipose Tissue",[1194],{"intervention":1219,"totalTrials":559,"cells":1220},"Normal saline",{"EARLY_PHASE1":1221,"PHASE1":1223,"PHASE2":1225,"PHASE3":1251,"PHASE4":1265,"NA":1279},{"trials":1222,"activeCount":100},[],{"trials":1224,"activeCount":100},[],{"trials":1226,"activeCount":100},[1227,1236,1240],{"nctId":1228,"briefTitle":1229,"status":122,"phases":1230,"primaryCompletion":1231,"completion":1231,"start":180,"enrollment":1232,"conditions":1233,"interventions":1234},"NCT02260258","Neuromuscular Blockade for Post-Cardiac Arrest Care",[89],"2019-05-29",83,[535],[1235,537],"Rocuronium",{"nctId":528,"briefTitle":529,"status":122,"phases":1237,"primaryCompletion":531,"completion":531,"start":532,"enrollment":533,"conditions":1238,"interventions":1239},[88,89],[535],[537,506],{"nctId":1241,"briefTitle":1242,"status":555,"phases":1243,"primaryCompletion":1244,"completion":1245,"start":1246,"enrollment":1247,"conditions":1248,"interventions":1249},"NCT01662895","High-Dose Deferoxamine in Intracerebral Hemorrhage",[89],"2014-01-15","2018-05-10","2013-03-18",42,[287],[1250,1219],"Deferoxamine",{"trials":1252,"activeCount":100},[1253],{"nctId":1254,"briefTitle":1255,"status":122,"phases":1256,"primaryCompletion":1257,"completion":1258,"start":1259,"enrollment":1260,"conditions":1261,"interventions":1263},"NCT03389555","Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial",[89,90],"2019-11-26","2020-02-28","2018-02-09",205,[882,34,1262],"Metabolic Disturbance",[1264,1219],"vitamin C, vitamin B1, hydrocortisone",{"trials":1266,"activeCount":100},[1267],{"nctId":1268,"briefTitle":1269,"status":122,"phases":1270,"primaryCompletion":1271,"completion":1272,"start":1273,"enrollment":1274,"conditions":1275,"interventions":1277},"NCT04218695","Prophylactic Antibiotics in Admitted Cirrhotics",[91],"2021-05-31","2021-08-28","2020-08-24",32,[1276],"Cirrhosis, Liver",[1278,1219],"Ceftriaxone",{"trials":1280,"activeCount":100},[],{"intervention":1282,"totalTrials":449,"cells":1283},"Placebos",{"EARLY_PHASE1":1284,"PHASE1":1295,"PHASE2":1297,"PHASE3":1312,"PHASE4":1314,"NA":1333},{"trials":1285,"activeCount":100},[1286],{"nctId":1287,"briefTitle":1288,"status":555,"phases":1289,"primaryCompletion":1290,"completion":1290,"start":1291,"enrollment":9,"conditions":1292,"interventions":1294},"NCT03745781","Open-Label Placebo for Functional Dyspepsia",[87],"2019-10-07","2018-12-01",[1293],"Dyspepsia",[1282],{"trials":1296,"activeCount":100},[],{"trials":1298,"activeCount":100},[1299],{"nctId":1300,"briefTitle":1301,"status":555,"phases":1302,"primaryCompletion":1303,"completion":1304,"start":1305,"enrollment":30,"conditions":1306,"interventions":1309},"NCT03070730","Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist",[88,89],"2012-12-18","2014-07-28","2011-08-15",[1307,1308],"Postural Orthostatic Tachycardia Syndrome","Orthostatic Intolerance",[1310,1311,1282],"Droxidopa","Atenolol",{"trials":1313,"activeCount":100},[],{"trials":1315,"activeCount":100},[1316],{"nctId":1317,"briefTitle":1318,"status":122,"phases":1319,"primaryCompletion":1320,"completion":1321,"start":1322,"enrollment":11,"conditions":1323,"interventions":1331},"NCT03805607","IV Ketorolac on Platelet Function Post-Cesarean Delivery",[91],"2022-02-03","2024-03-30","2021-01-18",[1324,1325,1326,1327,1328,1329,1330],"Analgesia, Obstetrical","Coagulation Defect; Postpartum","Nonsteroidals (NSAIDs)Toxicity","Postpartum Hemorrhage","Postoperative Pain","Ketorolac Adverse Reaction","Blood Loss, Postoperative",[1332,1282],"Ketorolac Tromethamine 30 MG\u002FML",{"trials":1334,"activeCount":100},[],{"intervention":1336,"totalTrials":96,"cells":1337},"Dexamethasone",{"EARLY_PHASE1":1338,"PHASE1":1340,"PHASE2":1342,"PHASE3":1356,"PHASE4":1358,"NA":1372},{"trials":1339,"activeCount":100},[],{"trials":1341,"activeCount":100},[],{"trials":1343,"activeCount":100},[1344],{"nctId":1345,"briefTitle":1346,"status":122,"phases":1347,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":116,"conditions":1350,"interventions":1351},"NCT01250717","Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer",[89],"2011-05","2001-01",[27],[1352,1336,1353,1354,1355],"Docetaxel","Estramustine","Zoladex","Casodex",{"trials":1357,"activeCount":100},[],{"trials":1359,"activeCount":100},[1360],{"nctId":1361,"briefTitle":1362,"status":122,"phases":1363,"primaryCompletion":1364,"completion":1364,"start":1365,"enrollment":1366,"conditions":1367,"interventions":1370},"NCT05692245","Dexamethasone vs Ondansetron After Cesarean Delivery",[91],"2024-04-30","2023-03-30",100,[1368,1369],"Nausea and Vomiting, Postoperative","Cesarean Section Complications",[1371,1336],"Ondansetron",{"trials":1373,"activeCount":100},[],{"intervention":1375,"totalTrials":96,"cells":1376},"Self-Administered Nitrous Oxide",{"EARLY_PHASE1":1377,"PHASE1":1379,"PHASE2":1381,"PHASE3":1383,"PHASE4":1385,"NA":1409},{"trials":1378,"activeCount":100},[],{"trials":1380,"activeCount":100},[],{"trials":1382,"activeCount":100},[],{"trials":1384,"activeCount":100},[],{"trials":1386,"activeCount":100},[1387,1399],{"nctId":1388,"briefTitle":1389,"status":122,"phases":1390,"primaryCompletion":1391,"completion":1392,"start":1393,"enrollment":1394,"conditions":1395,"interventions":1398},"NCT05803096","Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain",[91],"2022-09-02","2022-09-09","2021-12-12",143,[401,1396,399,27,1093,1397,258],"Malignancy","Anxiety and Fear",[1375],{"nctId":1400,"briefTitle":1401,"status":122,"phases":1402,"primaryCompletion":1403,"completion":1404,"start":1405,"enrollment":1406,"conditions":1407,"interventions":1408},"NCT05883332","A Pilot Study to Assess Effects of Self-Administered Nitrous Oxide (SANO) on Urodynamic Study (UDS) Parameters",[91],"2023-03-02","2023-03-09","2023-01-10",19,[404],[1375],{"trials":1410,"activeCount":100},[],{"intervention":1412,"totalTrials":133,"cells":1413},"Oxytocin",{"EARLY_PHASE1":1414,"PHASE1":1416,"PHASE2":1418,"PHASE3":1420,"PHASE4":1422,"NA":1435},{"trials":1415,"activeCount":100},[],{"trials":1417,"activeCount":100},[],{"trials":1419,"activeCount":100},[],{"trials":1421,"activeCount":100},[],{"trials":1423,"activeCount":100},[1424],{"nctId":1425,"briefTitle":1426,"status":434,"phases":1427,"primaryCompletion":1428,"completion":1429,"start":1430,"enrollment":100,"conditions":1431,"interventions":1434},"NCT05608070","IV Oxytocin for Post Operative Pain After Minimally Invasive Hysterectomy",[91],"2024-06","2025-06","2023-06-01",[255,1432,1328,1433,1412],"Analgesia","Pain, Post Operative",[1412],{"trials":1436,"activeCount":100},[],{"intervention":1332,"totalTrials":133,"cells":1438},{"EARLY_PHASE1":1439,"PHASE1":1441,"PHASE2":1443,"PHASE3":1445,"PHASE4":1447,"NA":1453},{"trials":1440,"activeCount":100},[],{"trials":1442,"activeCount":100},[],{"trials":1444,"activeCount":100},[],{"trials":1446,"activeCount":100},[],{"trials":1448,"activeCount":100},[1449],{"nctId":1317,"briefTitle":1318,"status":122,"phases":1450,"primaryCompletion":1320,"completion":1321,"start":1322,"enrollment":11,"conditions":1451,"interventions":1452},[91],[1324,1325,1326,1327,1328,1329,1330],[1332,1282],{"trials":1454,"activeCount":100},[],{"intervention":1456,"totalTrials":133,"cells":1457},"First Treatment Period",{"EARLY_PHASE1":1458,"PHASE1":1460,"PHASE2":1462,"PHASE3":1464,"PHASE4":1466,"NA":1478},{"trials":1459,"activeCount":100},[],{"trials":1461,"activeCount":100},[],{"trials":1463,"activeCount":100},[],{"trials":1465,"activeCount":100},[],{"trials":1467,"activeCount":100},[1468],{"nctId":1469,"briefTitle":1470,"status":122,"phases":1471,"primaryCompletion":1472,"completion":1058,"start":1473,"enrollment":9,"conditions":1474,"interventions":1476},"NCT02322879","Protective Effects of Propylene Glycol in Daily Acetaminophen Dosing",[91],"2016-08","2013-05",[1475],"Acetaminophen Toxicity",[1456,1477],"Second Treatment Period",{"trials":1479,"activeCount":100},[],{"intervention":1477,"totalTrials":133,"cells":1481},{"EARLY_PHASE1":1482,"PHASE1":1484,"PHASE2":1486,"PHASE3":1488,"PHASE4":1490,"NA":1496},{"trials":1483,"activeCount":100},[],{"trials":1485,"activeCount":100},[],{"trials":1487,"activeCount":100},[],{"trials":1489,"activeCount":100},[],{"trials":1491,"activeCount":100},[1492],{"nctId":1469,"briefTitle":1470,"status":122,"phases":1493,"primaryCompletion":1472,"completion":1058,"start":1473,"enrollment":9,"conditions":1494,"interventions":1495},[91],[1475],[1456,1477],{"trials":1497,"activeCount":100},[],{"intervention":1126,"totalTrials":133,"cells":1499},{"EARLY_PHASE1":1500,"PHASE1":1502,"PHASE2":1504,"PHASE3":1506,"PHASE4":1508,"NA":1525},{"trials":1501,"activeCount":100},[],{"trials":1503,"activeCount":100},[],{"trials":1505,"activeCount":100},[],{"trials":1507,"activeCount":100},[],{"trials":1509,"activeCount":100},[1510],{"nctId":1511,"briefTitle":1512,"status":555,"phases":1513,"primaryCompletion":1514,"completion":1514,"start":1515,"enrollment":449,"conditions":1516,"interventions":1523},"NCT03962725","Avoiding Neuromuscular Blockers to Reduce Complications",[91],"2022-12-19","2019-08-07",[1517,1518,1519,1520,1521,1522],"Respiratory Failure","Respiratory Infection","Aspiration Pneumonia","Pneumonitis","Atelectasis","Bronchospasm",[1126,1524],"Anesthetic Adjuncts",{"trials":1526,"activeCount":100},[],{"intervention":1524,"totalTrials":133,"cells":1528},{"EARLY_PHASE1":1529,"PHASE1":1531,"PHASE2":1533,"PHASE3":1535,"PHASE4":1537,"NA":1543},{"trials":1530,"activeCount":100},[],{"trials":1532,"activeCount":100},[],{"trials":1534,"activeCount":100},[],{"trials":1536,"activeCount":100},[],{"trials":1538,"activeCount":100},[1539],{"nctId":1511,"briefTitle":1512,"status":555,"phases":1540,"primaryCompletion":1514,"completion":1514,"start":1515,"enrollment":449,"conditions":1541,"interventions":1542},[91],[1517,1518,1519,1520,1521,1522],[1126,1524],{"trials":1544,"activeCount":100},[],{"intervention":1546,"totalTrials":133,"cells":1547},"interferon beta 1a 30 ug IM once weekly",{"EARLY_PHASE1":1548,"PHASE1":1550,"PHASE2":1552,"PHASE3":1554,"PHASE4":1556,"NA":1571},{"trials":1549,"activeCount":100},[],{"trials":1551,"activeCount":100},[],{"trials":1553,"activeCount":100},[],{"trials":1555,"activeCount":100},[],{"trials":1557,"activeCount":100},[1558],{"nctId":1559,"briefTitle":1560,"status":122,"phases":1561,"primaryCompletion":1562,"completion":1562,"start":1563,"enrollment":1564,"conditions":1565,"interventions":1570},"NCT00179478","Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis",[91],"2009-03","2001-02",155,[1566,1567,1568,1569],"Multiple Sclerosis","Optic Neuritis","Transverse Myelitis","Acute Brainstem\u002FCerebellar Syndrome",[1546],{"trials":1572,"activeCount":100},[],{"intervention":1574,"totalTrials":133,"cells":1575},"pancrelipase",{"EARLY_PHASE1":1576,"PHASE1":1578,"PHASE2":1580,"PHASE3":1582,"PHASE4":1584,"NA":1596},{"trials":1577,"activeCount":100},[],{"trials":1579,"activeCount":100},[],{"trials":1581,"activeCount":100},[],{"trials":1583,"activeCount":100},[],{"trials":1585,"activeCount":100},[1586],{"nctId":1587,"briefTitle":1588,"status":555,"phases":1589,"primaryCompletion":1590,"completion":1591,"start":1592,"enrollment":9,"conditions":1593,"interventions":1595},"NCT02475369","Pancreatic Enzyme Supplementation for Celiac Disease",[91],"2019-06","2019-12","2015-05",[1594],"Celiac Disease",[1574],{"trials":1597,"activeCount":100},[],{"intervention":1371,"totalTrials":133,"cells":1599},{"EARLY_PHASE1":1600,"PHASE1":1602,"PHASE2":1604,"PHASE3":1606,"PHASE4":1608,"NA":1614},{"trials":1601,"activeCount":100},[],{"trials":1603,"activeCount":100},[],{"trials":1605,"activeCount":100},[],{"trials":1607,"activeCount":100},[],{"trials":1609,"activeCount":100},[1610],{"nctId":1361,"briefTitle":1362,"status":122,"phases":1611,"primaryCompletion":1364,"completion":1364,"start":1365,"enrollment":1366,"conditions":1612,"interventions":1613},[91],[1368,1369],[1371,1336],{"trials":1615,"activeCount":100},[],{"intervention":1617,"totalTrials":133,"cells":1618},"Canagliflozin",{"EARLY_PHASE1":1619,"PHASE1":1621,"PHASE2":1623,"PHASE3":1625,"PHASE4":1627,"NA":1639},{"trials":1620,"activeCount":100},[],{"trials":1622,"activeCount":100},[],{"trials":1624,"activeCount":100},[],{"trials":1626,"activeCount":100},[],{"trials":1628,"activeCount":100},[1629],{"nctId":1630,"briefTitle":1631,"status":122,"phases":1632,"primaryCompletion":1633,"completion":1633,"start":1634,"enrollment":477,"conditions":1635,"interventions":1638},"NCT02360774","Mechanisms of Weight Loss With SGLT2 Inhibition",[91],"2018-08","2015-02",[1636,1637,18],"Type 2 Diabetes","Overweight",[1617],{"trials":1640,"activeCount":100},[],{"intervention":1642,"totalTrials":133,"cells":1643},"exenatide",{"EARLY_PHASE1":1644,"PHASE1":1646,"PHASE2":1648,"PHASE3":1650,"PHASE4":1652,"NA":1664},{"trials":1645,"activeCount":100},[],{"trials":1647,"activeCount":100},[],{"trials":1649,"activeCount":100},[],{"trials":1651,"activeCount":100},[],{"trials":1653,"activeCount":100},[1654],{"nctId":1655,"briefTitle":1656,"status":122,"phases":1657,"primaryCompletion":1658,"completion":1658,"start":1659,"enrollment":1660,"conditions":1661,"interventions":1663},"NCT00456885","The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women",[91],"2010-09","2007-04",41,[18,1662],"Impaired Glucose Tolerance",[1642],{"trials":1665,"activeCount":100},[],{"intervention":1667,"totalTrials":133,"cells":1668},"Dexamethasone 8mg iv x1",{"EARLY_PHASE1":1669,"PHASE1":1671,"PHASE2":1673,"PHASE3":1675,"PHASE4":1677,"NA":1688},{"trials":1670,"activeCount":100},[],{"trials":1672,"activeCount":100},[],{"trials":1674,"activeCount":100},[],{"trials":1676,"activeCount":100},[],{"trials":1678,"activeCount":100},[1679],{"nctId":1680,"briefTitle":1681,"status":555,"phases":1682,"primaryCompletion":1683,"completion":1683,"start":627,"enrollment":788,"conditions":1684,"interventions":1687},"NCT01149616","Effects of Perioperative Intravenous Dexamethasone on Pain in Out Patient Knee Surgery",[91],"2012-12",[1685,1686],"Post Operative Pain","Nausea",[1667],{"trials":1689,"activeCount":100},[],{"intervention":1691,"totalTrials":133,"cells":1692},"Emgality 120 MG in 1 ML Prefilled Syringe",{"EARLY_PHASE1":1693,"PHASE1":1695,"PHASE2":1697,"PHASE3":1699,"PHASE4":1701,"NA":1713},{"trials":1694,"activeCount":100},[],{"trials":1696,"activeCount":100},[],{"trials":1698,"activeCount":100},[],{"trials":1700,"activeCount":100},[],{"trials":1702,"activeCount":100},[1703],{"nctId":1704,"briefTitle":1705,"status":122,"phases":1706,"primaryCompletion":1707,"completion":1707,"start":1708,"enrollment":1709,"conditions":1710,"interventions":1712},"NCT04271202","Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action",[91],"2023-11-22","2020-07-29",64,[1711],"Chronic Migraine",[1691],{"trials":1714,"activeCount":100},[],{"intervention":1716,"totalTrials":133,"cells":1717},"PEG -Intron",{"EARLY_PHASE1":1718,"PHASE1":1720,"PHASE2":1722,"PHASE3":1724,"PHASE4":1726,"NA":1742},{"trials":1719,"activeCount":100},[],{"trials":1721,"activeCount":100},[],{"trials":1723,"activeCount":100},[],{"trials":1725,"activeCount":100},[],{"trials":1727,"activeCount":100},[1728],{"nctId":1729,"briefTitle":1730,"status":122,"phases":1731,"primaryCompletion":1732,"completion":1733,"start":1734,"enrollment":1735,"conditions":1736,"interventions":1740},"NCT00179413","Study of Long-term Peg Intron vs. Colchicine in Non-responders.",[91],"2009-12-31","2010-03-03","2000-01-15",549,[1737,1738,1739],"Hepatitis C Virus","Advanced Fibrosis","Cirrhosis",[1716,1741],"Colchicine",{"trials":1743,"activeCount":100},[],{"intervention":1741,"totalTrials":133,"cells":1745},{"EARLY_PHASE1":1746,"PHASE1":1748,"PHASE2":1750,"PHASE3":1752,"PHASE4":1754,"NA":1760},{"trials":1747,"activeCount":100},[],{"trials":1749,"activeCount":100},[],{"trials":1751,"activeCount":100},[],{"trials":1753,"activeCount":100},[],{"trials":1755,"activeCount":100},[1756],{"nctId":1729,"briefTitle":1730,"status":122,"phases":1757,"primaryCompletion":1732,"completion":1733,"start":1734,"enrollment":1735,"conditions":1758,"interventions":1759},[91],[1737,1738,1739],[1716,1741],{"trials":1761,"activeCount":100},[],{"intervention":1763,"totalTrials":133,"cells":1764},"Hyperoxia",{"EARLY_PHASE1":1765,"PHASE1":1767,"PHASE2":1769,"PHASE3":1771,"PHASE4":1773,"NA":1784},{"trials":1766,"activeCount":100},[],{"trials":1768,"activeCount":100},[],{"trials":1770,"activeCount":100},[],{"trials":1772,"activeCount":100},[],{"trials":1774,"activeCount":100},[1775],{"nctId":1776,"briefTitle":1777,"status":434,"phases":1778,"primaryCompletion":1779,"completion":1779,"start":1780,"enrollment":100,"conditions":1781,"interventions":1783},"NCT03730779","Oxygen Therapy for Retinal Ischemia",[91],"2020-01-01","2018-11-30",[1782],"Retinal Ischemia",[1763],{"trials":1785,"activeCount":100},[],{"intervention":1787,"totalTrials":133,"cells":1788},"Altreno",{"EARLY_PHASE1":1789,"PHASE1":1791,"PHASE2":1793,"PHASE3":1795,"PHASE4":1797,"NA":1810},{"trials":1790,"activeCount":100},[],{"trials":1792,"activeCount":100},[],{"trials":1794,"activeCount":100},[],{"trials":1796,"activeCount":100},[],{"trials":1798,"activeCount":100},[1799],{"nctId":1800,"briefTitle":1801,"status":122,"phases":1802,"primaryCompletion":1803,"completion":1803,"start":1804,"enrollment":1805,"conditions":1806,"interventions":1808},"NCT04548349","Profiling the Skin Microbiome in Response to Altreno in Acne Patients",[91],"2022-08-22","2021-04-23",25,[1807,24],"Acne",[1787,1809],"Benzoyl peroxide",{"trials":1811,"activeCount":100},[],{"intervention":1809,"totalTrials":133,"cells":1813},{"EARLY_PHASE1":1814,"PHASE1":1816,"PHASE2":1818,"PHASE3":1820,"PHASE4":1822,"NA":1828},{"trials":1815,"activeCount":100},[],{"trials":1817,"activeCount":100},[],{"trials":1819,"activeCount":100},[],{"trials":1821,"activeCount":100},[],{"trials":1823,"activeCount":100},[1824],{"nctId":1800,"briefTitle":1801,"status":122,"phases":1825,"primaryCompletion":1803,"completion":1803,"start":1804,"enrollment":1805,"conditions":1826,"interventions":1827},[91],[1807,24],[1787,1809],{"trials":1829,"activeCount":100},[],{"intervention":1831,"totalTrials":133,"cells":1832},"OnabotulinumtoxinA 145 UNT [Botox]",{"EARLY_PHASE1":1833,"PHASE1":1835,"PHASE2":1837,"PHASE3":1839,"PHASE4":1841,"NA":1852},{"trials":1834,"activeCount":100},[],{"trials":1836,"activeCount":100},[],{"trials":1838,"activeCount":100},[],{"trials":1840,"activeCount":100},[],{"trials":1842,"activeCount":100},[1843],{"nctId":1844,"briefTitle":1845,"status":555,"phases":1846,"primaryCompletion":1847,"completion":1847,"start":1848,"enrollment":449,"conditions":1849,"interventions":1851},"NCT05605756","BOTOX Effects on Seizure Severity and Susceptibility",[91],"2024-12-01","2023-03-01",[1850],"Drug-resistant Focal Seizure",[1831],{"trials":1853,"activeCount":100},[],{"intervention":1855,"totalTrials":133,"cells":1856},"Atorvastatin 80mg",{"EARLY_PHASE1":1857,"PHASE1":1859,"PHASE2":1861,"PHASE3":1863,"PHASE4":1865,"NA":1878},{"trials":1858,"activeCount":100},[],{"trials":1860,"activeCount":100},[],{"trials":1862,"activeCount":100},[],{"trials":1864,"activeCount":100},[],{"trials":1866,"activeCount":100},[1867],{"nctId":1868,"briefTitle":1869,"status":555,"phases":1870,"primaryCompletion":1871,"completion":1872,"start":1873,"enrollment":1874,"conditions":1875,"interventions":1877},"NCT00344019","Effects of Atorvastatin on Myonecrosis",[91],"2008-10","2009-01","2006-05",97,[1876],"Coronary Disease",[1855],{"trials":1879,"activeCount":100},[],{"intervention":1881,"totalTrials":133,"cells":1882},"Morphine Sulfate",{"EARLY_PHASE1":1883,"PHASE1":1885,"PHASE2":1887,"PHASE3":1889,"PHASE4":1891,"NA":1902},{"trials":1884,"activeCount":100},[],{"trials":1886,"activeCount":100},[],{"trials":1888,"activeCount":100},[],{"trials":1890,"activeCount":100},[],{"trials":1892,"activeCount":100},[1893],{"nctId":1894,"briefTitle":1895,"status":122,"phases":1896,"primaryCompletion":1897,"completion":1897,"start":1898,"enrollment":1899,"conditions":1900,"interventions":1901},"NCT05069012","Intrathecal Morphine for Cesarean Delivery",[91],"2022-07-23","2021-11-15",72,[1328],[1881],{"trials":1903,"activeCount":100},[],{"intervention":1278,"totalTrials":133,"cells":1905},{"EARLY_PHASE1":1906,"PHASE1":1908,"PHASE2":1910,"PHASE3":1912,"PHASE4":1914,"NA":1920},{"trials":1907,"activeCount":100},[],{"trials":1909,"activeCount":100},[],{"trials":1911,"activeCount":100},[],{"trials":1913,"activeCount":100},[],{"trials":1915,"activeCount":100},[1916],{"nctId":1268,"briefTitle":1269,"status":122,"phases":1917,"primaryCompletion":1271,"completion":1272,"start":1273,"enrollment":1274,"conditions":1918,"interventions":1919},[91],[1276],[1278,1219],{"trials":1921,"activeCount":100},[],{"intervention":1923,"totalTrials":133,"cells":1924},"Fremanezumab Prefilled Syringe [Ajovy]",{"EARLY_PHASE1":1925,"PHASE1":1927,"PHASE2":1929,"PHASE3":1931,"PHASE4":1933,"NA":1946},{"trials":1926,"activeCount":100},[],{"trials":1928,"activeCount":100},[],{"trials":1930,"activeCount":100},[],{"trials":1932,"activeCount":100},[],{"trials":1934,"activeCount":100},[1935],{"nctId":1936,"briefTitle":1937,"status":555,"phases":1938,"primaryCompletion":1939,"completion":1939,"start":1940,"enrollment":1941,"conditions":1942,"interventions":1945},"NCT04693533","Fremanezumab, Migraine and Sleep",[91],"2024-04-01","2021-07-29",22,[1943,1944],"Migraine Disorders","Sleep Disorder",[1923],{"trials":1947,"activeCount":100},[],{"intervention":1949,"totalTrials":133,"cells":1950},"Linagliptin",{"EARLY_PHASE1":1951,"PHASE1":1953,"PHASE2":1955,"PHASE3":1957,"PHASE4":1959,"NA":1970},{"trials":1952,"activeCount":100},[],{"trials":1954,"activeCount":100},[],{"trials":1956,"activeCount":100},[],{"trials":1958,"activeCount":100},[],{"trials":1960,"activeCount":100},[1961],{"nctId":1962,"briefTitle":1963,"status":122,"phases":1964,"primaryCompletion":1965,"completion":1965,"start":1966,"enrollment":880,"conditions":1967,"interventions":1969},"NCT01969084","The Effect of Linagliptin on Mitochondrial and Endothelial Function",[91],"2016-07","2013-10",[1968],"Type II Diabetes Mellitus",[1949],{"trials":1971,"activeCount":100},[],{"intervention":1973,"totalTrials":133,"cells":1974},"clopidogrel 600 mg",{"EARLY_PHASE1":1975,"PHASE1":1977,"PHASE2":1979,"PHASE3":1981,"PHASE4":1983,"NA":1998},{"trials":1976,"activeCount":100},[],{"trials":1978,"activeCount":100},[],{"trials":1980,"activeCount":100},[],{"trials":1982,"activeCount":100},[],{"trials":1984,"activeCount":100},[1985],{"nctId":1986,"briefTitle":1987,"status":555,"phases":1988,"primaryCompletion":1989,"completion":1990,"start":1991,"enrollment":1992,"conditions":1993,"interventions":1997},"NCT00421252","Role of Plavix in Hemorrhagic and Ischemic Complications of Catheterization.",[91],"2007-11","2008-01","2007-01",18,[1994,1995,1996],"Coronary Artery Disease","Myocardial Ischemia","Bleeding",[1973],{"trials":1999,"activeCount":100},[],{"intervention":443,"totalTrials":133,"cells":2001},{"EARLY_PHASE1":2002,"PHASE1":2004,"PHASE2":2006,"PHASE3":2008,"PHASE4":2010,"NA":2016},{"trials":2003,"activeCount":100},[],{"trials":2005,"activeCount":100},[],{"trials":2007,"activeCount":100},[],{"trials":2009,"activeCount":100},[],{"trials":2011,"activeCount":100},[2012],{"nctId":432,"briefTitle":433,"status":434,"phases":2013,"primaryCompletion":436,"completion":436,"start":437,"enrollment":100,"conditions":2014,"interventions":2015},[91],[439],[441,442,443,444],{"trials":2017,"activeCount":100},[],{"intervention":2019,"totalTrials":133,"cells":2020},"IV acetaminophen & IV propofol",{"EARLY_PHASE1":2021,"PHASE1":2023,"PHASE2":2025,"PHASE3":2027,"PHASE4":2029,"NA":2045},{"trials":2022,"activeCount":100},[],{"trials":2024,"activeCount":100},[],{"trials":2026,"activeCount":100},[],{"trials":2028,"activeCount":100},[],{"trials":2030,"activeCount":100},[2031],{"nctId":2032,"briefTitle":2033,"status":122,"phases":2034,"primaryCompletion":2035,"completion":2036,"start":2037,"enrollment":2038,"conditions":2039,"interventions":2041},"NCT02546765","Dexmedetomidine and IV Acetaminophen for the Prevention of Postoperative Delirium Following Cardiac Surgery",[91],"2018-05","2019-07","2015-10",140,[2040],"Delirium",[2019,2042,2043,2044],"IV acetaminophen & IV dexmedetomidine","IV propofol & placebo","IV dexmedetomidine & placebo",{"trials":2046,"activeCount":100},[],{"intervention":2042,"totalTrials":133,"cells":2048},{"EARLY_PHASE1":2049,"PHASE1":2051,"PHASE2":2053,"PHASE3":2055,"PHASE4":2057,"NA":2063},{"trials":2050,"activeCount":100},[],{"trials":2052,"activeCount":100},[],{"trials":2054,"activeCount":100},[],{"trials":2056,"activeCount":100},[],{"trials":2058,"activeCount":100},[2059],{"nctId":2032,"briefTitle":2033,"status":122,"phases":2060,"primaryCompletion":2035,"completion":2036,"start":2037,"enrollment":2038,"conditions":2061,"interventions":2062},[91],[2040],[2019,2042,2043,2044],{"trials":2064,"activeCount":100},[],{"intervention":2043,"totalTrials":133,"cells":2066},{"EARLY_PHASE1":2067,"PHASE1":2069,"PHASE2":2071,"PHASE3":2073,"PHASE4":2075,"NA":2081},{"trials":2068,"activeCount":100},[],{"trials":2070,"activeCount":100},[],{"trials":2072,"activeCount":100},[],{"trials":2074,"activeCount":100},[],{"trials":2076,"activeCount":100},[2077],{"nctId":2032,"briefTitle":2033,"status":122,"phases":2078,"primaryCompletion":2035,"completion":2036,"start":2037,"enrollment":2038,"conditions":2079,"interventions":2080},[91],[2040],[2019,2042,2043,2044],{"trials":2082,"activeCount":100},[],{"intervention":2044,"totalTrials":133,"cells":2084},{"EARLY_PHASE1":2085,"PHASE1":2087,"PHASE2":2089,"PHASE3":2091,"PHASE4":2093,"NA":2099},{"trials":2086,"activeCount":100},[],{"trials":2088,"activeCount":100},[],{"trials":2090,"activeCount":100},[],{"trials":2092,"activeCount":100},[],{"trials":2094,"activeCount":100},[2095],{"nctId":2032,"briefTitle":2033,"status":122,"phases":2096,"primaryCompletion":2035,"completion":2036,"start":2037,"enrollment":2038,"conditions":2097,"interventions":2098},[91],[2040],[2019,2042,2043,2044],{"trials":2100,"activeCount":100},[],{"intervention":2102,"totalTrials":133,"cells":2103},"Maxalt",{"EARLY_PHASE1":2104,"PHASE1":2106,"PHASE2":2108,"PHASE3":2110,"PHASE4":2112,"NA":2124},{"trials":2105,"activeCount":100},[],{"trials":2107,"activeCount":100},[],{"trials":2109,"activeCount":100},[],{"trials":2111,"activeCount":100},[],{"trials":2113,"activeCount":100},[2114],{"nctId":2115,"briefTitle":2116,"status":122,"phases":2117,"primaryCompletion":2118,"completion":2118,"start":2119,"enrollment":2120,"conditions":2121,"interventions":2123},"NCT00719134","The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache",[91],"2013-12","2008-09",76,[2122],"Episodic Migraine",[2102],{"trials":2125,"activeCount":100},[],{"intervention":2127,"totalTrials":133,"cells":2128},"Crofelemer",{"EARLY_PHASE1":2129,"PHASE1":2131,"PHASE2":2133,"PHASE3":2135,"PHASE4":2137,"NA":2148},{"trials":2130,"activeCount":100},[],{"trials":2132,"activeCount":100},[],{"trials":2134,"activeCount":100},[],{"trials":2136,"activeCount":100},[],{"trials":2138,"activeCount":100},[2139],{"nctId":2140,"briefTitle":2141,"status":555,"phases":2142,"primaryCompletion":2143,"completion":2143,"start":2144,"enrollment":19,"conditions":2145,"interventions":2147},"NCT04486326","Crofelemer for Functional Diarrhea",[91],"2022-09-23","2020-08-20",[2146],"Diarrhea",[2127],{"trials":2149,"activeCount":100},[],{"intervention":2151,"totalTrials":133,"cells":2152},"Suvorexant 20 mg",{"EARLY_PHASE1":2153,"PHASE1":2155,"PHASE2":2157,"PHASE3":2159,"PHASE4":2161,"NA":2174},{"trials":2154,"activeCount":100},[],{"trials":2156,"activeCount":100},[],{"trials":2158,"activeCount":100},[],{"trials":2160,"activeCount":100},[],{"trials":2162,"activeCount":100},[2163],{"nctId":2164,"briefTitle":2165,"status":122,"phases":2166,"primaryCompletion":2167,"completion":2168,"start":1258,"enrollment":1366,"conditions":2169,"interventions":2173},"NCT04092894","Suvorexant and Sleep\u002FDelirium in ICU Patients",[91],"2025-02-26","2025-07-01",[1060,2170,2171,2172],"Sleep Fragmentation","Sleep Initiation and Maintenance Disorders","Postoperative Delirium",[2151],{"trials":2175,"activeCount":100},[],{"intervention":2177,"totalTrials":133,"cells":2178},"Progesterone Lozenges",{"EARLY_PHASE1":2179,"PHASE1":2181,"PHASE2":2183,"PHASE3":2185,"PHASE4":2197,"NA":2199},{"trials":2180,"activeCount":100},[],{"trials":2182,"activeCount":100},[],{"trials":2184,"activeCount":100},[],{"trials":2186,"activeCount":100},[2187],{"nctId":2188,"briefTitle":2189,"status":122,"phases":2190,"primaryCompletion":2191,"completion":2191,"start":2192,"enrollment":2193,"conditions":2194,"interventions":2196},"NCT00029536","Progesterone vs Placebo Therapy for Women With Epilepsy",[90],"2010-06","2000-10",294,[2195],"Epilepsy",[2177],{"trials":2198,"activeCount":100},[],{"trials":2200,"activeCount":100},[],{"intervention":2202,"totalTrials":133,"cells":2203},"Double blinded IVIg",{"EARLY_PHASE1":2204,"PHASE1":2206,"PHASE2":2208,"PHASE3":2210,"PHASE4":2222,"NA":2224},{"trials":2205,"activeCount":100},[],{"trials":2207,"activeCount":100},[],{"trials":2209,"activeCount":100},[],{"trials":2211,"activeCount":100},[2212],{"nctId":2213,"briefTitle":2214,"status":122,"phases":2215,"primaryCompletion":124,"completion":2216,"start":2217,"enrollment":2218,"conditions":2219,"interventions":2221},"NCT01522235","Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy",[89,90],"2015-09","2012-02",6,[2220],"Autoimmune Autonomic Ganglionopathy (AAG)",[2202],{"trials":2223,"activeCount":100},[],{"trials":2225,"activeCount":100},[],{"intervention":2227,"totalTrials":133,"cells":2228},"Simvastatin",{"EARLY_PHASE1":2229,"PHASE1":2231,"PHASE2":2233,"PHASE3":2235,"PHASE4":2244,"NA":2246},{"trials":2230,"activeCount":100},[],{"trials":2232,"activeCount":100},[],{"trials":2234,"activeCount":100},[],{"trials":2236,"activeCount":100},[2237],{"nctId":2238,"briefTitle":2239,"status":122,"phases":2240,"primaryCompletion":2241,"completion":2241,"start":589,"enrollment":1992,"conditions":2242,"interventions":2243},"NCT00676897","Statin Therapy in the Treatment of Sepsis",[89,90],"2010-12",[34],[2227],{"trials":2245,"activeCount":100},[],{"trials":2247,"activeCount":100},[],{"intervention":1264,"totalTrials":133,"cells":2249},{"EARLY_PHASE1":2250,"PHASE1":2252,"PHASE2":2254,"PHASE3":2256,"PHASE4":2262,"NA":2264},{"trials":2251,"activeCount":100},[],{"trials":2253,"activeCount":100},[],{"trials":2255,"activeCount":100},[],{"trials":2257,"activeCount":100},[2258],{"nctId":1254,"briefTitle":1255,"status":122,"phases":2259,"primaryCompletion":1257,"completion":1258,"start":1259,"enrollment":1260,"conditions":2260,"interventions":2261},[89,90],[882,34,1262],[1264,1219],{"trials":2263,"activeCount":100},[],{"trials":2265,"activeCount":100},[],{"intervention":2267,"totalTrials":133,"cells":2268},"IV acetaminophen",{"EARLY_PHASE1":2269,"PHASE1":2271,"PHASE2":2273,"PHASE3":2275,"PHASE4":2287,"NA":2289},{"trials":2270,"activeCount":100},[],{"trials":2272,"activeCount":100},[],{"trials":2274,"activeCount":100},[],{"trials":2276,"activeCount":100},[2277],{"nctId":2278,"briefTitle":2279,"status":122,"phases":2280,"primaryCompletion":2281,"completion":2282,"start":2283,"enrollment":2284,"conditions":2285,"interventions":2286},"NCT04093219","PANDORA: Delirium Prevention After Cardiac Surgery Using IV Acetaminophen to Prevent Postoperative Delirium in Older Cardiac Surgical Patients",[90],"2026-03-30","2026-04-05","2020-08-11",900,[314,2040,1994],[2267],{"trials":2288,"activeCount":100},[],{"trials":2290,"activeCount":100},[],{"intervention":2292,"totalTrials":133,"cells":2293},"Amiodarone",{"EARLY_PHASE1":2294,"PHASE1":2296,"PHASE2":2298,"PHASE3":2300,"PHASE4":2312,"NA":2314},{"trials":2295,"activeCount":100},[],{"trials":2297,"activeCount":100},[],{"trials":2299,"activeCount":100},[],{"trials":2301,"activeCount":100},[2302],{"nctId":2303,"briefTitle":2304,"status":555,"phases":2305,"primaryCompletion":2306,"completion":2306,"start":2307,"enrollment":1406,"conditions":2308,"interventions":2311},"NCT00300495","Study of Amiodarone Given Before Lung Surgery to Prevent Atrial Fibrillation After Lung Resection",[90],"2009-10-13","2006-02",[2309,2310],"Atrial Fibrillation","Lung Cancer",[2292],{"trials":2313,"activeCount":100},[],{"trials":2315,"activeCount":100},[],{"intervention":2317,"totalTrials":133,"cells":2318},"Isoflavone supplement",{"EARLY_PHASE1":2319,"PHASE1":2321,"PHASE2":2323,"PHASE3":2325,"PHASE4":2338,"NA":2340},{"trials":2320,"activeCount":100},[],{"trials":2322,"activeCount":100},[],{"trials":2324,"activeCount":100},[],{"trials":2326,"activeCount":100},[2327],{"nctId":2328,"briefTitle":2329,"status":122,"phases":2330,"primaryCompletion":2331,"completion":2332,"start":2333,"enrollment":2334,"conditions":2335,"interventions":2337},"NCT00179556","Effects of Soy Isoflavones on Menopausal Hot Flashes",[89,90],"2005-07","2005-09","2003-06",210,[2336],"Menopausal Symptoms",[2317],{"trials":2339,"activeCount":100},[],{"trials":2341,"activeCount":100},[],{"intervention":2343,"totalTrials":133,"cells":2344},"Bupivacaine Group",{"EARLY_PHASE1":2345,"PHASE1":2347,"PHASE2":2349,"PHASE3":2351,"PHASE4":2364,"NA":2366},{"trials":2346,"activeCount":100},[],{"trials":2348,"activeCount":100},[],{"trials":2350,"activeCount":100},[],{"trials":2352,"activeCount":100},[2353],{"nctId":2354,"briefTitle":2355,"status":122,"phases":2356,"primaryCompletion":2357,"completion":2358,"start":2359,"enrollment":2360,"conditions":2361,"interventions":2363},"NCT03482973","Pecto-Intercostal Fascial Block for Postoperative Analgesia After Cardiac Surgery",[90],"2019-11-25","2019-11-27","2018-06-21",80,[1994,2362],"Sternal Pain",[2343],{"trials":2365,"activeCount":100},[],{"trials":2367,"activeCount":100},[],{"intervention":2369,"totalTrials":1027,"cells":2370},"r-metHuLeptin",{"EARLY_PHASE1":2371,"PHASE1":2373,"PHASE2":2384,"PHASE3":2416,"PHASE4":2418,"NA":2420},{"trials":2372,"activeCount":100},[],{"trials":2374,"activeCount":100},[2375],{"nctId":2376,"briefTitle":2377,"status":122,"phases":2378,"primaryCompletion":2379,"completion":1058,"start":1563,"enrollment":2380,"conditions":2381,"interventions":2383},"NCT00140205","Pharmacokinetics of Leptin Administration During Fasting",[88],"2004-06",15,[2382],"Energy Deficiency Due to Short-term Fasting",[2369],{"trials":2385,"activeCount":100},[2386,2396,2406],{"nctId":2387,"briefTitle":2388,"status":122,"phases":2389,"primaryCompletion":2390,"completion":2390,"start":2391,"enrollment":2392,"conditions":2393,"interventions":2395},"NCT00140244","Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome",[89],"2011-06","2001-12",7,[2394],"HAART-induced Lipodystrophy and Metabolic Syndrome",[2369],{"nctId":2397,"briefTitle":2398,"status":122,"phases":2399,"primaryCompletion":2400,"completion":1058,"start":2401,"enrollment":726,"conditions":2402,"interventions":2404},"NCT00130117","Study of Leptin for the Treatment of Hypothalamic Amenorrhea",[89],"2011-08","2010-04",[2403],"Amenorrhea",[2369,2405],"Oral Contraceptive Pills",{"nctId":2407,"briefTitle":2408,"status":122,"phases":2409,"primaryCompletion":2410,"completion":1058,"start":2411,"enrollment":2412,"conditions":2413,"interventions":2415},"NCT00140231","Role of Leptin in the Neuroendocrine and Immune Response to Fasting",[88,89],"2011-03","2002-10",13,[2414],"Fasting",[2369],{"trials":2417,"activeCount":100},[],{"trials":2419,"activeCount":100},[],{"trials":2421,"activeCount":100},[],{"intervention":2423,"totalTrials":449,"cells":2424},"Leptin",{"EARLY_PHASE1":2425,"PHASE1":2427,"PHASE2":2441,"PHASE3":2460,"PHASE4":2462,"NA":2464},{"trials":2426,"activeCount":100},[],{"trials":2428,"activeCount":100},[2429],{"nctId":2430,"briefTitle":2431,"status":122,"phases":2432,"primaryCompletion":2118,"completion":2433,"start":2434,"enrollment":22,"conditions":2435,"interventions":2439},"NCT01275053","In Vivo Leptin Signaling in Humans After Acute Leptin Administration",[88],"2017-01","2002-07",[2436,2437,2438],"Lean","Obese","Obese Diabetics",[2440],"leptin",{"trials":2442,"activeCount":100},[2443,2452],{"nctId":2444,"briefTitle":2445,"status":122,"phases":2446,"primaryCompletion":1348,"completion":2390,"start":2447,"enrollment":25,"conditions":2448,"interventions":2450},"NCT00362440","Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome",[89],"2006-08",[2449],"HIV Lipodystrophy",[2423,2451],"Pioglitazone or metformin",{"nctId":2453,"briefTitle":2454,"status":122,"phases":2455,"primaryCompletion":1683,"completion":1058,"start":2456,"enrollment":2457,"conditions":2458,"interventions":2459},"NCT01155180","Leptin in the Maintenance of Reduced Body Weight",[89],"2008-07",24,[18],[2423],{"trials":2461,"activeCount":100},[],{"trials":2463,"activeCount":100},[],{"trials":2465,"activeCount":100},[],{"intervention":2467,"totalTrials":449,"cells":2468},"docetaxel",{"EARLY_PHASE1":2469,"PHASE1":2471,"PHASE2":2484,"PHASE3":2499,"PHASE4":2501,"NA":2503},{"trials":2470,"activeCount":100},[],{"trials":2472,"activeCount":100},[2473],{"nctId":2474,"briefTitle":2475,"status":122,"phases":2476,"primaryCompletion":2477,"completion":2241,"start":2478,"conditions":2479,"interventions":2482},"NCT00004082","Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors",[88],"2003-09","1999-07",[2480,601,32,2481],"Endometrial Cancer","Primary Peritoneal Cavity Cancer",[465,2467,2483],"gemcitabine hydrochloride",{"trials":2485,"activeCount":100},[2486,2495],{"nctId":2487,"briefTitle":2488,"status":122,"phases":2489,"primaryCompletion":2490,"completion":2491,"start":2478,"enrollment":477,"conditions":2492,"interventions":2494},"NCT00004081","Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer",[89],"2002-01","2003-03",[32,2493],"Peritoneal Cavity Cancer",[2467],{"nctId":1345,"briefTitle":1346,"status":122,"phases":2496,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":116,"conditions":2497,"interventions":2498},[89],[27],[1352,1336,1353,1354,1355],{"trials":2500,"activeCount":100},[],{"trials":2502,"activeCount":100},[],{"trials":2504,"activeCount":100},[],{"intervention":497,"totalTrials":449,"cells":2506},{"EARLY_PHASE1":2507,"PHASE1":2509,"PHASE2":2511,"PHASE3":2541,"PHASE4":2543,"NA":2545},{"trials":2508,"activeCount":100},[],{"trials":2510,"activeCount":100},[],{"trials":2512,"activeCount":100},[2513,2517,2521],{"nctId":458,"briefTitle":459,"status":434,"phases":2514,"primaryCompletion":461,"completion":461,"start":461,"enrollment":100,"conditions":2515,"interventions":2516},[88,89],[15],[464,465,466,467,468,469],{"nctId":488,"briefTitle":489,"status":122,"phases":2518,"primaryCompletion":491,"completion":492,"start":493,"enrollment":494,"conditions":2519,"interventions":2520},[89],[15],[448,497,498],{"nctId":2522,"briefTitle":2523,"status":122,"phases":2524,"primaryCompletion":2525,"start":2478,"enrollment":1805,"conditions":2526,"interventions":2536},"NCT00636909","Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders",[89],"2006-03",[2527,2528,2529,2530,2531,2532,2533,2534,2535],"AML","ALL","CML Chronic Phase, Accelerated Phase, or Blast Crisis","CLL","MDS","RELAPSED NON-HODGKIN'S OR HODGKIN'S LYMPHOMA","APLASTIC ANEMIA","MULTIPLE MYELOMA","MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET)",[497,2537,2538,2539,2540],"fludarabine","cyclosporine","methotrexate","G-CSF",{"trials":2542,"activeCount":100},[],{"trials":2544,"activeCount":100},[],{"trials":2546,"activeCount":100},[],{"intervention":2548,"totalTrials":96,"cells":2549},"Deferoxamine Mesylate",{"EARLY_PHASE1":2550,"PHASE1":2552,"PHASE2":2561,"PHASE3":2571,"PHASE4":2573,"NA":2575},{"trials":2551,"activeCount":100},[],{"trials":2553,"activeCount":100},[2554],{"nctId":2555,"briefTitle":2556,"status":122,"phases":2557,"primaryCompletion":2558,"completion":2401,"start":2456,"enrollment":726,"conditions":2559,"interventions":2560},"NCT00598572","Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage",[88],"2010-01",[287],[2548],{"trials":2562,"activeCount":100},[2563],{"nctId":2564,"briefTitle":2565,"status":122,"phases":2566,"primaryCompletion":2567,"completion":2568,"start":180,"enrollment":2193,"conditions":2569,"interventions":2570},"NCT02175225","Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial",[89],"2018-02-10","2018-05-30",[287],[2548],{"trials":2572,"activeCount":100},[],{"trials":2574,"activeCount":100},[],{"trials":2576,"activeCount":100},[],{"intervention":2578,"totalTrials":96,"cells":2579},"0.9% Sodium Chloride",{"EARLY_PHASE1":2580,"PHASE1":2582,"PHASE2":2584,"PHASE3":2608,"PHASE4":2610,"NA":2612},{"trials":2581,"activeCount":100},[],{"trials":2583,"activeCount":100},[],{"trials":2585,"activeCount":100},[2586,2597],{"nctId":2587,"briefTitle":2588,"status":122,"phases":2589,"primaryCompletion":2590,"completion":2590,"start":2591,"enrollment":726,"conditions":2592,"interventions":2595},"NCT03401073","IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3",[89],"2022-02-01","2018-09-01",[2593,2594],"Small Fiber Neuropathy","Idiopathic Peripheral Neuropathy",[2596,2578],"Intravenous immunoglobulin",{"nctId":2598,"briefTitle":2599,"status":555,"phases":2600,"primaryCompletion":2590,"completion":2590,"start":2601,"enrollment":2412,"conditions":2602,"interventions":2606},"NCT02915263","The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes",[89],"2017-09-11",[2603,2604,2605],"Diabetes Complications","Diabetes Mellitus","Diabetic Neuropathies",[2607,2578],"IGIV-C",{"trials":2609,"activeCount":100},[],{"trials":2611,"activeCount":100},[],{"trials":2613,"activeCount":100},[],{"intervention":2615,"totalTrials":96,"cells":2616},"Ubiquinol",{"EARLY_PHASE1":2617,"PHASE1":2619,"PHASE2":2621,"PHASE3":2640,"PHASE4":2642,"NA":2644},{"trials":2618,"activeCount":100},[],{"trials":2620,"activeCount":100},[],{"trials":2622,"activeCount":100},[2623,2633],{"nctId":2624,"briefTitle":2625,"status":122,"phases":2626,"primaryCompletion":2627,"completion":2628,"start":2629,"enrollment":2630,"conditions":2631,"interventions":2632},"NCT02934555","Ubiquinol as a Metabolic Resuscitator in Post-Cardiac Arrest",[89],"2019-05-25","2019-06-02","2016-03",48,[535],[2615],{"nctId":2634,"briefTitle":2635,"status":122,"phases":2636,"primaryCompletion":531,"completion":531,"start":493,"enrollment":2637,"conditions":2638,"interventions":2639},"NCT01948063","Ubiquinol (Reduced COQ10) for Patients With Sepsis",[89],38,[882],[2615],{"trials":2641,"activeCount":100},[],{"trials":2643,"activeCount":100},[],{"trials":2645,"activeCount":100},[],{"intervention":2647,"totalTrials":96,"cells":2648},"boronophenylalanine-fructose complex",{"EARLY_PHASE1":2649,"PHASE1":2651,"PHASE2":2662,"PHASE3":2674,"PHASE4":2676,"NA":2678},{"trials":2650,"activeCount":100},[],{"trials":2652,"activeCount":100},[2653],{"nctId":2654,"briefTitle":2655,"status":2656,"phases":2657,"start":2658,"enrollment":2380,"conditions":2659,"interventions":2661},"NCT00002781","Boron Neutron Capture Therapy in Treating Patients With Stage III Melanoma","UNKNOWN",[88],"1996-04",[2660],"Melanoma (Skin)",[2647],{"trials":2663,"activeCount":100},[2664],{"nctId":2665,"briefTitle":2666,"status":122,"phases":2667,"completion":2668,"start":2669,"conditions":2670,"interventions":2673},"NCT00039572","Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain",[88,89],"2005-01","2002-05",[2671,2660,2672],"Brain and Central Nervous System Tumors","Metastatic Cancer",[2647],{"trials":2675,"activeCount":100},[],{"trials":2677,"activeCount":100},[],{"trials":2679,"activeCount":100},[],{"intervention":2681,"totalTrials":96,"cells":2682},"Enoxaparin",{"EARLY_PHASE1":2683,"PHASE1":2685,"PHASE2":2687,"PHASE3":2709,"PHASE4":2711,"NA":2713},{"trials":2684,"activeCount":100},[],{"trials":2686,"activeCount":100},[],{"trials":2688,"activeCount":100},[2689,2699],{"nctId":2690,"briefTitle":2691,"status":122,"phases":2692,"primaryCompletion":2693,"completion":2694,"start":2695,"enrollment":2457,"conditions":2696,"interventions":2697},"NCT03532139","Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)",[89],"2023-12-31","2024-05-31","2018-07-25",[32],[2681,2698],"Enoxaparin + Rosuvastatin",{"nctId":2700,"briefTitle":2701,"status":122,"phases":2702,"primaryCompletion":2703,"completion":493,"start":2704,"enrollment":2705,"conditions":2706,"interventions":2708},"NCT00908960","Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles",[89],"2012-04","2009-05",70,[2707],"Advanced Pancreatic, Colon, Lung, Gastric and Ovarian Cancer",[2681],{"trials":2710,"activeCount":100},[],{"trials":2712,"activeCount":100},[],{"trials":2714,"activeCount":100},[],{"intervention":2716,"totalTrials":96,"cells":2717},"Everolimus",{"EARLY_PHASE1":2718,"PHASE1":2720,"PHASE2":2722,"PHASE3":2741,"PHASE4":2743,"NA":2745},{"trials":2719,"activeCount":100},[],{"trials":2721,"activeCount":100},[],{"trials":2723,"activeCount":100},[2724,2733],{"nctId":2725,"briefTitle":2726,"status":122,"phases":2727,"primaryCompletion":2728,"completion":2729,"start":1562,"enrollment":1805,"conditions":2730,"interventions":2732},"NCT00827359","Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma",[89],"2018-01","2018-06",[29,2731],"Renal Cancer",[2716],{"nctId":2734,"briefTitle":2735,"status":122,"phases":2736,"primaryCompletion":2401,"completion":2401,"start":1659,"enrollment":2737,"conditions":2738,"interventions":2739},"NCT00458237","Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer",[88,89],11,[15],[2716,2740],"Trastuzumab",{"trials":2742,"activeCount":100},[],{"trials":2744,"activeCount":100},[],{"trials":2746,"activeCount":100},[],{"intervention":2748,"totalTrials":96,"cells":2749},"Furosemide",{"EARLY_PHASE1":2750,"PHASE1":2752,"PHASE2":2754,"PHASE3":2776,"PHASE4":2778,"NA":2780},{"trials":2751,"activeCount":100},[],{"trials":2753,"activeCount":100},[],{"trials":2755,"activeCount":100},[2756,2767],{"nctId":2757,"briefTitle":2758,"status":122,"phases":2759,"primaryCompletion":2760,"completion":2761,"start":2762,"enrollment":2457,"conditions":2763,"interventions":2765},"NCT02524054","Aerosol Inhalation Treatment for Dyspnea - Patients",[88,89],"2016-11-30","2017-12-01","2014-11-01",[2764],"Dyspnea",[2748,2766],"Aerosolized saline",{"nctId":2768,"briefTitle":2769,"status":122,"phases":2770,"primaryCompletion":2771,"completion":2772,"start":1070,"enrollment":2457,"conditions":2773,"interventions":2774},"NCT01440764","Aerosol Inhalation Treatment for Dyspnea",[88,89],"2016-04","2017-04",[24,2764],[2748,2775],"Saline",{"trials":2777,"activeCount":100},[],{"trials":2779,"activeCount":100},[],{"trials":2781,"activeCount":100},[],{"intervention":2783,"totalTrials":96,"cells":2784},"N-Acetylcysteine",{"EARLY_PHASE1":2785,"PHASE1":2787,"PHASE2":2789,"PHASE3":2810,"PHASE4":2812,"NA":2814},{"trials":2786,"activeCount":100},[],{"trials":2788,"activeCount":100},[],{"trials":2790,"activeCount":100},[2791,2802],{"nctId":2792,"briefTitle":2793,"status":122,"phases":2794,"primaryCompletion":2795,"completion":2795,"start":2796,"enrollment":2797,"conditions":2798,"interventions":2800},"NCT00780962","N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients",[89],"2010-08-09","2007-10-16",399,[2799],"Radiocontrast Nephropathy",[2783,2801],"0.9% Sodium-chloride",{"nctId":2803,"briefTitle":2804,"status":122,"phases":2805,"primaryCompletion":587,"completion":587,"start":1348,"enrollment":726,"conditions":2806,"interventions":2808},"NCT01354132","N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis",[89],[2807],"Schizophrenic Psychoses",[2809],"n-acetylcysteine",{"trials":2811,"activeCount":100},[],{"trials":2813,"activeCount":100},[],{"trials":2815,"activeCount":100},[],{"intervention":465,"totalTrials":96,"cells":2817},{"EARLY_PHASE1":2818,"PHASE1":2820,"PHASE2":2826,"PHASE3":2832,"PHASE4":2834,"NA":2836},{"trials":2819,"activeCount":100},[],{"trials":2821,"activeCount":100},[2822],{"nctId":2474,"briefTitle":2475,"status":122,"phases":2823,"primaryCompletion":2477,"completion":2241,"start":2478,"conditions":2824,"interventions":2825},[88],[2480,601,32,2481],[465,2467,2483],{"trials":2827,"activeCount":100},[2828],{"nctId":458,"briefTitle":459,"status":434,"phases":2829,"primaryCompletion":461,"completion":461,"start":461,"enrollment":100,"conditions":2830,"interventions":2831},[88,89],[15],[464,465,466,467,468,469],{"trials":2833,"activeCount":100},[],{"trials":2835,"activeCount":100},[],{"trials":2837,"activeCount":100},[],{"intervention":2839,"totalTrials":96,"cells":2840},"CT-011",{"EARLY_PHASE1":2841,"PHASE1":2843,"PHASE2":2845,"PHASE3":2865,"PHASE4":2867,"NA":2869},{"trials":2842,"activeCount":100},[],{"trials":2844,"activeCount":100},[],{"trials":2846,"activeCount":100},[2847,2855],{"nctId":2848,"briefTitle":2849,"status":555,"phases":2850,"primaryCompletion":1965,"completion":1965,"start":2851,"enrollment":2737,"conditions":2852,"interventions":2853},"NCT01441765","PD-1 Alone or With Dendritic Cell\u002FRenal Cell Carcinoma Fusion Cell Vaccine",[89],"2011-11",[29],[2839,2854],"DC\u002FRCC fusion vaccine",{"nctId":2856,"briefTitle":2857,"status":122,"phases":2858,"primaryCompletion":2859,"completion":2860,"start":2861,"enrollment":205,"conditions":2862,"interventions":2863},"NCT01067287","Blockade of PD-1 in Conjunction With the Dendritic Cell\u002FMyeloma Vaccines Following Stem Cell Transplantation",[89],"2025-09","2025-12","2010-03",[561],[2839,2864],"Dendritic Cell Fusion Vaccine",{"trials":2866,"activeCount":100},[],{"trials":2868,"activeCount":100},[],{"trials":2870,"activeCount":100},[],{"intervention":464,"totalTrials":96,"cells":2872},{"EARLY_PHASE1":2873,"PHASE1":2875,"PHASE2":2877,"PHASE3":2887,"PHASE4":2889,"NA":2891},{"trials":2874,"activeCount":100},[],{"trials":2876,"activeCount":100},[],{"trials":2878,"activeCount":100},[2879,2883],{"nctId":458,"briefTitle":459,"status":434,"phases":2880,"primaryCompletion":461,"completion":461,"start":461,"enrollment":100,"conditions":2881,"interventions":2882},[88,89],[15],[464,465,466,467,468,469],{"nctId":2734,"briefTitle":2735,"status":122,"phases":2884,"primaryCompletion":2401,"completion":2401,"start":1659,"enrollment":2737,"conditions":2885,"interventions":2886},[88,89],[15],[2716,2740],{"trials":2888,"activeCount":100},[],{"trials":2890,"activeCount":100},[],{"trials":2892,"activeCount":100},[],{"intervention":2894,"totalTrials":96,"cells":2895},"Sevoflurane",{"EARLY_PHASE1":2896,"PHASE1":2910,"PHASE2":2912,"PHASE3":2927,"PHASE4":2929,"NA":2931},{"trials":2897,"activeCount":100},[2898],{"nctId":2899,"briefTitle":2900,"status":122,"phases":2901,"primaryCompletion":2902,"completion":2903,"start":2904,"enrollment":1941,"conditions":2905,"interventions":2906},"NCT04016740","The PATHFINDER Study: A Feasibility Trial",[87],"2020-02-19","2020-07-07","2019-08-20",[1994,2040],[2907,444,441,2908,1235,2909,2894,2908,2909],"Ropivacaine","Dexmedetomidine","Propofol",{"trials":2911,"activeCount":100},[],{"trials":2913,"activeCount":100},[2914],{"nctId":2915,"briefTitle":2916,"status":122,"phases":2917,"primaryCompletion":2918,"completion":2919,"start":2920,"enrollment":2921,"conditions":2922,"interventions":2926},"NCT02918877","Anesthetics to Prevent Lung Injury in Cardiac Surgery",[88,89],"2018-12-24","2021-02-01","2017-06-09",51,[2923,2924,2925],"Inflammatory Lung Injury","Ischemia-Reperfusion Lung Injury","Postoperative Pulmonary Complications",[2894,2909],{"trials":2928,"activeCount":100},[],{"trials":2930,"activeCount":100},[],{"trials":2932,"activeCount":100},[],{"intervention":2934,"totalTrials":96,"cells":2935},"Docosahexaenoic Acid",{"EARLY_PHASE1":2936,"PHASE1":2938,"PHASE2":2951,"PHASE3":2957,"PHASE4":2959,"NA":2961},{"trials":2937,"activeCount":100},[],{"trials":2939,"activeCount":100},[2940],{"nctId":2941,"briefTitle":2942,"status":122,"phases":2943,"primaryCompletion":2944,"completion":2944,"start":2945,"enrollment":2946,"conditions":2947,"interventions":2950},"NCT00325013","Evaluation of DHA for the Treatment of PSC",[88],"2012-05","2005-12",10,[2948,2949],"Primary Sclerosing Cholangitis","Colitis",[2934],{"trials":2952,"activeCount":100},[2953],{"nctId":1067,"briefTitle":1068,"status":122,"phases":2954,"primaryCompletion":1070,"completion":1070,"start":1071,"enrollment":1072,"conditions":2955,"interventions":2956},[89],[1074,1075,1049],[70,1077],{"trials":2958,"activeCount":100},[],{"trials":2960,"activeCount":100},[],{"trials":2962,"activeCount":100},[],{"intervention":2964,"totalTrials":96,"cells":2965},"rituximab",{"EARLY_PHASE1":2966,"PHASE1":2968,"PHASE2":2970,"PHASE3":2990,"PHASE4":2992,"NA":2994},{"trials":2967,"activeCount":100},[],{"trials":2969,"activeCount":100},[],{"trials":2971,"activeCount":100},[2972,2980],{"nctId":2973,"briefTitle":2974,"status":555,"phases":2975,"primaryCompletion":2944,"completion":2976,"start":2977,"enrollment":22,"conditions":2978,"interventions":2979},"NCT00110149","Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma",[89],"2015-03","2004-05",[954],[2964],{"nctId":2981,"briefTitle":2982,"status":122,"phases":2983,"primaryCompletion":2984,"completion":2984,"start":2985,"enrollment":1805,"conditions":2986,"interventions":2987},"NCT00073957","Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma",[89],"2012-01-01","2003-12",[954],[2964,2988,2989],"cytarabine","liposomal cytarabine",{"trials":2991,"activeCount":100},[],{"trials":2993,"activeCount":100},[],{"trials":2995,"activeCount":100},[],{"intervention":2997,"totalTrials":96,"cells":2998},"Abatacept",{"EARLY_PHASE1":2999,"PHASE1":3001,"PHASE2":3003,"PHASE3":3025,"PHASE4":3027,"NA":3029},{"trials":3000,"activeCount":100},[],{"trials":3002,"activeCount":100},[],{"trials":3004,"activeCount":100},[3005,3015],{"nctId":3006,"briefTitle":3007,"status":434,"phases":3008,"primaryCompletion":3009,"completion":3010,"start":3011,"enrollment":100,"conditions":3012,"interventions":3014},"NCT04477642","Abatacept for Patients With COVID-19 and Respiratory Distress",[88,89],"2020-10","2020-12","2020-08",[3013],"COVID-19",[2997],{"nctId":3016,"briefTitle":3017,"status":122,"phases":3018,"primaryCompletion":1430,"completion":3019,"start":3020,"enrollment":3021,"conditions":3022,"interventions":3024},"NCT01954979","Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)",[88,89],"2024-01-16","2014-03-27",56,[3023],"Chronic Graft Versus Host Disease",[2997],{"trials":3026,"activeCount":100},[],{"trials":3028,"activeCount":100},[],{"trials":3030,"activeCount":100},[],{"intervention":3032,"totalTrials":96,"cells":3033},"Incobotulinum Toxin A",{"EARLY_PHASE1":3034,"PHASE1":3036,"PHASE2":3038,"PHASE3":3057,"PHASE4":3059,"NA":3061},{"trials":3035,"activeCount":100},[],{"trials":3037,"activeCount":100},[],{"trials":3039,"activeCount":100},[3040,3049],{"nctId":3041,"briefTitle":3042,"status":434,"phases":3043,"primaryCompletion":3044,"completion":3044,"start":125,"enrollment":100,"conditions":3045,"interventions":3048},"NCT01565395","Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)\u002FParkinsonism and Amyotrophic Lateral Sclerosis (ALS)",[89],"2013-07",[3046,3047],"Parkinson Disease","Amyotrophic Lateral Sclerosis",[3032],{"nctId":3050,"briefTitle":3051,"status":122,"phases":3052,"primaryCompletion":3053,"completion":3053,"start":125,"enrollment":2946,"conditions":3054,"interventions":3056},"NCT01653132","Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)\u002FParkinsonism",[89],"2014-09",[3055],"Sialorrhea",[3032],{"trials":3058,"activeCount":100},[],{"trials":3060,"activeCount":100},[],{"trials":3062,"activeCount":100},[],{"intervention":3064,"totalTrials":96,"cells":3065},"Dendritic Cell Tumor Fusion Vaccine",{"EARLY_PHASE1":3066,"PHASE1":3068,"PHASE2":3079,"PHASE3":3091,"PHASE4":3093,"NA":3095},{"trials":3067,"activeCount":100},[],{"trials":3069,"activeCount":100},[3070],{"nctId":3071,"briefTitle":3072,"status":122,"phases":3073,"primaryCompletion":3074,"completion":3075,"start":3076,"enrollment":1992,"conditions":3077,"interventions":3078},"NCT00459069","The Use of Dendritic Cell\u002FTumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma",[88],"2008-06","2009-11","2004-07",[561],[3064],{"trials":3080,"activeCount":100},[3081],{"nctId":3082,"briefTitle":3083,"status":122,"phases":3084,"primaryCompletion":3085,"completion":3086,"start":3087,"enrollment":2637,"conditions":3088,"interventions":3089},"NCT00458536","Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF",[88,89],"2014-12","2023-07","2004-10",[2731],[3064,3090],"Granulocyte Macrophage Colony Stimulating Factor",{"trials":3092,"activeCount":100},[],{"trials":3094,"activeCount":100},[],{"trials":3096,"activeCount":100},[],{"intervention":3098,"totalTrials":133,"cells":3099},"Electrofusion DC vaccine",{"EARLY_PHASE1":3100,"PHASE1":3102,"PHASE2":3104,"PHASE3":3114,"PHASE4":3116,"NA":3118},{"trials":3101,"activeCount":100},[],{"trials":3103,"activeCount":100},[],{"trials":3105,"activeCount":100},[3106],{"nctId":3107,"briefTitle":3108,"status":122,"phases":3109,"primaryCompletion":3110,"completion":589,"start":3111,"enrollment":11,"conditions":3112,"interventions":3113},"NCT00625755","A Phase I\u002FII Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma",[88,89],"2005-06","2002-12",[29],[3098],{"trials":3115,"activeCount":100},[],{"trials":3117,"activeCount":100},[],{"trials":3119,"activeCount":100},[],{"intervention":3121,"totalTrials":133,"cells":3122},"Zafirlukast",{"EARLY_PHASE1":3123,"PHASE1":3125,"PHASE2":3127,"PHASE3":3137,"PHASE4":3139,"NA":3141},{"trials":3124,"activeCount":100},[],{"trials":3126,"activeCount":100},[],{"trials":3128,"activeCount":100},[3129],{"nctId":3130,"briefTitle":3131,"status":122,"phases":3132,"primaryCompletion":2693,"completion":3133,"start":3134,"enrollment":559,"conditions":3135,"interventions":3136},"NCT04339140","Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer",[89],"2024-12-31","2020-06-24",[32],[3121],{"trials":3138,"activeCount":100},[],{"trials":3140,"activeCount":100},[],{"trials":3142,"activeCount":100},[],{"intervention":3144,"totalTrials":133,"cells":3145},"rosuvastatin",{"EARLY_PHASE1":3146,"PHASE1":3148,"PHASE2":3150,"PHASE3":3160,"PHASE4":3162,"NA":3164},{"trials":3147,"activeCount":100},[],{"trials":3149,"activeCount":100},[],{"trials":3151,"activeCount":100},[3152],{"nctId":3153,"briefTitle":3154,"status":122,"phases":3155,"primaryCompletion":3156,"completion":2118,"start":3157,"enrollment":726,"conditions":3158,"interventions":3159},"NCT01299038","Rosuvastatin to Lower Circulating Tissue Factor Bearing Microparticles in Metastatic Breast Cancer",[89],"2013-11","2010-10",[15],[3144],{"trials":3161,"activeCount":100},[],{"trials":3163,"activeCount":100},[],{"trials":3165,"activeCount":100},[],{"intervention":3167,"totalTrials":133,"cells":3168},"Capecitabine",{"EARLY_PHASE1":3169,"PHASE1":3171,"PHASE2":3173,"PHASE3":3184,"PHASE4":3186,"NA":3188},{"trials":3170,"activeCount":100},[],{"trials":3172,"activeCount":100},[],{"trials":3174,"activeCount":100},[3175],{"nctId":3176,"briefTitle":3177,"status":122,"phases":3178,"primaryCompletion":3179,"completion":3179,"start":2977,"enrollment":11,"conditions":3180,"interventions":3182},"NCT00585078","Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma",[89],"2011-12",[3181],"Pancreatic Cancer",[3167,3183],"Oxaliplatin",{"trials":3185,"activeCount":100},[],{"trials":3187,"activeCount":100},[],{"trials":3189,"activeCount":100},[],{"intervention":3183,"totalTrials":133,"cells":3191},{"EARLY_PHASE1":3192,"PHASE1":3194,"PHASE2":3196,"PHASE3":3202,"PHASE4":3204,"NA":3206},{"trials":3193,"activeCount":100},[],{"trials":3195,"activeCount":100},[],{"trials":3197,"activeCount":100},[3198],{"nctId":3176,"briefTitle":3177,"status":122,"phases":3199,"primaryCompletion":3179,"completion":3179,"start":2977,"enrollment":11,"conditions":3200,"interventions":3201},[89],[3181],[3167,3183],{"trials":3203,"activeCount":100},[],{"trials":3205,"activeCount":100},[],{"trials":3207,"activeCount":100},[],{"intervention":3209,"totalTrials":133,"cells":3210},"D5W",{"EARLY_PHASE1":3211,"PHASE1":3213,"PHASE2":3215,"PHASE3":3227,"PHASE4":3229,"NA":3231},{"trials":3212,"activeCount":100},[],{"trials":3214,"activeCount":100},[],{"trials":3216,"activeCount":100},[3217],{"nctId":3218,"briefTitle":3219,"status":122,"phases":3220,"primaryCompletion":3221,"completion":3221,"start":3222,"enrollment":3223,"conditions":3224,"interventions":3225},"NCT01070810","Thiamine as a Metabolic Resuscitator in Septic Shock",[88,89],"2014-11","2010-02",88,[34],[3209,3226],"Thiamine",{"trials":3228,"activeCount":100},[],{"trials":3230,"activeCount":100},[],{"trials":3232,"activeCount":100},[],{"intervention":3234,"totalTrials":133,"cells":3235},"Dantrolene",{"EARLY_PHASE1":3236,"PHASE1":3238,"PHASE2":3240,"PHASE3":3252,"PHASE4":3254,"NA":3256},{"trials":3237,"activeCount":100},[],{"trials":3239,"activeCount":100},[],{"trials":3241,"activeCount":100},[3242],{"nctId":3243,"briefTitle":3244,"status":122,"phases":3245,"primaryCompletion":3246,"completion":3246,"start":3247,"enrollment":3248,"conditions":3249,"interventions":3251},"NCT03762109","The Use of Dantrolene to Improve Analgesia in Posterior Lumbar Surgery",[89],"2024-06-01","2019-07-29",90,[3250],"Lumbar Spine Injury",[3234],{"trials":3253,"activeCount":100},[],{"trials":3255,"activeCount":100},[],{"trials":3257,"activeCount":100},[],{"intervention":3259,"totalTrials":133,"cells":3260},"Coenzyme Q10",{"EARLY_PHASE1":3261,"PHASE1":3263,"PHASE2":3265,"PHASE3":3276,"PHASE4":3278,"NA":3280},{"trials":3262,"activeCount":100},[],{"trials":3264,"activeCount":100},[],{"trials":3266,"activeCount":100},[3267],{"nctId":3268,"briefTitle":3269,"status":122,"phases":3270,"primaryCompletion":3271,"completion":3271,"start":3272,"enrollment":2946,"conditions":3273,"interventions":3275},"NCT01319110","Coenzyme Q10 in Post-Cardiac Arrest Cerebral Resuscitation",[89],"2011-12-31","2011-02",[535,3274],"Sudden Cardiac Arrest",[3259],{"trials":3277,"activeCount":100},[],{"trials":3279,"activeCount":100},[],{"trials":3281,"activeCount":100},[],{"intervention":2596,"totalTrials":133,"cells":3283},{"EARLY_PHASE1":3284,"PHASE1":3286,"PHASE2":3288,"PHASE3":3294,"PHASE4":3296,"NA":3298},{"trials":3285,"activeCount":100},[],{"trials":3287,"activeCount":100},[],{"trials":3289,"activeCount":100},[3290],{"nctId":2587,"briefTitle":2588,"status":122,"phases":3291,"primaryCompletion":2590,"completion":2590,"start":2591,"enrollment":726,"conditions":3292,"interventions":3293},[89],[2593,2594],[2596,2578],{"trials":3295,"activeCount":100},[],{"trials":3297,"activeCount":100},[],{"trials":3299,"activeCount":100},[],{"intervention":3301,"totalTrials":133,"cells":3302},"Normal Saline placebo",{"EARLY_PHASE1":3303,"PHASE1":3305,"PHASE2":3307,"PHASE3":3315,"PHASE4":3317,"NA":3319},{"trials":3304,"activeCount":100},[],{"trials":3306,"activeCount":100},[],{"trials":3308,"activeCount":100},[3309],{"nctId":3310,"briefTitle":3311,"status":122,"phases":3312,"primaryCompletion":2191,"completion":2390,"start":627,"enrollment":1406,"conditions":3313,"interventions":3314},"NCT01089361","Immunomodulatory Properties of Ketamine in Sepsis",[88,89],[882],[444,3301],{"trials":3316,"activeCount":100},[],{"trials":3318,"activeCount":100},[],{"trials":3320,"activeCount":100},[],{"intervention":3322,"totalTrials":133,"cells":3323},"23.4% Hypertonic saline",{"EARLY_PHASE1":3324,"PHASE1":3326,"PHASE2":3328,"PHASE3":3338,"PHASE4":3340,"NA":3342},{"trials":3325,"activeCount":100},[],{"trials":3327,"activeCount":100},[],{"trials":3329,"activeCount":100},[3330],{"nctId":3331,"briefTitle":3332,"status":122,"phases":3333,"primaryCompletion":3334,"completion":3334,"start":1472,"enrollment":9,"conditions":3335,"interventions":3337},"NCT02805595","Effect of Sclerotherapy on Fistulas and Sinus Tracts in Hidradenitis Suppurativa",[89],"2022-11",[3336],"Hidradenitis Suppurativa",[3322],{"trials":3339,"activeCount":100},[],{"trials":3341,"activeCount":100},[],{"trials":3343,"activeCount":100},[],{"intervention":2698,"totalTrials":133,"cells":3345},{"EARLY_PHASE1":3346,"PHASE1":3348,"PHASE2":3350,"PHASE3":3356,"PHASE4":3358,"NA":3360},{"trials":3347,"activeCount":100},[],{"trials":3349,"activeCount":100},[],{"trials":3351,"activeCount":100},[3352],{"nctId":2690,"briefTitle":2691,"status":122,"phases":3353,"primaryCompletion":2693,"completion":2694,"start":2695,"enrollment":2457,"conditions":3354,"interventions":3355},[89],[32],[2681,2698],{"trials":3357,"activeCount":100},[],{"trials":3359,"activeCount":100},[],{"trials":3361,"activeCount":100},[],{"intervention":3363,"totalTrials":133,"cells":3364},"Deucravacitinib",{"EARLY_PHASE1":3365,"PHASE1":3367,"PHASE2":3369,"PHASE3":3378,"PHASE4":3380,"NA":3382},{"trials":3366,"activeCount":100},[],{"trials":3368,"activeCount":100},[],{"trials":3370,"activeCount":100},[3371],{"nctId":3372,"briefTitle":3373,"status":555,"phases":3374,"primaryCompletion":3375,"completion":924,"start":232,"enrollment":2392,"conditions":3376,"interventions":3377},"NCT05997277","Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).",[89],"2025-02-25",[3336],[3363],{"trials":3379,"activeCount":100},[],{"trials":3381,"activeCount":100},[],{"trials":3383,"activeCount":100},[],{"intervention":2451,"totalTrials":133,"cells":3385},{"EARLY_PHASE1":3386,"PHASE1":3388,"PHASE2":3390,"PHASE3":3396,"PHASE4":3398,"NA":3400},{"trials":3387,"activeCount":100},[],{"trials":3389,"activeCount":100},[],{"trials":3391,"activeCount":100},[3392],{"nctId":2444,"briefTitle":2445,"status":122,"phases":3393,"primaryCompletion":1348,"completion":2390,"start":2447,"enrollment":25,"conditions":3394,"interventions":3395},[89],[2449],[2423,2451],{"trials":3397,"activeCount":100},[],{"trials":3399,"activeCount":100},[],{"trials":3401,"activeCount":100},[],{"intervention":3403,"totalTrials":133,"cells":3404},"DC\u002Ftumor fusion vaccine",{"EARLY_PHASE1":3405,"PHASE1":3407,"PHASE2":3409,"PHASE3":3419,"PHASE4":3421,"NA":3423},{"trials":3406,"activeCount":100},[],{"trials":3408,"activeCount":100},[],{"trials":3410,"activeCount":100},[3411],{"nctId":3412,"briefTitle":3413,"status":122,"phases":3414,"primaryCompletion":2490,"completion":3415,"start":461,"enrollment":726,"conditions":3416,"interventions":3418},"NCT00626860","The Use of Dendritic Cell\u002FTumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma",[88,89],"2008-09-10",[3417],"Metastatic Melanoma",[3403],{"trials":3420,"activeCount":100},[],{"trials":3422,"activeCount":100},[],{"trials":3424,"activeCount":100},[],{"intervention":2766,"totalTrials":133,"cells":3426},{"EARLY_PHASE1":3427,"PHASE1":3429,"PHASE2":3431,"PHASE3":3437,"PHASE4":3439,"NA":3441},{"trials":3428,"activeCount":100},[],{"trials":3430,"activeCount":100},[],{"trials":3432,"activeCount":100},[3433],{"nctId":2757,"briefTitle":2758,"status":122,"phases":3434,"primaryCompletion":2760,"completion":2761,"start":2762,"enrollment":2457,"conditions":3435,"interventions":3436},[88,89],[2764],[2748,2766],{"trials":3438,"activeCount":100},[],{"trials":3440,"activeCount":100},[],{"trials":3442,"activeCount":100},[],{"intervention":2801,"totalTrials":133,"cells":3444},{"EARLY_PHASE1":3445,"PHASE1":3447,"PHASE2":3449,"PHASE3":3455,"PHASE4":3457,"NA":3459},{"trials":3446,"activeCount":100},[],{"trials":3448,"activeCount":100},[],{"trials":3450,"activeCount":100},[3451],{"nctId":2792,"briefTitle":2793,"status":122,"phases":3452,"primaryCompletion":2795,"completion":2795,"start":2796,"enrollment":2797,"conditions":3453,"interventions":3454},[89],[2799],[2783,2801],{"trials":3456,"activeCount":100},[],{"trials":3458,"activeCount":100},[],{"trials":3460,"activeCount":100},[],{"intervention":3462,"totalTrials":133,"cells":3463},"Anastrozole 1mg",{"EARLY_PHASE1":3464,"PHASE1":3466,"PHASE2":3468,"PHASE3":3481,"PHASE4":3483,"NA":3485},{"trials":3465,"activeCount":100},[],{"trials":3467,"activeCount":100},[],{"trials":3469,"activeCount":100},[3470],{"nctId":3471,"briefTitle":3472,"status":122,"phases":3473,"primaryCompletion":3474,"completion":3474,"start":3475,"enrollment":11,"conditions":3476,"interventions":3480},"NCT00179517","Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo",[89],"2008-04","2001-06",[3477,3478,3479],"Seizure Disorder","Hypogonadism","Erectile Dysfunction",[3462],{"trials":3482,"activeCount":100},[],{"trials":3484,"activeCount":100},[],{"trials":3486,"activeCount":100},[],{"intervention":563,"totalTrials":133,"cells":3488},{"EARLY_PHASE1":3489,"PHASE1":3491,"PHASE2":3493,"PHASE3":3499,"PHASE4":3501,"NA":3503},{"trials":3490,"activeCount":100},[],{"trials":3492,"activeCount":100},[],{"trials":3494,"activeCount":100},[3495],{"nctId":553,"briefTitle":554,"status":555,"phases":3496,"primaryCompletion":557,"completion":557,"start":558,"enrollment":559,"conditions":3497,"interventions":3498},[89],[561],[40,563],{"trials":3500,"activeCount":100},[],{"trials":3502,"activeCount":100},[],{"trials":3504,"activeCount":100},[],{"intervention":2854,"totalTrials":133,"cells":3506},{"EARLY_PHASE1":3507,"PHASE1":3509,"PHASE2":3511,"PHASE3":3517,"PHASE4":3519,"NA":3521},{"trials":3508,"activeCount":100},[],{"trials":3510,"activeCount":100},[],{"trials":3512,"activeCount":100},[3513],{"nctId":2848,"briefTitle":2849,"status":555,"phases":3514,"primaryCompletion":1965,"completion":1965,"start":2851,"enrollment":2737,"conditions":3515,"interventions":3516},[89],[29],[2839,2854],{"trials":3518,"activeCount":100},[],{"trials":3520,"activeCount":100},[],{"trials":3522,"activeCount":100},[],{"intervention":3524,"totalTrials":133,"cells":3525},"temsirolimus",{"EARLY_PHASE1":3526,"PHASE1":3528,"PHASE2":3530,"PHASE3":3541,"PHASE4":3543,"NA":3545},{"trials":3527,"activeCount":100},[],{"trials":3529,"activeCount":100},[],{"trials":3531,"activeCount":100},[3532],{"nctId":3533,"briefTitle":3534,"status":122,"phases":3535,"primaryCompletion":1592,"completion":1592,"start":3536,"enrollment":1660,"conditions":3537,"interventions":3539},"NCT00782275","Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma",[89],"2009-04",[29,3538],"Kidney Cancer",[3540,3524],"bevacizumab",{"trials":3542,"activeCount":100},[],{"trials":3544,"activeCount":100},[],{"trials":3546,"activeCount":100},[],{"intervention":3548,"totalTrials":133,"cells":3549},"Ketoconazole, Hydrocortisone and Dutasteride",{"EARLY_PHASE1":3550,"PHASE1":3552,"PHASE2":3554,"PHASE3":3564,"PHASE4":3566,"NA":3568},{"trials":3551,"activeCount":100},[],{"trials":3553,"activeCount":100},[],{"trials":3555,"activeCount":100},[3556],{"nctId":3557,"briefTitle":3558,"status":122,"phases":3559,"primaryCompletion":2217,"completion":1683,"start":3560,"enrollment":3561,"conditions":3562,"interventions":3563},"NCT00673127","Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer",[89],"2005-02",57,[27],[3548],{"trials":3565,"activeCount":100},[],{"trials":3567,"activeCount":100},[],{"trials":3569,"activeCount":100},[],{"intervention":3571,"totalTrials":133,"cells":3572},"Sorafenib",{"EARLY_PHASE1":3573,"PHASE1":3575,"PHASE2":3577,"PHASE3":3586,"PHASE4":3588,"NA":3590},{"trials":3574,"activeCount":100},[],{"trials":3576,"activeCount":100},[],{"trials":3578,"activeCount":100},[3579],{"nctId":3580,"briefTitle":3581,"status":122,"phases":3582,"primaryCompletion":3156,"completion":3156,"start":1071,"enrollment":726,"conditions":3583,"interventions":3585},"NCT00813293","Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer",[89],[3584],"Hepatocellular Cancer",[3571],{"trials":3587,"activeCount":100},[],{"trials":3589,"activeCount":100},[],{"trials":3591,"activeCount":100},[],{"intervention":3593,"totalTrials":133,"cells":3594},"HD IL2",{"EARLY_PHASE1":3595,"PHASE1":3597,"PHASE2":3599,"PHASE3":3611,"PHASE4":3613,"NA":3615},{"trials":3596,"activeCount":100},[],{"trials":3598,"activeCount":100},[],{"trials":3600,"activeCount":100},[3601],{"nctId":3602,"briefTitle":3603,"status":122,"phases":3604,"primaryCompletion":3605,"completion":3605,"start":3606,"enrollment":3607,"conditions":3608,"interventions":3610},"NCT00554515","The High-Dose Aldesleukin (IL-2) \"Select\" Trial for Patients With Metastatic Renal Cell Carcinoma",[89],"2013-10-31","2006-11",123,[3609],"Metastatic Renal Cell Carcinoma",[3593],{"trials":3612,"activeCount":100},[],{"trials":3614,"activeCount":100},[],{"trials":3616,"activeCount":100},[],{"intervention":466,"totalTrials":133,"cells":3618},{"EARLY_PHASE1":3619,"PHASE1":3621,"PHASE2":3623,"PHASE3":3629,"PHASE4":3631,"NA":3633},{"trials":3620,"activeCount":100},[],{"trials":3622,"activeCount":100},[],{"trials":3624,"activeCount":100},[3625],{"nctId":458,"briefTitle":459,"status":434,"phases":3626,"primaryCompletion":461,"completion":461,"start":461,"enrollment":100,"conditions":3627,"interventions":3628},[88,89],[15],[464,465,466,467,468,469],{"trials":3630,"activeCount":100},[],{"trials":3632,"activeCount":100},[],{"trials":3634,"activeCount":100},[],{"intervention":469,"totalTrials":133,"cells":3636},{"EARLY_PHASE1":3637,"PHASE1":3639,"PHASE2":3641,"PHASE3":3647,"PHASE4":3649,"NA":3651},{"trials":3638,"activeCount":100},[],{"trials":3640,"activeCount":100},[],{"trials":3642,"activeCount":100},[3643],{"nctId":458,"briefTitle":459,"status":434,"phases":3644,"primaryCompletion":461,"completion":461,"start":461,"enrollment":100,"conditions":3645,"interventions":3646},[88,89],[15],[464,465,466,467,468,469],{"trials":3648,"activeCount":100},[],{"trials":3650,"activeCount":100},[],{"trials":3652,"activeCount":100},[],{"intervention":3654,"totalTrials":133,"cells":3655},"Secukinumab",{"EARLY_PHASE1":3656,"PHASE1":3658,"PHASE2":3660,"PHASE3":3672,"PHASE4":3674,"NA":3676},{"trials":3657,"activeCount":100},[],{"trials":3659,"activeCount":100},[],{"trials":3661,"activeCount":100},[3662],{"nctId":3663,"briefTitle":3664,"status":555,"phases":3665,"primaryCompletion":3666,"completion":3667,"start":3668,"enrollment":1027,"conditions":3669,"interventions":3671},"NCT03791060","Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)",[89],"2021-01-17","2021-04-10","2019-04-03",[3670],"Necrobiosis Lipoidica Diabeticorum",[3654],{"trials":3673,"activeCount":100},[],{"trials":3675,"activeCount":100},[],{"trials":3677,"activeCount":100},[],{"intervention":3679,"totalTrials":133,"cells":3680},"Dupilumab",{"EARLY_PHASE1":3681,"PHASE1":3683,"PHASE2":3685,"PHASE3":3697,"PHASE4":3699,"NA":3701},{"trials":3682,"activeCount":100},[],{"trials":3684,"activeCount":100},[],{"trials":3686,"activeCount":100},[3687],{"nctId":3688,"briefTitle":3689,"status":122,"phases":3690,"primaryCompletion":3691,"completion":3692,"start":3693,"enrollment":726,"conditions":3694,"interventions":3696},"NCT05128383","Study to Assess Efficacy and Safety of Dupilumab in the Treatment of Keloids",[89],"2025-05-19","2025-06-10","2023-01-13",[3695],"Keloid",[3679],{"trials":3698,"activeCount":100},[],{"trials":3700,"activeCount":100},[],{"trials":3702,"activeCount":100},[],{"intervention":3704,"totalTrials":133,"cells":3705},"DS-01",{"EARLY_PHASE1":3706,"PHASE1":3708,"PHASE2":3710,"PHASE3":3722,"PHASE4":3724,"NA":3726},{"trials":3707,"activeCount":100},[],{"trials":3709,"activeCount":100},[],{"trials":3711,"activeCount":100},[3712],{"nctId":3713,"briefTitle":3714,"status":122,"phases":3715,"primaryCompletion":3716,"completion":3717,"start":3718,"enrollment":2630,"conditions":3719,"interventions":3721},"NCT04598295","SH-DS01 on Fecal Metagenomic Stability",[89],"2022-10-17","2022-10-26","2020-10-20",[3720],"Irritable Bowel Syndrome",[3704],{"trials":3723,"activeCount":100},[],{"trials":3725,"activeCount":100},[],{"trials":3727,"activeCount":100},[],{"intervention":3729,"totalTrials":133,"cells":3730},"donepezil",{"EARLY_PHASE1":3731,"PHASE1":3733,"PHASE2":3735,"PHASE3":3745,"PHASE4":3747,"NA":3749},{"trials":3732,"activeCount":100},[],{"trials":3734,"activeCount":100},[],{"trials":3736,"activeCount":100},[3737],{"nctId":3738,"briefTitle":3739,"status":122,"phases":3740,"primaryCompletion":3741,"completion":3741,"start":1991,"enrollment":3742,"conditions":3743,"interventions":3744},"NCT00586196","Supporting the Health of Adults Undergoing Orthopedic Surgery During the Recovery Period",[89],"2013-02",16,[2040],[3729],{"trials":3746,"activeCount":100},[],{"trials":3748,"activeCount":100},[],{"trials":3750,"activeCount":100},[],{"intervention":3752,"totalTrials":133,"cells":3753},"200mg IV thiamine in 50mL 0.9% saline",{"EARLY_PHASE1":3754,"PHASE1":3756,"PHASE2":3758,"PHASE3":3770,"PHASE4":3772,"NA":3774},{"trials":3755,"activeCount":100},[],{"trials":3757,"activeCount":100},[],{"trials":3759,"activeCount":100},[3760],{"nctId":3761,"briefTitle":3762,"status":122,"phases":3763,"primaryCompletion":3764,"completion":3765,"start":3766,"enrollment":1366,"conditions":3767,"interventions":3769},"NCT03717896","Thiamine As Adjunctive Therapy for Diabetic Ketoacidosis",[89],"2024-09-30","2024-10-01","2018-11-21",[3768],"Diabetic Ketoacidosis",[3752],{"trials":3771,"activeCount":100},[],{"trials":3773,"activeCount":100},[],{"trials":3775,"activeCount":100},[],{"intervention":3777,"totalTrials":133,"cells":3778},"Neratinib",{"EARLY_PHASE1":3779,"PHASE1":3781,"PHASE2":3783,"PHASE3":3796,"PHASE4":3798,"NA":3800},{"trials":3780,"activeCount":100},[],{"trials":3782,"activeCount":100},[],{"trials":3784,"activeCount":100},[3785],{"nctId":3786,"briefTitle":3787,"status":434,"phases":3788,"primaryCompletion":3789,"completion":3789,"start":3790,"enrollment":100,"conditions":3791,"interventions":3795},"NCT04781374","Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer",[89],"2021-09-24","2021-05-21",[3792,3793,27,3794],"Metastatic Prostate Adenocarcinoma","Castration-resistant Prostate Cancer","Prostate Cancer Metastatic",[3777],{"trials":3797,"activeCount":100},[],{"trials":3799,"activeCount":100},[],{"trials":3801,"activeCount":100},[],{"intervention":2988,"totalTrials":133,"cells":3803},{"EARLY_PHASE1":3804,"PHASE1":3806,"PHASE2":3808,"PHASE3":3814,"PHASE4":3816,"NA":3818},{"trials":3805,"activeCount":100},[],{"trials":3807,"activeCount":100},[],{"trials":3809,"activeCount":100},[3810],{"nctId":2981,"briefTitle":2982,"status":122,"phases":3811,"primaryCompletion":2984,"completion":2984,"start":2985,"enrollment":1805,"conditions":3812,"interventions":3813},[89],[954],[2964,2988,2989],{"trials":3815,"activeCount":100},[],{"trials":3817,"activeCount":100},[],{"trials":3819,"activeCount":100},[],{"intervention":2989,"totalTrials":133,"cells":3821},{"EARLY_PHASE1":3822,"PHASE1":3824,"PHASE2":3826,"PHASE3":3832,"PHASE4":3834,"NA":3836},{"trials":3823,"activeCount":100},[],{"trials":3825,"activeCount":100},[],{"trials":3827,"activeCount":100},[3828],{"nctId":2981,"briefTitle":2982,"status":122,"phases":3829,"primaryCompletion":2984,"completion":2984,"start":2985,"enrollment":1805,"conditions":3830,"interventions":3831},[89],[954],[2964,2988,2989],{"trials":3833,"activeCount":100},[],{"trials":3835,"activeCount":100},[],{"trials":3837,"activeCount":100},[],{"intervention":3839,"totalTrials":133,"cells":3840},"Intranasal insulin",{"EARLY_PHASE1":3841,"PHASE1":3843,"PHASE2":3845,"PHASE3":3856,"PHASE4":3858,"NA":3860},{"trials":3842,"activeCount":100},[],{"trials":3844,"activeCount":100},[],{"trials":3846,"activeCount":100},[3847],{"nctId":3848,"briefTitle":3849,"status":122,"phases":3850,"primaryCompletion":3851,"completion":3851,"start":3852,"enrollment":477,"conditions":3853,"interventions":3855},"NCT01206322","Enhancement of Cerebral Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes",[89],"2013-04","2010-05",[3854],"Type 2 Diabetes Mellitus",[3839],{"trials":3857,"activeCount":100},[],{"trials":3859,"activeCount":100},[],{"trials":3861,"activeCount":100},[],{"intervention":498,"totalTrials":133,"cells":3863},{"EARLY_PHASE1":3864,"PHASE1":3866,"PHASE2":3868,"PHASE3":3874,"PHASE4":3876,"NA":3878},{"trials":3865,"activeCount":100},[],{"trials":3867,"activeCount":100},[],{"trials":3869,"activeCount":100},[3870],{"nctId":488,"briefTitle":489,"status":122,"phases":3871,"primaryCompletion":491,"completion":492,"start":493,"enrollment":494,"conditions":3872,"interventions":3873},[89],[15],[448,497,498],{"trials":3875,"activeCount":100},[],{"trials":3877,"activeCount":100},[],{"trials":3879,"activeCount":100},[],{"intervention":3881,"totalTrials":133,"cells":3882},"Normal saline solution",{"EARLY_PHASE1":3883,"PHASE1":3885,"PHASE2":3887,"PHASE3":3899,"PHASE4":3901,"NA":3903},{"trials":3884,"activeCount":100},[],{"trials":3886,"activeCount":100},[],{"trials":3888,"activeCount":100},[3889],{"nctId":3890,"briefTitle":3891,"status":122,"phases":3892,"primaryCompletion":3893,"completion":3893,"start":3894,"enrollment":1709,"conditions":3895,"interventions":3898},"NCT02322892","Thiamine as an Adjunctive Therapy in Cardiac Surgery",[89],"2015-08","2015-01",[3896,3897],"Coronary Artery Bypass","Cardiac Surgical Procedures",[3226,3881],{"trials":3900,"activeCount":100},[],{"trials":3902,"activeCount":100},[],{"trials":3904,"activeCount":100},[],{"intervention":2405,"totalTrials":133,"cells":3906},{"EARLY_PHASE1":3907,"PHASE1":3909,"PHASE2":3911,"PHASE3":3917,"PHASE4":3919,"NA":3921},{"trials":3908,"activeCount":100},[],{"trials":3910,"activeCount":100},[],{"trials":3912,"activeCount":100},[3913],{"nctId":2397,"briefTitle":2398,"status":122,"phases":3914,"primaryCompletion":2400,"completion":1058,"start":2401,"enrollment":726,"conditions":3915,"interventions":3916},[89],[2403],[2369,2405],{"trials":3918,"activeCount":100},[],{"trials":3920,"activeCount":100},[],{"trials":3922,"activeCount":100},[],{"intervention":3924,"totalTrials":133,"cells":3925},"GO-203-2c",{"EARLY_PHASE1":3926,"PHASE1":3928,"PHASE2":3930,"PHASE3":3942,"PHASE4":3944,"NA":3946},{"trials":3927,"activeCount":100},[],{"trials":3929,"activeCount":100},[],{"trials":3931,"activeCount":100},[3932],{"nctId":3933,"briefTitle":3934,"status":122,"phases":3935,"primaryCompletion":2859,"completion":2860,"start":3053,"enrollment":3936,"conditions":3937,"interventions":3940},"NCT02204085","A Phase I\u002FII Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia",[88,89],33,[3938,3939],"Acute Myeloid Leukemia, in Relapse","Recurrent Adult Acute Myeloid Leukemia",[3924,3941],"GO-203-2c + Decitabine",{"trials":3943,"activeCount":100},[],{"trials":3945,"activeCount":100},[],{"trials":3947,"activeCount":100},[],{"intervention":3941,"totalTrials":133,"cells":3949},{"EARLY_PHASE1":3950,"PHASE1":3952,"PHASE2":3954,"PHASE3":3960,"PHASE4":3962,"NA":3964},{"trials":3951,"activeCount":100},[],{"trials":3953,"activeCount":100},[],{"trials":3955,"activeCount":100},[3956],{"nctId":3933,"briefTitle":3934,"status":122,"phases":3957,"primaryCompletion":2859,"completion":2860,"start":3053,"enrollment":3936,"conditions":3958,"interventions":3959},[88,89],[3938,3939],[3924,3941],{"trials":3961,"activeCount":100},[],{"trials":3963,"activeCount":100},[],{"trials":3965,"activeCount":100},[],{"intervention":3090,"totalTrials":133,"cells":3967},{"EARLY_PHASE1":3968,"PHASE1":3970,"PHASE2":3972,"PHASE3":3978,"PHASE4":3980,"NA":3982},{"trials":3969,"activeCount":100},[],{"trials":3971,"activeCount":100},[],{"trials":3973,"activeCount":100},[3974],{"nctId":3082,"briefTitle":3083,"status":122,"phases":3975,"primaryCompletion":3085,"completion":3086,"start":3087,"enrollment":2637,"conditions":3976,"interventions":3977},[88,89],[2731],[3064,3090],{"trials":3979,"activeCount":100},[],{"trials":3981,"activeCount":100},[],{"trials":3983,"activeCount":100},[],{"intervention":2607,"totalTrials":133,"cells":3985},{"EARLY_PHASE1":3986,"PHASE1":3988,"PHASE2":3990,"PHASE3":3996,"PHASE4":3998,"NA":4000},{"trials":3987,"activeCount":100},[],{"trials":3989,"activeCount":100},[],{"trials":3991,"activeCount":100},[3992],{"nctId":2598,"briefTitle":2599,"status":555,"phases":3993,"primaryCompletion":2590,"completion":2590,"start":2601,"enrollment":2412,"conditions":3994,"interventions":3995},[89],[2603,2604,2605],[2607,2578],{"trials":3997,"activeCount":100},[],{"trials":3999,"activeCount":100},[],{"trials":4001,"activeCount":100},[],{"intervention":2537,"totalTrials":133,"cells":4003},{"EARLY_PHASE1":4004,"PHASE1":4006,"PHASE2":4008,"PHASE3":4014,"PHASE4":4016,"NA":4018},{"trials":4005,"activeCount":100},[],{"trials":4007,"activeCount":100},[],{"trials":4009,"activeCount":100},[4010],{"nctId":2522,"briefTitle":2523,"status":122,"phases":4011,"primaryCompletion":2525,"start":2478,"enrollment":1805,"conditions":4012,"interventions":4013},[89],[2527,2528,2529,2530,2531,2532,2533,2534,2535],[497,2537,2538,2539,2540],{"trials":4015,"activeCount":100},[],{"trials":4017,"activeCount":100},[],{"trials":4019,"activeCount":100},[],{"intervention":2538,"totalTrials":133,"cells":4021},{"EARLY_PHASE1":4022,"PHASE1":4024,"PHASE2":4026,"PHASE3":4032,"PHASE4":4034,"NA":4036},{"trials":4023,"activeCount":100},[],{"trials":4025,"activeCount":100},[],{"trials":4027,"activeCount":100},[4028],{"nctId":2522,"briefTitle":2523,"status":122,"phases":4029,"primaryCompletion":2525,"start":2478,"enrollment":1805,"conditions":4030,"interventions":4031},[89],[2527,2528,2529,2530,2531,2532,2533,2534,2535],[497,2537,2538,2539,2540],{"trials":4033,"activeCount":100},[],{"trials":4035,"activeCount":100},[],{"trials":4037,"activeCount":100},[],{"intervention":2539,"totalTrials":133,"cells":4039},{"EARLY_PHASE1":4040,"PHASE1":4042,"PHASE2":4044,"PHASE3":4050,"PHASE4":4052,"NA":4054},{"trials":4041,"activeCount":100},[],{"trials":4043,"activeCount":100},[],{"trials":4045,"activeCount":100},[4046],{"nctId":2522,"briefTitle":2523,"status":122,"phases":4047,"primaryCompletion":2525,"start":2478,"enrollment":1805,"conditions":4048,"interventions":4049},[89],[2527,2528,2529,2530,2531,2532,2533,2534,2535],[497,2537,2538,2539,2540],{"trials":4051,"activeCount":100},[],{"trials":4053,"activeCount":100},[],{"trials":4055,"activeCount":100},[],{"intervention":2540,"totalTrials":133,"cells":4057},{"EARLY_PHASE1":4058,"PHASE1":4060,"PHASE2":4062,"PHASE3":4068,"PHASE4":4070,"NA":4072},{"trials":4059,"activeCount":100},[],{"trials":4061,"activeCount":100},[],{"trials":4063,"activeCount":100},[4064],{"nctId":2522,"briefTitle":2523,"status":122,"phases":4065,"primaryCompletion":2525,"start":2478,"enrollment":1805,"conditions":4066,"interventions":4067},[89],[2527,2528,2529,2530,2531,2532,2533,2534,2535],[497,2537,2538,2539,2540],{"trials":4069,"activeCount":100},[],{"trials":4071,"activeCount":100},[],{"trials":4073,"activeCount":100},[],{"intervention":1310,"totalTrials":133,"cells":4075},{"EARLY_PHASE1":4076,"PHASE1":4078,"PHASE2":4080,"PHASE3":4086,"PHASE4":4088,"NA":4090},{"trials":4077,"activeCount":100},[],{"trials":4079,"activeCount":100},[],{"trials":4081,"activeCount":100},[4082],{"nctId":1300,"briefTitle":1301,"status":555,"phases":4083,"primaryCompletion":1303,"completion":1304,"start":1305,"enrollment":30,"conditions":4084,"interventions":4085},[88,89],[1307,1308],[1310,1311,1282],{"trials":4087,"activeCount":100},[],{"trials":4089,"activeCount":100},[],{"trials":4091,"activeCount":100},[],{"intervention":1311,"totalTrials":133,"cells":4093},{"EARLY_PHASE1":4094,"PHASE1":4096,"PHASE2":4098,"PHASE3":4104,"PHASE4":4106,"NA":4108},{"trials":4095,"activeCount":100},[],{"trials":4097,"activeCount":100},[],{"trials":4099,"activeCount":100},[4100],{"nctId":1300,"briefTitle":1301,"status":555,"phases":4101,"primaryCompletion":1303,"completion":1304,"start":1305,"enrollment":30,"conditions":4102,"interventions":4103},[88,89],[1307,1308],[1310,1311,1282],{"trials":4105,"activeCount":100},[],{"trials":4107,"activeCount":100},[],{"trials":4109,"activeCount":100},[],{"intervention":4111,"totalTrials":133,"cells":4112},"Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF",{"EARLY_PHASE1":4113,"PHASE1":4115,"PHASE2":4117,"PHASE3":4130,"PHASE4":4132,"NA":4134},{"trials":4114,"activeCount":100},[],{"trials":4116,"activeCount":100},[],{"trials":4118,"activeCount":100},[4119],{"nctId":4120,"briefTitle":4121,"status":122,"phases":4122,"primaryCompletion":1991,"completion":1991,"start":3111,"enrollment":1805,"conditions":4123,"interventions":4129},"NCT00533923","Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders",[89],[2527,2528,2530,4124,4125,4126,561,4127,4128],"Myelodysplastic Syndrome","Non-Hodgkin's Lymphoma","Hodgkin's Lymphoma","Aplastic Anemia","Myeloproliferative Disorder",[4111],{"trials":4131,"activeCount":100},[],{"trials":4133,"activeCount":100},[],{"trials":4135,"activeCount":100},[],{"intervention":2864,"totalTrials":133,"cells":4137},{"EARLY_PHASE1":4138,"PHASE1":4140,"PHASE2":4142,"PHASE3":4148,"PHASE4":4150,"NA":4152},{"trials":4139,"activeCount":100},[],{"trials":4141,"activeCount":100},[],{"trials":4143,"activeCount":100},[4144],{"nctId":2856,"briefTitle":2857,"status":122,"phases":4145,"primaryCompletion":2859,"completion":2860,"start":2861,"enrollment":205,"conditions":4146,"interventions":4147},[89],[561],[2839,2864],{"trials":4149,"activeCount":100},[],{"trials":4151,"activeCount":100},[],{"trials":4153,"activeCount":100},[],{"intervention":4155,"totalTrials":133,"cells":4156},"Esmolol",{"EARLY_PHASE1":4157,"PHASE1":4159,"PHASE2":4161,"PHASE3":4172,"PHASE4":4174,"NA":4176},{"trials":4158,"activeCount":100},[],{"trials":4160,"activeCount":100},[],{"trials":4162,"activeCount":100},[4163],{"nctId":4164,"briefTitle":4165,"status":555,"phases":4166,"primaryCompletion":4167,"completion":4167,"start":2976,"enrollment":11,"conditions":4168,"interventions":4171},"NCT02369900","Esmolol to Treat the Hemodynamic Effects of Septic Shock",[89],"2019-12-31",[34,4169,4170],"Hypotension","Tachycardia",[4155],{"trials":4173,"activeCount":100},[],{"trials":4175,"activeCount":100},[],{"trials":4177,"activeCount":100},[],{"intervention":4179,"totalTrials":133,"cells":4180},"Thiamine Hydrochloride",{"EARLY_PHASE1":4181,"PHASE1":4183,"PHASE2":4185,"PHASE3":4198,"PHASE4":4200,"NA":4202},{"trials":4182,"activeCount":100},[],{"trials":4184,"activeCount":100},[],{"trials":4186,"activeCount":100},[4187],{"nctId":4188,"briefTitle":4189,"status":122,"phases":4190,"primaryCompletion":4191,"completion":4191,"start":4192,"enrollment":4193,"conditions":4194,"interventions":4197},"NCT03550794","Thiamine as a Renal Protective Agent in Septic Shock",[89],"2022-04-05","2018-09-04",95,[882,4195,4196],"Kidney Injury","Thiamine Deficiency",[4179],{"trials":4199,"activeCount":100},[],{"trials":4201,"activeCount":100},[],{"trials":4203,"activeCount":100},[],{"intervention":4205,"totalTrials":133,"cells":4206},"Regular Human Insulin",{"EARLY_PHASE1":4207,"PHASE1":4209,"PHASE2":4211,"PHASE3":4222,"PHASE4":4224,"NA":4226},{"trials":4208,"activeCount":100},[],{"trials":4210,"activeCount":100},[],{"trials":4212,"activeCount":100},[4213],{"nctId":4214,"briefTitle":4215,"status":122,"phases":4216,"primaryCompletion":4217,"completion":4217,"start":4218,"enrollment":4219,"conditions":4220,"interventions":4221},"NCT02415556","Memory Aid by Intranasal Insulin in Diabetes (MemAID)",[89],"2020-05-31","2015-10-06",289,[3854],[4205],{"trials":4223,"activeCount":100},[],{"trials":4225,"activeCount":100},[],{"trials":4227,"activeCount":100},[],{"intervention":4229,"totalTrials":133,"cells":4230},"Interleukin-2",{"EARLY_PHASE1":4231,"PHASE1":4233,"PHASE2":4235,"PHASE3":4245,"PHASE4":4247,"NA":4249},{"trials":4232,"activeCount":100},[],{"trials":4234,"activeCount":100},[],{"trials":4236,"activeCount":100},[4237],{"nctId":4238,"briefTitle":4239,"status":122,"phases":4240,"primaryCompletion":4241,"completion":4241,"start":115,"enrollment":2218,"conditions":4242,"interventions":4244},"NCT02739412","Efficacy of Low Dose, SubQ Interleukin-2 (IL-2) to Expand Endogenous Regulatory T-Cells in Liver Transplant Recipients",[89],"2022-07",[4243],"Liver Transplantation",[4229],{"trials":4246,"activeCount":100},[],{"trials":4248,"activeCount":100},[],{"trials":4250,"activeCount":100},[],{"intervention":4252,"totalTrials":133,"cells":4253},"DC AML Vaccine",{"EARLY_PHASE1":4254,"PHASE1":4256,"PHASE2":4258,"PHASE3":4267,"PHASE4":4269,"NA":4271},{"trials":4255,"activeCount":100},[],{"trials":4257,"activeCount":100},[],{"trials":4259,"activeCount":100},[4260],{"nctId":4261,"briefTitle":4262,"status":122,"phases":4263,"primaryCompletion":436,"completion":1428,"start":3852,"enrollment":4264,"conditions":4265,"interventions":4266},"NCT01096602","Blockade of PD-1 in Conjunction With the Dendritic Cell\u002FAML Vaccine Following Chemotherapy Induced Remission",[89],63,[790,2527],[4252],{"trials":4268,"activeCount":100},[],{"trials":4270,"activeCount":100},[],{"trials":4272,"activeCount":100},[],{"intervention":630,"totalTrials":133,"cells":4274},{"EARLY_PHASE1":4275,"PHASE1":4277,"PHASE2":4279,"PHASE3":4285,"PHASE4":4287,"NA":4289},{"trials":4276,"activeCount":100},[],{"trials":4278,"activeCount":100},[],{"trials":4280,"activeCount":100},[4281],{"nctId":624,"briefTitle":625,"status":555,"phases":4282,"primaryCompletion":180,"completion":180,"start":627,"enrollment":30,"conditions":4283,"interventions":4284},[88,89],[15],[603,630,630],{"trials":4286,"activeCount":100},[],{"trials":4288,"activeCount":100},[],{"trials":4290,"activeCount":100},[],{"intervention":4292,"totalTrials":133,"cells":4293},"Atorvastatin",{"EARLY_PHASE1":4294,"PHASE1":4296,"PHASE2":4298,"PHASE3":4309,"PHASE4":4311,"NA":4313},{"trials":4295,"activeCount":100},[],{"trials":4297,"activeCount":100},[],{"trials":4299,"activeCount":100},[4300],{"nctId":4301,"briefTitle":4302,"status":122,"phases":4303,"primaryCompletion":4304,"completion":4304,"start":1966,"enrollment":4305,"conditions":4306,"interventions":4308},"NCT02056340","Statin Therapy in Acute Influenza",[89],"2018-06-30",116,[4307],"Influenza",[4292],{"trials":4310,"activeCount":100},[],{"trials":4312,"activeCount":100},[],{"trials":4314,"activeCount":100},[],{"intervention":1353,"totalTrials":133,"cells":4316},{"EARLY_PHASE1":4317,"PHASE1":4319,"PHASE2":4321,"PHASE3":4327,"PHASE4":4329,"NA":4331},{"trials":4318,"activeCount":100},[],{"trials":4320,"activeCount":100},[],{"trials":4322,"activeCount":100},[4323],{"nctId":1345,"briefTitle":1346,"status":122,"phases":4324,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":116,"conditions":4325,"interventions":4326},[89],[27],[1352,1336,1353,1354,1355],{"trials":4328,"activeCount":100},[],{"trials":4330,"activeCount":100},[],{"trials":4332,"activeCount":100},[],{"intervention":1354,"totalTrials":133,"cells":4334},{"EARLY_PHASE1":4335,"PHASE1":4337,"PHASE2":4339,"PHASE3":4345,"PHASE4":4347,"NA":4349},{"trials":4336,"activeCount":100},[],{"trials":4338,"activeCount":100},[],{"trials":4340,"activeCount":100},[4341],{"nctId":1345,"briefTitle":1346,"status":122,"phases":4342,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":116,"conditions":4343,"interventions":4344},[89],[27],[1352,1336,1353,1354,1355],{"trials":4346,"activeCount":100},[],{"trials":4348,"activeCount":100},[],{"trials":4350,"activeCount":100},[],{"intervention":1355,"totalTrials":133,"cells":4352},{"EARLY_PHASE1":4353,"PHASE1":4355,"PHASE2":4357,"PHASE3":4363,"PHASE4":4365,"NA":4367},{"trials":4354,"activeCount":100},[],{"trials":4356,"activeCount":100},[],{"trials":4358,"activeCount":100},[4359],{"nctId":1345,"briefTitle":1346,"status":122,"phases":4360,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":116,"conditions":4361,"interventions":4362},[89],[27],[1352,1336,1353,1354,1355],{"trials":4364,"activeCount":100},[],{"trials":4366,"activeCount":100},[],{"trials":4368,"activeCount":100},[],{"intervention":4370,"totalTrials":133,"cells":4371},"Sodium Nitroprusside",{"EARLY_PHASE1":4372,"PHASE1":4374,"PHASE2":4376,"PHASE3":4388,"PHASE4":4390,"NA":4392},{"trials":4373,"activeCount":100},[],{"trials":4375,"activeCount":100},[],{"trials":4377,"activeCount":100},[4378],{"nctId":4379,"briefTitle":4380,"status":555,"phases":4381,"primaryCompletion":3246,"completion":4382,"start":4383,"enrollment":133,"conditions":4384,"interventions":4386},"NCT04986072","Sodium Nitroprusside in Early Course Schizophrenia",[89],"2024-07-01","2022-03-14",[21,4385],"Schizoaffective Disorder",[4370,4387],"5% Dextrose solution",{"trials":4389,"activeCount":100},[],{"trials":4391,"activeCount":100},[],{"trials":4393,"activeCount":100},[],{"intervention":4387,"totalTrials":133,"cells":4395},{"EARLY_PHASE1":4396,"PHASE1":4398,"PHASE2":4400,"PHASE3":4406,"PHASE4":4408,"NA":4410},{"trials":4397,"activeCount":100},[],{"trials":4399,"activeCount":100},[],{"trials":4401,"activeCount":100},[4402],{"nctId":4379,"briefTitle":4380,"status":555,"phases":4403,"primaryCompletion":3246,"completion":4382,"start":4383,"enrollment":133,"conditions":4404,"interventions":4405},[89],[21,4385],[4370,4387],{"trials":4407,"activeCount":100},[],{"trials":4409,"activeCount":100},[],{"trials":4411,"activeCount":100},[],{"intervention":1250,"totalTrials":133,"cells":4413},{"EARLY_PHASE1":4414,"PHASE1":4416,"PHASE2":4418,"PHASE3":4424,"PHASE4":4426,"NA":4428},{"trials":4415,"activeCount":100},[],{"trials":4417,"activeCount":100},[],{"trials":4419,"activeCount":100},[4420],{"nctId":1241,"briefTitle":1242,"status":555,"phases":4421,"primaryCompletion":1244,"completion":1245,"start":1246,"enrollment":1247,"conditions":4422,"interventions":4423},[89],[287],[1250,1219],{"trials":4425,"activeCount":100},[],{"trials":4427,"activeCount":100},[],{"trials":4429,"activeCount":100},[],{"intervention":4431,"totalTrials":133,"cells":4432},"Lenalidomide",{"EARLY_PHASE1":4433,"PHASE1":4435,"PHASE2":4444,"PHASE3":4446,"PHASE4":4448,"NA":4450},{"trials":4434,"activeCount":100},[],{"trials":4436,"activeCount":100},[4437],{"nctId":4438,"briefTitle":4439,"status":555,"phases":4440,"primaryCompletion":4441,"completion":4441,"start":1683,"enrollment":133,"conditions":4442,"interventions":4443},"NCT01750762","Lenalidomide After Allo Transplant",[88],"2014-03",[561,954],[4431],{"trials":4445,"activeCount":100},[],{"trials":4447,"activeCount":100},[],{"trials":4449,"activeCount":100},[],{"trials":4451,"activeCount":100},[],{"intervention":4453,"totalTrials":133,"cells":4454},"topotecan hydrochloride",{"EARLY_PHASE1":4455,"PHASE1":4457,"PHASE2":4465,"PHASE3":4467,"PHASE4":4469,"NA":4471},{"trials":4456,"activeCount":100},[],{"trials":4458,"activeCount":100},[4459],{"nctId":4460,"briefTitle":4461,"status":122,"phases":4462,"completion":532,"start":2669,"enrollment":726,"conditions":4463,"interventions":4464},"NCT00055614","Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",[88],[601,32,2481],[4453],{"trials":4466,"activeCount":100},[],{"trials":4468,"activeCount":100},[],{"trials":4470,"activeCount":100},[],{"trials":4472,"activeCount":100},[],{"intervention":4474,"totalTrials":133,"cells":4475},"Fecal Microbial Transplantation",{"EARLY_PHASE1":4476,"PHASE1":4478,"PHASE2":4487,"PHASE3":4489,"PHASE4":4491,"NA":4493},{"trials":4477,"activeCount":100},[],{"trials":4479,"activeCount":100},[4480],{"nctId":4481,"briefTitle":4482,"status":122,"phases":4483,"primaryCompletion":115,"completion":115,"start":1473,"enrollment":1941,"conditions":4484,"interventions":4486},"NCT01847170","Impact of Fecal Biotherapy (FBT) on Microbial Diversity in Patients With Moderate to Severe Inflammatory Bowel Disease",[88],[4485],"Crohn's Disease",[4474],{"trials":4488,"activeCount":100},[],{"trials":4490,"activeCount":100},[],{"trials":4492,"activeCount":100},[],{"trials":4494,"activeCount":100},[],{"intervention":4496,"totalTrials":133,"cells":4497},"Trichuris suis ova",{"EARLY_PHASE1":4498,"PHASE1":4500,"PHASE2":4509,"PHASE3":4511,"PHASE4":4513,"NA":4515},{"trials":4499,"activeCount":100},[],{"trials":4501,"activeCount":100},[4502],{"nctId":4503,"briefTitle":4504,"status":122,"phases":4505,"primaryCompletion":3179,"completion":3179,"start":3222,"enrollment":1992,"conditions":4506,"interventions":4508},"NCT01070498","Trichuris Suis Ova in Peanut and Tree Nut Allergy",[88],[4507],"Food Allergy",[4496],{"trials":4510,"activeCount":100},[],{"trials":4512,"activeCount":100},[],{"trials":4514,"activeCount":100},[],{"trials":4516,"activeCount":100},[],{"intervention":2483,"totalTrials":133,"cells":4518},{"EARLY_PHASE1":4519,"PHASE1":4521,"PHASE2":4527,"PHASE3":4529,"PHASE4":4531,"NA":4533},{"trials":4520,"activeCount":100},[],{"trials":4522,"activeCount":100},[4523],{"nctId":2474,"briefTitle":2475,"status":122,"phases":4524,"primaryCompletion":2477,"completion":2241,"start":2478,"conditions":4525,"interventions":4526},[88],[2480,601,32,2481],[465,2467,2483],{"trials":4528,"activeCount":100},[],{"trials":4530,"activeCount":100},[],{"trials":4532,"activeCount":100},[],{"trials":4534,"activeCount":100},[],{"intervention":4536,"totalTrials":133,"cells":4537},"Arsenic trioxide",{"EARLY_PHASE1":4538,"PHASE1":4540,"PHASE2":4550,"PHASE3":4552,"PHASE4":4554,"NA":4556},{"trials":4539,"activeCount":100},[],{"trials":4541,"activeCount":100},[4542],{"nctId":4543,"briefTitle":4544,"status":555,"phases":4545,"primaryCompletion":4546,"completion":4546,"start":1070,"enrollment":2392,"conditions":4547,"interventions":4549},"NCT01397734","Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)",[88],"2018-08-06",[4548],"Chronic Myelogenous Leukemia",[4536],{"trials":4551,"activeCount":100},[],{"trials":4553,"activeCount":100},[],{"trials":4555,"activeCount":100},[],{"trials":4557,"activeCount":100},[],{"intervention":4559,"totalTrials":133,"cells":4560},"eszopiclone",{"EARLY_PHASE1":4561,"PHASE1":4563,"PHASE2":4574,"PHASE3":4576,"PHASE4":4578,"NA":4580},{"trials":4562,"activeCount":100},[],{"trials":4564,"activeCount":100},[4565],{"nctId":4566,"briefTitle":4567,"status":555,"phases":4568,"primaryCompletion":3893,"completion":1591,"start":493,"enrollment":726,"conditions":4569,"interventions":4573},"NCT01887691","Sleep Effectiveness and Insulin and Glucose Homeostasis",[88],[127,4570,4571,4572],"Prediabetic","Prediabetes","Glucose Intolerance",[4559],{"trials":4575,"activeCount":100},[],{"trials":4577,"activeCount":100},[],{"trials":4579,"activeCount":100},[],{"trials":4581,"activeCount":100},[],{"intervention":4583,"totalTrials":133,"cells":4584},"Omalizumab Injection [Xolair]",{"EARLY_PHASE1":4585,"PHASE1":4587,"PHASE2":4599,"PHASE3":4601,"PHASE4":4603,"NA":4605},{"trials":4586,"activeCount":100},[],{"trials":4588,"activeCount":100},[4589],{"nctId":4590,"briefTitle":4591,"status":434,"phases":4592,"primaryCompletion":4593,"completion":4593,"start":4594,"enrollment":100,"conditions":4595,"interventions":4598},"NCT04535817","Xolair Interventional Study in ASD Patients With Comorbid Atopy",[88],"2022-01-01","2021-01-01",[4596,4597],"Autism Spectrum Disorder","Atopy",[4583],{"trials":4600,"activeCount":100},[],{"trials":4602,"activeCount":100},[],{"trials":4604,"activeCount":100},[],{"trials":4606,"activeCount":100},[],{"intervention":4608,"totalTrials":133,"cells":4609},"monoclonal antibody HeFi-1",{"EARLY_PHASE1":4610,"PHASE1":4612,"PHASE2":4622,"PHASE3":4624,"PHASE4":4626,"NA":4628},{"trials":4611,"activeCount":100},[],{"trials":4613,"activeCount":100},[4614],{"nctId":4615,"briefTitle":4616,"status":122,"phases":4617,"completion":4618,"start":4619,"conditions":4620,"interventions":4621},"NCT00003741","Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma",[88],"2007-12","1999-02",[954],[4608],{"trials":4623,"activeCount":100},[],{"trials":4625,"activeCount":100},[],{"trials":4627,"activeCount":100},[],{"trials":4629,"activeCount":100},[],{"intervention":4631,"totalTrials":133,"cells":4632},"Dendritic Cell Tumor Fusion",{"EARLY_PHASE1":4633,"PHASE1":4635,"PHASE2":4645,"PHASE3":4647,"PHASE4":4649,"NA":4651},{"trials":4634,"activeCount":100},[],{"trials":4636,"activeCount":100},[4637],{"nctId":4638,"briefTitle":4639,"status":122,"phases":4640,"primaryCompletion":2703,"completion":4641,"start":4642,"enrollment":880,"conditions":4643,"interventions":4644},"NCT00458653","Vaccination With Dendritic Cell\u002FTumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma",[88],"2020-07","2005-04",[561],[4631],{"trials":4646,"activeCount":100},[],{"trials":4648,"activeCount":100},[],{"trials":4650,"activeCount":100},[],{"trials":4652,"activeCount":100},[],{"intervention":4654,"totalTrials":133,"cells":4655},"thalidomide",{"EARLY_PHASE1":4656,"PHASE1":4658,"PHASE2":4668,"PHASE3":4670,"PHASE4":4672,"NA":4674},{"trials":4657,"activeCount":100},[],{"trials":4659,"activeCount":100},[4660],{"nctId":4661,"briefTitle":4662,"status":122,"phases":4663,"completion":4664,"start":2411,"conditions":4665,"interventions":4667},"NCT00052416","Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",[88],"2003-01",[4666,954],"Leukemia",[4654],{"trials":4669,"activeCount":100},[],{"trials":4671,"activeCount":100},[],{"trials":4673,"activeCount":100},[],{"trials":4675,"activeCount":100},[],{"intervention":4677,"totalTrials":133,"cells":4678},"recombinant interleukin-12",{"EARLY_PHASE1":4679,"PHASE1":4681,"PHASE2":4690,"PHASE3":4692,"PHASE4":4694,"NA":4696},{"trials":4680,"activeCount":100},[],{"trials":4682,"activeCount":100},[4683],{"nctId":4684,"briefTitle":4685,"status":2656,"phases":4686,"start":4687,"enrollment":205,"conditions":4688,"interventions":4689},"NCT00003412","Interleukin-12 in Treating Women With Metastatic Breast Cancer Who Have Received High-Dose Chemotherapy and Peripheral Stem Cell Transplantation",[88],"1998-06",[15],[4677],{"trials":4691,"activeCount":100},[],{"trials":4693,"activeCount":100},[],{"trials":4695,"activeCount":100},[],{"trials":4697,"activeCount":100},[],{"intervention":593,"totalTrials":133,"cells":4699},{"EARLY_PHASE1":4700,"PHASE1":4702,"PHASE2":4708,"PHASE3":4710,"PHASE4":4712,"NA":4714},{"trials":4701,"activeCount":100},[],{"trials":4703,"activeCount":100},[4704],{"nctId":584,"briefTitle":585,"status":122,"phases":4705,"primaryCompletion":587,"completion":588,"start":589,"enrollment":25,"conditions":4706,"interventions":4707},[88],[591],[593,45],{"trials":4709,"activeCount":100},[],{"trials":4711,"activeCount":100},[],{"trials":4713,"activeCount":100},[],{"trials":4715,"activeCount":100},[],{"intervention":4717,"totalTrials":133,"cells":4718},"Antithymocyte Globulin",{"EARLY_PHASE1":4719,"PHASE1":4721,"PHASE2":4737,"PHASE3":4739,"PHASE4":4741,"NA":4743},{"trials":4720,"activeCount":100},[],{"trials":4722,"activeCount":100},[4723],{"nctId":4724,"briefTitle":4725,"status":122,"phases":4726,"primaryCompletion":3010,"completion":4727,"start":3074,"enrollment":568,"conditions":4728,"interventions":4735},"NCT00697684","Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant",[88],"2023-11",[4729,4124,4730,4731,4732,4733,4734],"Acute Myeloid Leukemia","Acute Lymphocytic Leukemia","Relapsed\u002FRefractory Chronic Lymphocytic Leukemia","Relapsed\u002FRefractory Non Hodgkin's Lymphoma","Hodgkins Disease","Relapsed Refractory Multiple Myeloma",[4717,4736,4736,4736],"Clofarabine",{"trials":4738,"activeCount":100},[],{"trials":4740,"activeCount":100},[],{"trials":4742,"activeCount":100},[],{"trials":4744,"activeCount":100},[],{"intervention":4736,"totalTrials":133,"cells":4746},{"EARLY_PHASE1":4747,"PHASE1":4749,"PHASE2":4755,"PHASE3":4757,"PHASE4":4759,"NA":4761},{"trials":4748,"activeCount":100},[],{"trials":4750,"activeCount":100},[4751],{"nctId":4724,"briefTitle":4725,"status":122,"phases":4752,"primaryCompletion":3010,"completion":4727,"start":3074,"enrollment":568,"conditions":4753,"interventions":4754},[88],[4729,4124,4730,4731,4732,4733,4734],[4717,4736,4736,4736],{"trials":4756,"activeCount":100},[],{"trials":4758,"activeCount":100},[],{"trials":4760,"activeCount":100},[],{"trials":4762,"activeCount":100},[],{"intervention":4764,"totalTrials":133,"cells":4765},"isoquercetin or quercetin",{"EARLY_PHASE1":4766,"PHASE1":4774,"PHASE2":4776,"PHASE3":4778,"PHASE4":4780,"NA":4782},{"trials":4767,"activeCount":100},[4768],{"nctId":4769,"briefTitle":4770,"status":122,"phases":4771,"primaryCompletion":1591,"completion":1591,"start":2944,"enrollment":2637,"conditions":4772,"interventions":4773},"NCT01722669","Quercetin PK\u002FPD Study in Healthy Adults and Patients With Hypercoagulable States",[87],[24],[4764],{"trials":4775,"activeCount":100},[],{"trials":4777,"activeCount":100},[],{"trials":4779,"activeCount":100},[],{"trials":4781,"activeCount":100},[],{"trials":4783,"activeCount":100},[],{"intervention":1042,"totalTrials":133,"cells":4785},{"EARLY_PHASE1":4786,"PHASE1":4792,"PHASE2":4794,"PHASE3":4796,"PHASE4":4798,"NA":4800},{"trials":4787,"activeCount":100},[4788],{"nctId":1032,"briefTitle":1033,"status":122,"phases":4789,"primaryCompletion":1035,"completion":1036,"start":1037,"enrollment":1038,"conditions":4790,"interventions":4791},[87],[1040,24],[70,1042],{"trials":4793,"activeCount":100},[],{"trials":4795,"activeCount":100},[],{"trials":4797,"activeCount":100},[],{"trials":4799,"activeCount":100},[],{"trials":4801,"activeCount":100},[],{"intervention":4803,"totalTrials":133,"cells":4804},"Oral niacinamide, 1 gram daily",{"EARLY_PHASE1":4805,"PHASE1":4817,"PHASE2":4819,"PHASE3":4821,"PHASE4":4823,"NA":4825},{"trials":4806,"activeCount":100},[4807],{"nctId":4808,"briefTitle":4809,"status":122,"phases":4810,"primaryCompletion":4811,"completion":4812,"start":2629,"enrollment":1072,"conditions":4813,"interventions":4815},"NCT02701127","Molecular Effects of Vitamin B3 (Niacinamide) in Acute Kidney Injury",[87],"2017-02","2017-07",[4814],"Acute Kidney Injury",[4803,4816],"Oral niacinamide, 3 gram daily",{"trials":4818,"activeCount":100},[],{"trials":4820,"activeCount":100},[],{"trials":4822,"activeCount":100},[],{"trials":4824,"activeCount":100},[],{"trials":4826,"activeCount":100},[],{"intervention":4816,"totalTrials":133,"cells":4828},{"EARLY_PHASE1":4829,"PHASE1":4835,"PHASE2":4837,"PHASE3":4839,"PHASE4":4841,"NA":4843},{"trials":4830,"activeCount":100},[4831],{"nctId":4808,"briefTitle":4809,"status":122,"phases":4832,"primaryCompletion":4811,"completion":4812,"start":2629,"enrollment":1072,"conditions":4833,"interventions":4834},[87],[4814],[4803,4816],{"trials":4836,"activeCount":100},[],{"trials":4838,"activeCount":100},[],{"trials":4840,"activeCount":100},[],{"trials":4842,"activeCount":100},[],{"trials":4844,"activeCount":100},[],{"intervention":3226,"totalTrials":559,"cells":4846},{"EARLY_PHASE1":4847,"PHASE1":4849,"PHASE2":4851,"PHASE3":4881,"PHASE4":4883,"NA":4885},{"trials":4848,"activeCount":100},[],{"trials":4850,"activeCount":100},[],{"trials":4852,"activeCount":100},[4853,4857,4869,4873],{"nctId":3218,"briefTitle":3219,"status":122,"phases":4854,"primaryCompletion":3221,"completion":3221,"start":3222,"enrollment":3223,"conditions":4855,"interventions":4856},[88,89],[34],[3209,3226],{"nctId":4858,"briefTitle":4859,"status":555,"phases":4860,"primaryCompletion":4861,"completion":4862,"start":4863,"enrollment":1660,"conditions":4864,"interventions":4868},"NCT02974257","Thiamine vs. Placebo to Increase Oxygen Consumption After Cardiac Arrest",[89],"2022-02-07","2022-08-01","2017-05-01",[535,4865,4866,4867],"Shock","Lactic Acidosis","Thiamin Deficiency",[3226],{"nctId":3890,"briefTitle":3891,"status":122,"phases":4870,"primaryCompletion":3893,"completion":3893,"start":3894,"enrollment":1709,"conditions":4871,"interventions":4872},[89],[3896,3897],[3226,3881],{"nctId":4874,"briefTitle":4875,"status":122,"phases":4876,"primaryCompletion":4877,"completion":1058,"start":1966,"enrollment":1046,"conditions":4878,"interventions":4880},"NCT01985685","The Effect of Thiamine vs. Placebo on VO2 in Critical Illness",[89],"2016-05",[4879,1517],"Critically Ill",[3226],{"trials":4882,"activeCount":100},[],{"trials":4884,"activeCount":100},[],{"trials":4886,"activeCount":100},[4887],{"nctId":4888,"briefTitle":4889,"status":122,"phases":4890,"primaryCompletion":493,"completion":493,"start":1070,"enrollment":726,"conditions":4891,"interventions":4893},"NCT01462279","Effect of Thiamine on Oxygen Utilization (VO2) in Critical Illness",[92],[4892],"Acute Respiratory Failure",[3226],{"intervention":444,"totalTrials":1027,"cells":4895},{"EARLY_PHASE1":4896,"PHASE1":4902,"PHASE2":4904,"PHASE3":4910,"PHASE4":4912,"NA":4918},{"trials":4897,"activeCount":100},[4898],{"nctId":2899,"briefTitle":2900,"status":122,"phases":4899,"primaryCompletion":2902,"completion":2903,"start":2904,"enrollment":1941,"conditions":4900,"interventions":4901},[87],[1994,2040],[2907,444,441,2908,1235,2909,2894,2908,2909],{"trials":4903,"activeCount":100},[],{"trials":4905,"activeCount":100},[4906],{"nctId":3310,"briefTitle":3311,"status":122,"phases":4907,"primaryCompletion":2191,"completion":2390,"start":627,"enrollment":1406,"conditions":4908,"interventions":4909},[88,89],[882],[444,3301],{"trials":4911,"activeCount":100},[],{"trials":4913,"activeCount":100},[4914],{"nctId":432,"briefTitle":433,"status":434,"phases":4915,"primaryCompletion":436,"completion":436,"start":437,"enrollment":100,"conditions":4916,"interventions":4917},[91],[439],[441,442,443,444],{"trials":4919,"activeCount":100},[4920],{"nctId":4921,"briefTitle":4922,"status":122,"phases":4923,"primaryCompletion":4924,"completion":3133,"start":4925,"enrollment":2705,"conditions":4926,"interventions":4929},"NCT05279898","Perioperative Multimodal General AnesTHesia Focusing on Specific CNS Targets in Patients Undergoing carDiac surgERies",[92],"2024-06-30","2023-02-28",[2172,4927,258,4928],"Hemodynamic Instability","Neurocognitive Dysfunction",[2907,444,441,2908,1235,2909],{"intervention":1235,"totalTrials":449,"cells":4931},{"EARLY_PHASE1":4932,"PHASE1":4938,"PHASE2":4940,"PHASE3":4946,"PHASE4":4948,"NA":4950},{"trials":4933,"activeCount":100},[4934],{"nctId":2899,"briefTitle":2900,"status":122,"phases":4935,"primaryCompletion":2902,"completion":2903,"start":2904,"enrollment":1941,"conditions":4936,"interventions":4937},[87],[1994,2040],[2907,444,441,2908,1235,2909,2894,2908,2909],{"trials":4939,"activeCount":100},[],{"trials":4941,"activeCount":100},[4942],{"nctId":1228,"briefTitle":1229,"status":122,"phases":4943,"primaryCompletion":1231,"completion":1231,"start":180,"enrollment":1232,"conditions":4944,"interventions":4945},[89],[535],[1235,537],{"trials":4947,"activeCount":100},[],{"trials":4949,"activeCount":100},[],{"trials":4951,"activeCount":100},[4952],{"nctId":4921,"briefTitle":4922,"status":122,"phases":4953,"primaryCompletion":4924,"completion":3133,"start":4925,"enrollment":2705,"conditions":4954,"interventions":4955},[92],[2172,4927,258,4928],[2907,444,441,2908,1235,2909],{"intervention":2908,"totalTrials":449,"cells":4957},{"EARLY_PHASE1":4958,"PHASE1":4964,"PHASE2":4966,"PHASE3":4968,"PHASE4":4970,"NA":4972},{"trials":4959,"activeCount":100},[4960],{"nctId":2899,"briefTitle":2900,"status":122,"phases":4961,"primaryCompletion":2902,"completion":2903,"start":2904,"enrollment":1941,"conditions":4962,"interventions":4963},[87],[1994,2040],[2907,444,441,2908,1235,2909,2894,2908,2909],{"trials":4965,"activeCount":100},[],{"trials":4967,"activeCount":100},[],{"trials":4969,"activeCount":100},[],{"trials":4971,"activeCount":100},[],{"trials":4973,"activeCount":100},[4974,4984],{"nctId":4975,"briefTitle":4976,"status":122,"phases":4977,"primaryCompletion":4978,"completion":4979,"start":4980,"enrollment":1366,"conditions":4981,"interventions":4983},"NCT03370562","Dexmedetomidine After Cesarean for the Treatment of Nausea and Shivering",[92],"2020-03-20","2020-12-31","2020-02-18",[4982,1368],"Shivering",[2908],{"nctId":4921,"briefTitle":4922,"status":122,"phases":4985,"primaryCompletion":4924,"completion":3133,"start":4925,"enrollment":2705,"conditions":4986,"interventions":4987},[92],[2172,4927,258,4928],[2907,444,441,2908,1235,2909],{"intervention":2775,"totalTrials":449,"cells":4989},{"EARLY_PHASE1":4990,"PHASE1":4992,"PHASE2":4994,"PHASE3":5000,"PHASE4":5002,"NA":5004},{"trials":4991,"activeCount":100},[],{"trials":4993,"activeCount":100},[],{"trials":4995,"activeCount":100},[4996],{"nctId":2768,"briefTitle":2769,"status":122,"phases":4997,"primaryCompletion":2771,"completion":2772,"start":1070,"enrollment":2457,"conditions":4998,"interventions":4999},[88,89],[24,2764],[2748,2775],{"trials":5001,"activeCount":100},[],{"trials":5003,"activeCount":100},[],{"trials":5005,"activeCount":100},[5006,5016],{"nctId":5007,"briefTitle":5008,"status":122,"phases":5009,"primaryCompletion":2118,"completion":1058,"start":2851,"enrollment":5010,"conditions":5011,"interventions":5013},"NCT01520454","Effect of Increased Free Fatty Acids on Leptin Function",[92],26,[18,5012],"Leptin Resistance",[2775,5014,5015],"Intralipid","Heparin",{"nctId":5017,"briefTitle":5018,"status":555,"phases":5019,"primaryCompletion":3894,"completion":3894,"start":5020,"enrollment":1232,"conditions":5021,"interventions":5023},"NCT01146457","The Optimal Dosage of Intrathecal Morphine for Peripartum Analgesia",[92],"2010-07",[5022],"Labor Pain",[5024,2775],"Morphine",{"intervention":441,"totalTrials":449,"cells":5026},{"EARLY_PHASE1":5027,"PHASE1":5033,"PHASE2":5035,"PHASE3":5037,"PHASE4":5039,"NA":5045},{"trials":5028,"activeCount":100},[5029],{"nctId":2899,"briefTitle":2900,"status":122,"phases":5030,"primaryCompletion":2902,"completion":2903,"start":2904,"enrollment":1941,"conditions":5031,"interventions":5032},[87],[1994,2040],[2907,444,441,2908,1235,2909,2894,2908,2909],{"trials":5034,"activeCount":100},[],{"trials":5036,"activeCount":100},[],{"trials":5038,"activeCount":100},[],{"trials":5040,"activeCount":100},[5041],{"nctId":432,"briefTitle":433,"status":434,"phases":5042,"primaryCompletion":436,"completion":436,"start":437,"enrollment":100,"conditions":5043,"interventions":5044},[91],[439],[441,442,443,444],{"trials":5046,"activeCount":100},[5047],{"nctId":4921,"briefTitle":4922,"status":122,"phases":5048,"primaryCompletion":4924,"completion":3133,"start":4925,"enrollment":2705,"conditions":5049,"interventions":5050},[92],[2172,4927,258,4928],[2907,444,441,2908,1235,2909],{"intervention":2909,"totalTrials":449,"cells":5052},{"EARLY_PHASE1":5053,"PHASE1":5059,"PHASE2":5061,"PHASE3":5067,"PHASE4":5069,"NA":5071},{"trials":5054,"activeCount":100},[5055],{"nctId":2899,"briefTitle":2900,"status":122,"phases":5056,"primaryCompletion":2902,"completion":2903,"start":2904,"enrollment":1941,"conditions":5057,"interventions":5058},[87],[1994,2040],[2907,444,441,2908,1235,2909,2894,2908,2909],{"trials":5060,"activeCount":100},[],{"trials":5062,"activeCount":100},[5063],{"nctId":2915,"briefTitle":2916,"status":122,"phases":5064,"primaryCompletion":2918,"completion":2919,"start":2920,"enrollment":2921,"conditions":5065,"interventions":5066},[88,89],[2923,2924,2925],[2894,2909],{"trials":5068,"activeCount":100},[],{"trials":5070,"activeCount":100},[],{"trials":5072,"activeCount":100},[5073],{"nctId":4921,"briefTitle":4922,"status":122,"phases":5074,"primaryCompletion":4924,"completion":3133,"start":4925,"enrollment":2705,"conditions":5075,"interventions":5076},[92],[2172,4927,258,4928],[2907,444,441,2908,1235,2909],{"intervention":3540,"totalTrials":449,"cells":5078},{"EARLY_PHASE1":5079,"PHASE1":5081,"PHASE2":5083,"PHASE3":5097,"PHASE4":5099,"NA":5101},{"trials":5080,"activeCount":100},[],{"trials":5082,"activeCount":100},[],{"trials":5084,"activeCount":100},[5085,5089],{"nctId":3533,"briefTitle":3534,"status":122,"phases":5086,"primaryCompletion":1592,"completion":1592,"start":3536,"enrollment":1660,"conditions":5087,"interventions":5088},[89],[29,3538],[3540,3524],{"nctId":5090,"briefTitle":5091,"status":555,"phases":5092,"primaryCompletion":3179,"completion":5093,"start":1562,"enrollment":559,"conditions":5094,"interventions":5096},"NCT00866723","Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer",[89],"2012-06",[32,5095,601],"Primary Peritoneal Serous Cancer",[3540],{"trials":5098,"activeCount":100},[],{"trials":5100,"activeCount":100},[],{"trials":5102,"activeCount":100},[5103],{"nctId":5104,"briefTitle":5105,"status":434,"phases":5106,"primaryCompletion":3894,"completion":3894,"start":3222,"enrollment":100,"conditions":5107,"interventions":5108},"NCT01063010","Pilot Study of Bevacizumab (Avastin) in Patients With Septic Shock",[92],[34],[5109],"Bevacizumab",{"intervention":2907,"totalTrials":96,"cells":5111},{"EARLY_PHASE1":5112,"PHASE1":5118,"PHASE2":5120,"PHASE3":5122,"PHASE4":5124,"NA":5126},{"trials":5113,"activeCount":100},[5114],{"nctId":2899,"briefTitle":2900,"status":122,"phases":5115,"primaryCompletion":2902,"completion":2903,"start":2904,"enrollment":1941,"conditions":5116,"interventions":5117},[87],[1994,2040],[2907,444,441,2908,1235,2909,2894,2908,2909],{"trials":5119,"activeCount":100},[],{"trials":5121,"activeCount":100},[],{"trials":5123,"activeCount":100},[],{"trials":5125,"activeCount":100},[],{"trials":5127,"activeCount":100},[5128],{"nctId":4921,"briefTitle":4922,"status":122,"phases":5129,"primaryCompletion":4924,"completion":3133,"start":4925,"enrollment":2705,"conditions":5130,"interventions":5131},[92],[2172,4927,258,4928],[2907,444,441,2908,1235,2909],{"intervention":5133,"totalTrials":96,"cells":5134},"Levetiracetam",{"EARLY_PHASE1":5135,"PHASE1":5137,"PHASE2":5139,"PHASE3":5153,"PHASE4":5155,"NA":5157},{"trials":5136,"activeCount":100},[],{"trials":5138,"activeCount":100},[],{"trials":5140,"activeCount":100},[5141],{"nctId":5142,"briefTitle":5143,"status":122,"phases":5144,"primaryCompletion":5145,"completion":5145,"start":5146,"enrollment":5147,"conditions":5148,"interventions":5152},"NCT03875638","Treating Hyperexcitability in AD With Levetiracetam",[89],"2026-02-16","2019-08-22",58,[5149,1160,5150,5151],"Alzheimer Dementia","Dementia of Alzheimer Type","Mild Cognitive Impairment",[5133],{"trials":5154,"activeCount":100},[],{"trials":5156,"activeCount":100},[],{"trials":5158,"activeCount":100},[5159],{"nctId":5160,"briefTitle":5161,"status":122,"phases":5162,"primaryCompletion":2191,"completion":2191,"start":3474,"enrollment":2360,"conditions":5163,"interventions":5164},"NCT00612235","Premenstrual Dysphoric Disorder and Antiepileptic Drugs",[],[2195],[5165,5133,5166],"Lamotrigine","Carbamazepine",{"intervention":5168,"totalTrials":96,"cells":5169},"morphine",{"EARLY_PHASE1":5170,"PHASE1":5172,"PHASE2":5174,"PHASE3":5176,"PHASE4":5178,"NA":5180},{"trials":5171,"activeCount":100},[],{"trials":5173,"activeCount":100},[],{"trials":5175,"activeCount":100},[],{"trials":5177,"activeCount":100},[],{"trials":5179,"activeCount":100},[],{"trials":5181,"activeCount":100},[5182,5192],{"nctId":5183,"briefTitle":5184,"status":122,"phases":5185,"primaryCompletion":5186,"completion":2860,"start":3893,"enrollment":5187,"conditions":5188,"interventions":5190},"NCT02381717","Ultrasound Guided Femoral Nerve Block",[92],"2025-05",44,[5189],"Hip Fracture",[5191,5168],"bupivacaine",{"nctId":5017,"briefTitle":5018,"status":555,"phases":5193,"primaryCompletion":3894,"completion":3894,"start":5020,"enrollment":1232,"conditions":5194,"interventions":5195},[92],[5022],[5024,2775],{"intervention":5197,"totalTrials":133,"cells":5198},"Narcotics alone",{"EARLY_PHASE1":5199,"PHASE1":5201,"PHASE2":5203,"PHASE3":5205,"PHASE4":5207,"NA":5209},{"trials":5200,"activeCount":100},[],{"trials":5202,"activeCount":100},[],{"trials":5204,"activeCount":100},[],{"trials":5206,"activeCount":100},[],{"trials":5208,"activeCount":100},[],{"trials":5210,"activeCount":100},[5211],{"nctId":5212,"briefTitle":5213,"status":434,"phases":5214,"primaryCompletion":5215,"completion":5215,"start":5216,"enrollment":100,"conditions":5217,"interventions":5221},"NCT00240396","Bimodal Analgesia as Form of Pain Control Post Long Bone Fracture",[92],"2007-09-24","2005-10",[5218,5219,5220],"Tibia Fracture","Femur Fracture","Humerus Fracture",[5197,5222],"Narcotics and NSAIDS",{"intervention":5222,"totalTrials":133,"cells":5224},{"EARLY_PHASE1":5225,"PHASE1":5227,"PHASE2":5229,"PHASE3":5231,"PHASE4":5233,"NA":5235},{"trials":5226,"activeCount":100},[],{"trials":5228,"activeCount":100},[],{"trials":5230,"activeCount":100},[],{"trials":5232,"activeCount":100},[],{"trials":5234,"activeCount":100},[],{"trials":5236,"activeCount":100},[5237],{"nctId":5212,"briefTitle":5213,"status":434,"phases":5238,"primaryCompletion":5215,"completion":5215,"start":5216,"enrollment":100,"conditions":5239,"interventions":5240},[92],[5218,5219,5220],[5197,5222],{"intervention":5242,"totalTrials":133,"cells":5243},"Enteryx",{"EARLY_PHASE1":5244,"PHASE1":5246,"PHASE2":5248,"PHASE3":5250,"PHASE4":5252,"NA":5254},{"trials":5245,"activeCount":100},[],{"trials":5247,"activeCount":100},[],{"trials":5249,"activeCount":100},[],{"trials":5251,"activeCount":100},[],{"trials":5253,"activeCount":100},[],{"trials":5255,"activeCount":100},[5256],{"nctId":5257,"briefTitle":5258,"status":122,"phases":5259,"primaryCompletion":589,"completion":589,"start":5260,"enrollment":3742,"conditions":5261,"interventions":5263},"NCT00346905","Endoscopic Implantation of Enteryx for the Treatment of GERD",[92],"2003-10",[5262],"Gastroesophageal Reflux",[5242],{"intervention":5265,"totalTrials":133,"cells":5266},"insulin-like growth factor I",{"EARLY_PHASE1":5267,"PHASE1":5269,"PHASE2":5271,"PHASE3":5273,"PHASE4":5275,"NA":5277},{"trials":5268,"activeCount":100},[],{"trials":5270,"activeCount":100},[],{"trials":5272,"activeCount":100},[],{"trials":5274,"activeCount":100},[],{"trials":5276,"activeCount":100},[],{"trials":5278,"activeCount":100},[5279],{"nctId":5280,"briefTitle":5281,"status":122,"phases":5282,"completion":5283,"start":5284,"enrollment":1992,"conditions":5285,"interventions":5288},"NCT00004419","Study of Recombinant Human Insulin-Like Growth Factor I in Patients With Severe Insulin Resistance",[92],"2000-09","1998-04",[5286,5287],"Insulin Resistance","Hyperglycemia",[5265],{"intervention":5014,"totalTrials":133,"cells":5290},{"EARLY_PHASE1":5291,"PHASE1":5293,"PHASE2":5295,"PHASE3":5297,"PHASE4":5299,"NA":5301},{"trials":5292,"activeCount":100},[],{"trials":5294,"activeCount":100},[],{"trials":5296,"activeCount":100},[],{"trials":5298,"activeCount":100},[],{"trials":5300,"activeCount":100},[],{"trials":5302,"activeCount":100},[5303],{"nctId":5007,"briefTitle":5008,"status":122,"phases":5304,"primaryCompletion":2118,"completion":1058,"start":2851,"enrollment":5010,"conditions":5305,"interventions":5306},[92],[18,5012],[2775,5014,5015],{"intervention":5015,"totalTrials":133,"cells":5308},{"EARLY_PHASE1":5309,"PHASE1":5311,"PHASE2":5313,"PHASE3":5315,"PHASE4":5317,"NA":5319},{"trials":5310,"activeCount":100},[],{"trials":5312,"activeCount":100},[],{"trials":5314,"activeCount":100},[],{"trials":5316,"activeCount":100},[],{"trials":5318,"activeCount":100},[],{"trials":5320,"activeCount":100},[5321],{"nctId":5007,"briefTitle":5008,"status":122,"phases":5322,"primaryCompletion":2118,"completion":1058,"start":2851,"enrollment":5010,"conditions":5323,"interventions":5324},[92],[18,5012],[2775,5014,5015],{"intervention":5326,"totalTrials":133,"cells":5327},"IL-2",{"EARLY_PHASE1":5328,"PHASE1":5330,"PHASE2":5332,"PHASE3":5334,"PHASE4":5336,"NA":5338},{"trials":5329,"activeCount":100},[],{"trials":5331,"activeCount":100},[],{"trials":5333,"activeCount":100},[],{"trials":5335,"activeCount":100},[],{"trials":5337,"activeCount":100},[],{"trials":5339,"activeCount":100},[5340],{"nctId":5341,"briefTitle":5342,"status":122,"phases":5343,"primaryCompletion":3010,"completion":3010,"start":3222,"enrollment":5344,"conditions":5345,"interventions":5346},"NCT01288963","IL-2 \"SELECT\" Tissue Collection Protocol in Patients With Advanced Melanoma",[],153,[591],[5326],{"intervention":5348,"totalTrials":133,"cells":5349},"Low\u002FHigh\u002FPlacebo Dose Keppra",{"EARLY_PHASE1":5350,"PHASE1":5352,"PHASE2":5354,"PHASE3":5356,"PHASE4":5358,"NA":5360},{"trials":5351,"activeCount":100},[],{"trials":5353,"activeCount":100},[],{"trials":5355,"activeCount":100},[],{"trials":5357,"activeCount":100},[],{"trials":5359,"activeCount":100},[],{"trials":5361,"activeCount":100},[5362],{"nctId":5363,"briefTitle":5364,"status":122,"phases":5365,"primaryCompletion":5366,"completion":5366,"start":2217,"enrollment":22,"conditions":5367,"interventions":5370},"NCT01554683","Seizure Activity in Alzheimer's Disease",[92],"2017-07-01",[5368,5369],"Alzheimer's Disease","Seizures",[5348],{"intervention":5372,"totalTrials":133,"cells":5373},"Acetaminophen liquid formulation",{"EARLY_PHASE1":5374,"PHASE1":5376,"PHASE2":5378,"PHASE3":5380,"PHASE4":5382,"NA":5384},{"trials":5375,"activeCount":100},[],{"trials":5377,"activeCount":100},[],{"trials":5379,"activeCount":100},[],{"trials":5381,"activeCount":100},[],{"trials":5383,"activeCount":100},[],{"trials":5385,"activeCount":100},[5386],{"nctId":5387,"briefTitle":5388,"status":122,"phases":5389,"primaryCompletion":1348,"completion":5390,"start":2241,"enrollment":2380,"conditions":5391,"interventions":5395},"NCT01246713","Effect on Acetaminophen Metabolism by Liquid Formulations",[92],"2012-07",[5392,5393,5394],"Acetaminophen Metabolism","Acetaminophen Poisoning","Drug Metabolism by Excipients",[5372,5396],"Acetaminophen solid formulation",{"intervention":5396,"totalTrials":133,"cells":5398},{"EARLY_PHASE1":5399,"PHASE1":5401,"PHASE2":5403,"PHASE3":5405,"PHASE4":5407,"NA":5409},{"trials":5400,"activeCount":100},[],{"trials":5402,"activeCount":100},[],{"trials":5404,"activeCount":100},[],{"trials":5406,"activeCount":100},[],{"trials":5408,"activeCount":100},[],{"trials":5410,"activeCount":100},[5411],{"nctId":5387,"briefTitle":5388,"status":122,"phases":5412,"primaryCompletion":1348,"completion":5390,"start":2241,"enrollment":2380,"conditions":5413,"interventions":5414},[92],[5392,5393,5394],[5372,5396],{"intervention":5416,"totalTrials":133,"cells":5417},"Aliskiren",{"EARLY_PHASE1":5418,"PHASE1":5420,"PHASE2":5422,"PHASE3":5424,"PHASE4":5426,"NA":5428},{"trials":5419,"activeCount":100},[],{"trials":5421,"activeCount":100},[],{"trials":5423,"activeCount":100},[],{"trials":5425,"activeCount":100},[],{"trials":5427,"activeCount":100},[],{"trials":5429,"activeCount":100},[5430],{"nctId":5431,"briefTitle":5432,"status":122,"phases":5433,"primaryCompletion":5434,"start":3075,"enrollment":155,"conditions":5435,"interventions":5437},"NCT01165983","The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes",[92],"2012-01",[5436],"Diabetes Type 2",[5416],{"intervention":5165,"totalTrials":133,"cells":5439},{"EARLY_PHASE1":5440,"PHASE1":5442,"PHASE2":5444,"PHASE3":5446,"PHASE4":5448,"NA":5450},{"trials":5441,"activeCount":100},[],{"trials":5443,"activeCount":100},[],{"trials":5445,"activeCount":100},[],{"trials":5447,"activeCount":100},[],{"trials":5449,"activeCount":100},[],{"trials":5451,"activeCount":100},[5452],{"nctId":5160,"briefTitle":5161,"status":122,"phases":5453,"primaryCompletion":2191,"completion":2191,"start":3474,"enrollment":2360,"conditions":5454,"interventions":5455},[],[2195],[5165,5133,5166],{"intervention":5166,"totalTrials":133,"cells":5457},{"EARLY_PHASE1":5458,"PHASE1":5460,"PHASE2":5462,"PHASE3":5464,"PHASE4":5466,"NA":5468},{"trials":5459,"activeCount":100},[],{"trials":5461,"activeCount":100},[],{"trials":5463,"activeCount":100},[],{"trials":5465,"activeCount":100},[],{"trials":5467,"activeCount":100},[],{"trials":5469,"activeCount":100},[5470],{"nctId":5160,"briefTitle":5161,"status":122,"phases":5471,"primaryCompletion":2191,"completion":2191,"start":3474,"enrollment":2360,"conditions":5472,"interventions":5473},[],[2195],[5165,5133,5166],{"intervention":5475,"totalTrials":133,"cells":5476},"Ozanimod",{"EARLY_PHASE1":5477,"PHASE1":5479,"PHASE2":5481,"PHASE3":5483,"PHASE4":5485,"NA":5487},{"trials":5478,"activeCount":100},[],{"trials":5480,"activeCount":100},[],{"trials":5482,"activeCount":100},[],{"trials":5484,"activeCount":100},[],{"trials":5486,"activeCount":100},[],{"trials":5488,"activeCount":100},[5489],{"nctId":5490,"briefTitle":5491,"status":434,"phases":5492,"primaryCompletion":1847,"completion":1847,"start":5493,"enrollment":100,"conditions":5494,"interventions":5495},"NCT05809583","Define Predictors of Response to Ozanimod in UC Discovering Biomarkers in the Management of Ulcerative Colitis",[],"2023-04-12",[158],[5475],{"intervention":5497,"totalTrials":133,"cells":5498},"continuous intravenous insulin",{"EARLY_PHASE1":5499,"PHASE1":5501,"PHASE2":5503,"PHASE3":5505,"PHASE4":5507,"NA":5509},{"trials":5500,"activeCount":100},[],{"trials":5502,"activeCount":100},[],{"trials":5504,"activeCount":100},[],{"trials":5506,"activeCount":100},[],{"trials":5508,"activeCount":100},[],{"trials":5510,"activeCount":100},[5511],{"nctId":5512,"briefTitle":5513,"status":555,"phases":5514,"primaryCompletion":3474,"completion":2704,"start":2525,"enrollment":378,"conditions":5515,"interventions":5518},"NCT00328094","Glycemic Control to Prevent Cardiac Morbidity in Vascular Surgery",[92],[5516,5517],"Peripheral Vascular Disease","Abdominal Aortic Aneurysm",[5497],{"intervention":5191,"totalTrials":133,"cells":5520},{"EARLY_PHASE1":5521,"PHASE1":5523,"PHASE2":5525,"PHASE3":5527,"PHASE4":5529,"NA":5531},{"trials":5522,"activeCount":100},[],{"trials":5524,"activeCount":100},[],{"trials":5526,"activeCount":100},[],{"trials":5528,"activeCount":100},[],{"trials":5530,"activeCount":100},[],{"trials":5532,"activeCount":100},[5533],{"nctId":5183,"briefTitle":5184,"status":122,"phases":5534,"primaryCompletion":5186,"completion":2860,"start":3893,"enrollment":5187,"conditions":5535,"interventions":5536},[92],[5189],[5191,5168],{"intervention":5538,"totalTrials":133,"cells":5539},"Amoxicillin",{"EARLY_PHASE1":5540,"PHASE1":5542,"PHASE2":5544,"PHASE3":5546,"PHASE4":5548,"NA":5550},{"trials":5541,"activeCount":100},[],{"trials":5543,"activeCount":100},[],{"trials":5545,"activeCount":100},[],{"trials":5547,"activeCount":100},[],{"trials":5549,"activeCount":100},[],{"trials":5551,"activeCount":100},[5552],{"nctId":5553,"briefTitle":5554,"status":122,"phases":5555,"primaryCompletion":2217,"completion":2217,"start":2400,"enrollment":1274,"conditions":5556,"interventions":5558},"NCT01414010","Effects of Pre-, Pro- & Anti-biotics on Gut Microbiota",[92],[5557],"Human Gut Microbiota",[5538],{"intervention":5560,"totalTrials":133,"cells":5561},"Opioid",{"EARLY_PHASE1":5562,"PHASE1":5564,"PHASE2":5566,"PHASE3":5568,"PHASE4":5570,"NA":5572},{"trials":5563,"activeCount":100},[],{"trials":5565,"activeCount":100},[],{"trials":5567,"activeCount":100},[],{"trials":5569,"activeCount":100},[],{"trials":5571,"activeCount":100},[],{"trials":5573,"activeCount":100},[5574],{"nctId":5575,"briefTitle":5576,"status":555,"phases":5577,"primaryCompletion":5578,"completion":5578,"start":5579,"enrollment":2392,"conditions":5580,"interventions":5582},"NCT04816877","Use of Patient-Controlled Analgesia in Acute Pancreatitis",[],"2023-12-07","2022-02-22",[5581],"Acute Pancreatitis",[5560],{"intervention":5584,"totalTrials":133,"cells":5585},"Caffeine",{"EARLY_PHASE1":5586,"PHASE1":5588,"PHASE2":5590,"PHASE3":5592,"PHASE4":5594,"NA":5596},{"trials":5587,"activeCount":100},[],{"trials":5589,"activeCount":100},[],{"trials":5591,"activeCount":100},[],{"trials":5593,"activeCount":100},[],{"trials":5595,"activeCount":100},[],{"trials":5597,"activeCount":100},[5598],{"nctId":5599,"briefTitle":5600,"status":122,"phases":5601,"primaryCompletion":5216,"completion":5216,"start":5602,"enrollment":5603,"conditions":5604,"interventions":5606},"NCT00130026","Caffeine in the Prevention of Post-operative Nausea and Vomiting",[92],"2005-03",135,[5605],"Postoperative Nausea and Vomiting",[5584],{"intervention":5608,"totalTrials":133,"cells":5609},"Supplement",{"EARLY_PHASE1":5610,"PHASE1":5612,"PHASE2":5614,"PHASE3":5616,"PHASE4":5618,"NA":5620},{"trials":5611,"activeCount":100},[],{"trials":5613,"activeCount":100},[],{"trials":5615,"activeCount":100},[],{"trials":5617,"activeCount":100},[],{"trials":5619,"activeCount":100},[],{"trials":5621,"activeCount":100},[5622],{"nctId":5623,"briefTitle":5624,"status":122,"phases":5625,"primaryCompletion":531,"completion":531,"start":5626,"enrollment":2457,"conditions":5627,"interventions":5630},"NCT01915173","Response to Supplement and Placebo in GERD",[92],"2013-06",[5628,5629,1293],"Gastroesophageal Reflux Disease (GERD)","Heartburn",[5608],{"intervention":5632,"totalTrials":133,"cells":5633},"VSL#3",{"EARLY_PHASE1":5634,"PHASE1":5636,"PHASE2":5638,"PHASE3":5640,"PHASE4":5642,"NA":5644},{"trials":5635,"activeCount":100},[],{"trials":5637,"activeCount":100},[],{"trials":5639,"activeCount":100},[],{"trials":5641,"activeCount":100},[],{"trials":5643,"activeCount":100},[],{"trials":5645,"activeCount":100},[5646],{"nctId":5647,"briefTitle":5648,"status":555,"phases":5649,"primaryCompletion":5650,"completion":5650,"start":2668,"enrollment":5651,"conditions":5652,"interventions":5654},"NCT00179582","Dose Ranging Study With the Probiotic Combination (VSL#3) in Diarrhea IBS",[92],"2006-01",180,[5653],"IBS",[5632],{"intervention":5656,"totalTrials":133,"cells":5657},"nonmyeloablative stem cell transplant",{"EARLY_PHASE1":5658,"PHASE1":5660,"PHASE2":5662,"PHASE3":5664,"PHASE4":5666,"NA":5668},{"trials":5659,"activeCount":100},[],{"trials":5661,"activeCount":100},[],{"trials":5663,"activeCount":100},[],{"trials":5665,"activeCount":100},[],{"trials":5667,"activeCount":100},[],{"trials":5669,"activeCount":100},[5670],{"nctId":5671,"briefTitle":5672,"status":122,"phases":5673,"primaryCompletion":1989,"completion":2191,"start":5674,"enrollment":5675,"conditions":5676,"interventions":5678},"NCT00997529","Mini Allo Stem Cell Transplantation for the Treatment of Solid Tumors",[92],"2000-11",14,[5677],"Metastatic Solid Tumor",[5656],{"intervention":5680,"totalTrials":133,"cells":5681},"Amoxicillin Clavulanate",{"EARLY_PHASE1":5682,"PHASE1":5684,"PHASE2":5686,"PHASE3":5688,"PHASE4":5690,"NA":5692},{"trials":5683,"activeCount":100},[],{"trials":5685,"activeCount":100},[],{"trials":5687,"activeCount":100},[],{"trials":5689,"activeCount":100},[],{"trials":5691,"activeCount":100},[],{"trials":5693,"activeCount":100},[5694],{"nctId":5695,"briefTitle":5696,"status":122,"phases":5697,"primaryCompletion":3741,"completion":3741,"start":2703,"enrollment":5698,"conditions":5699,"interventions":5701},"NCT01473368","Effects of S. Boulardii and Amoxicillin\u002FClavulanate on Gut Microbiota",[92],53,[5700],"Healthy Volunteers",[5680],{"intervention":5703,"totalTrials":133,"cells":5704},"Ketorolac",{"EARLY_PHASE1":5705,"PHASE1":5707,"PHASE2":5709,"PHASE3":5711,"PHASE4":5713,"NA":5715},{"trials":5706,"activeCount":100},[],{"trials":5708,"activeCount":100},[],{"trials":5710,"activeCount":100},[],{"trials":5712,"activeCount":100},[],{"trials":5714,"activeCount":100},[],{"trials":5716,"activeCount":100},[5717],{"nctId":5718,"briefTitle":5719,"status":555,"phases":5720,"primaryCompletion":2217,"completion":2217,"start":3852,"enrollment":1992,"conditions":5721,"interventions":5723},"NCT01133639","Ketorolac Effects on Post-operative Pain and Bone Healing",[92],[5722],"Bunion",[5703],{"intervention":5725,"totalTrials":133,"cells":5726},"Black Tea",{"EARLY_PHASE1":5727,"PHASE1":5729,"PHASE2":5731,"PHASE3":5733,"PHASE4":5735,"NA":5737},{"trials":5728,"activeCount":100},[],{"trials":5730,"activeCount":100},[],{"trials":5732,"activeCount":100},[],{"trials":5734,"activeCount":100},[],{"trials":5736,"activeCount":100},[],{"trials":5738,"activeCount":100},[5739],{"nctId":5740,"briefTitle":5741,"status":122,"phases":5742,"completion":4642,"start":5743,"enrollment":477,"conditions":5744,"interventions":5746},"NCT00120107","Tea's Effect on Atherosclerosis Pilot Study (TEA Study)",[92],"2003-07",[5745],"Cardiovascular Disease",[5725],{"intervention":5748,"totalTrials":133,"cells":5749},"Genomic and proteomic biomarker discovery",{"EARLY_PHASE1":5750,"PHASE1":5752,"PHASE2":5754,"PHASE3":5756,"PHASE4":5758,"NA":5760},{"trials":5751,"activeCount":100},[],{"trials":5753,"activeCount":100},[],{"trials":5755,"activeCount":100},[],{"trials":5757,"activeCount":100},[],{"trials":5759,"activeCount":100},[],{"trials":5761,"activeCount":100},[5762],{"nctId":5763,"briefTitle":5764,"status":122,"phases":5765,"primaryCompletion":2390,"completion":2390,"start":2477,"enrollment":5766,"conditions":5767,"interventions":5773},"NCT00672087","Diagnostic Challenges in IC (and Male CPPS)",[],1000,[5768,5769,5770,5771,5772],"Chronic Prostatitis With Chronic Pelvic Pain Syndrome","Chronic Bacterial Prostatitis","Asymptomatic Inflammatory Prostatitis","Painful Bladder Syndrome","Cystitis, Interstitial",[5748],{"intervention":5775,"totalTrials":133,"cells":5776},"Liposyn III 20%",{"EARLY_PHASE1":5777,"PHASE1":5779,"PHASE2":5781,"PHASE3":5783,"PHASE4":5785,"NA":5787},{"trials":5778,"activeCount":100},[],{"trials":5780,"activeCount":100},[],{"trials":5782,"activeCount":100},[],{"trials":5784,"activeCount":100},[],{"trials":5786,"activeCount":100},[],{"trials":5788,"activeCount":100},[5789],{"nctId":5790,"briefTitle":5791,"status":555,"phases":5792,"completion":1659,"start":5650,"enrollment":788,"conditions":5793,"interventions":5795},"NCT00278928","Fat Tolerance From Lipid Emulsion Infusion Packaged in Glass or Plastic",[92],[5794],"Hypertriglyceridemia",[5775,5796],"Intralipid 20%",{"intervention":5796,"totalTrials":133,"cells":5798},{"EARLY_PHASE1":5799,"PHASE1":5801,"PHASE2":5803,"PHASE3":5805,"PHASE4":5807,"NA":5809},{"trials":5800,"activeCount":100},[],{"trials":5802,"activeCount":100},[],{"trials":5804,"activeCount":100},[],{"trials":5806,"activeCount":100},[],{"trials":5808,"activeCount":100},[],{"trials":5810,"activeCount":100},[5811],{"nctId":5790,"briefTitle":5791,"status":555,"phases":5812,"completion":1659,"start":5650,"enrollment":788,"conditions":5813,"interventions":5814},[92],[5794],[5775,5796],{"intervention":5816,"totalTrials":133,"cells":5817},"hypertonic saline",{"EARLY_PHASE1":5818,"PHASE1":5820,"PHASE2":5822,"PHASE3":5824,"PHASE4":5826,"NA":5828},{"trials":5819,"activeCount":100},[],{"trials":5821,"activeCount":100},[],{"trials":5823,"activeCount":100},[],{"trials":5825,"activeCount":100},[],{"trials":5827,"activeCount":100},[],{"trials":5829,"activeCount":100},[5830],{"nctId":5831,"briefTitle":5832,"status":434,"phases":5833,"primaryCompletion":5834,"completion":5834,"start":5434,"enrollment":100,"conditions":5835,"interventions":5837},"NCT01108744","Double Blind Study of Hypertonic Saline vs Mannitol in the Management of Increased Intracranial Pressure (ICP).",[92],"2014-01",[5836],"Elevated Intracranial Pressure",[5816,5838],"Mannitol",{"intervention":5838,"totalTrials":133,"cells":5840},{"EARLY_PHASE1":5841,"PHASE1":5843,"PHASE2":5845,"PHASE3":5847,"PHASE4":5849,"NA":5851},{"trials":5842,"activeCount":100},[],{"trials":5844,"activeCount":100},[],{"trials":5846,"activeCount":100},[],{"trials":5848,"activeCount":100},[],{"trials":5850,"activeCount":100},[],{"trials":5852,"activeCount":100},[5853],{"nctId":5831,"briefTitle":5832,"status":434,"phases":5854,"primaryCompletion":5834,"completion":5834,"start":5434,"enrollment":100,"conditions":5855,"interventions":5856},[92],[5836],[5816,5838],{"intervention":5858,"totalTrials":133,"cells":5859},"Rifaximin",{"EARLY_PHASE1":5860,"PHASE1":5862,"PHASE2":5864,"PHASE3":5866,"PHASE4":5868,"NA":5870},{"trials":5861,"activeCount":100},[],{"trials":5863,"activeCount":100},[],{"trials":5865,"activeCount":100},[],{"trials":5867,"activeCount":100},[],{"trials":5869,"activeCount":100},[],{"trials":5871,"activeCount":100},[5872],{"nctId":5873,"briefTitle":5874,"status":122,"phases":5875,"primaryCompletion":493,"completion":493,"start":5876,"enrollment":5877,"conditions":5878,"interventions":5880},"NCT01542541","A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans",[92],"2011-07",68,[5879],"Intestinal FDG Uptake",[5858],{"intervention":5882,"totalTrials":133,"cells":5883},"Conversion to Envarsus-XR and use of smart phone app, TransMedAx",{"EARLY_PHASE1":5884,"PHASE1":5886,"PHASE2":5888,"PHASE3":5890,"PHASE4":5892,"NA":5894},{"trials":5885,"activeCount":100},[],{"trials":5887,"activeCount":100},[],{"trials":5889,"activeCount":100},[],{"trials":5891,"activeCount":100},[],{"trials":5893,"activeCount":100},[],{"trials":5895,"activeCount":100},[5896],{"nctId":5897,"briefTitle":5898,"status":434,"phases":5899,"primaryCompletion":5900,"completion":5901,"start":787,"enrollment":100,"conditions":5902,"interventions":5905},"NCT04711291","Efficacy of Envarsus XR and Digital Health Technology in Reducing Tacrolimus Fluctuation and Frequency of Dose Changes",[92],"2022-12-31","2023-07-01",[5903,5904],"Medication Adherence","Renal Transplant",[5882,5906],"Convert to Envarsus XR once daily",{"intervention":5906,"totalTrials":133,"cells":5908},{"EARLY_PHASE1":5909,"PHASE1":5911,"PHASE2":5913,"PHASE3":5915,"PHASE4":5917,"NA":5919},{"trials":5910,"activeCount":100},[],{"trials":5912,"activeCount":100},[],{"trials":5914,"activeCount":100},[],{"trials":5916,"activeCount":100},[],{"trials":5918,"activeCount":100},[],{"trials":5920,"activeCount":100},[5921],{"nctId":5897,"briefTitle":5898,"status":434,"phases":5922,"primaryCompletion":5900,"completion":5901,"start":787,"enrollment":100,"conditions":5923,"interventions":5924},[92],[5903,5904],[5882,5906],{"intervention":5926,"totalTrials":133,"cells":5927},"statin",{"EARLY_PHASE1":5928,"PHASE1":5930,"PHASE2":5932,"PHASE3":5934,"PHASE4":5936,"NA":5938},{"trials":5929,"activeCount":100},[],{"trials":5931,"activeCount":100},[],{"trials":5933,"activeCount":100},[],{"trials":5935,"activeCount":100},[],{"trials":5937,"activeCount":100},[],{"trials":5939,"activeCount":100},[5940],{"nctId":5941,"briefTitle":5942,"status":122,"phases":5943,"primaryCompletion":1966,"completion":1966,"start":493,"enrollment":1941,"conditions":5944,"interventions":5948},"NCT01702987","Evaluation of Ubiquinol on Mitochondrial Oxidative Capacity in Statin Patients Using 31PMRS",[92],[5945,5946,5947],"Myopathy","HMG COA Reductase Inhibitor Adverse Reaction","Hypercholesterolemia",[5926],{"intervention":5950,"totalTrials":133,"cells":5951},"Gabapentin",{"EARLY_PHASE1":5952,"PHASE1":5954,"PHASE2":5956,"PHASE3":5958,"PHASE4":5960,"NA":5962},{"trials":5953,"activeCount":100},[],{"trials":5955,"activeCount":100},[],{"trials":5957,"activeCount":100},[],{"trials":5959,"activeCount":100},[],{"trials":5961,"activeCount":100},[],{"trials":5963,"activeCount":100},[5964],{"nctId":5965,"briefTitle":5966,"status":434,"phases":5967,"primaryCompletion":5968,"completion":5968,"start":124,"enrollment":100,"conditions":5969,"interventions":5972},"NCT02202707","Vasomotor Symptoms and Cardiovascular Control",[92],"2016-06",[5970,5971],"Vasomotor Symptoms","Cardiovascular Health",[5950]]